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An extract from Alois Alzheimer’s interview with the severely demented Auguste Deter in 1901. She 
represents the first reported case of Alzheimer’s disease.  
Reprinted from Maurer et al., Auguste D and Alzheimer’s disease. Lancet 349, 1546-9 (1997). 
 
What is your name?  
Auguste.  
Last name?  
Auguste.  
What is your husband’s name?  
 Auguste, I think…  
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ABSTRACT 
The blood-brain barrier (BBB) rigorously shields off the central nervous system from the periphery thereby 
protecting the fragile brain homeostasis. Yet, it also causes many potentially effective brain drugs to fail in vivo 
- not because of a lack of potency, but for they cannot enter the brain parenchyma. Nanoparticles enable brain 
drug delivery by acting as Trojan Horses, masking the original physicochemical properties of a drug and 
allowing targeted transport to biostructures, thereby enlarging the pool of brain drug candidates, such as 
potential anti-Alzheimer’s disease (AD) drugs. Flurbiprofen (FBP) is a non-steroidal anti-inflammatory drug 
(NSAID) that lowers amyloid beta (Aβ) and AD prevalence in high dose long-term treatment. Still, an FBP 
enantiomer failed in clinical trials with AD patients, likely for its poor brain penetrating capacity. This study 
revisits FBP as an anti-AD drug by packing the drug into poly(lactic acid) nanoparticles (PLA-FBP NP). 
PLA-FBP NP crossed an advanced in vitro BBB model (consisting of primary porcine brain capillary endothelial 
cells (pBCEC) on Transwell® inserts to allow a blood and a brain compartment separation). Also, PLA-FBP NP 
reduced Aβ42 burden (generated by AD model cells) in the brain compartment – notably without destroying 
barrier integrity. These promising in vitro findings highlight the potential of nanotechnology-based approaches 
as a chance in BBB crossing for the prevention and treatment of neurodegenerative disorders. 
 
Graphical abstract of this thesis. The drug flurbiprofen might positively impact amyloid-β (Aβ) burden, but failed in clinical trials for it crosses the blood-
brain barrier insufficiently in vivo. When the drug is incorporated in nanoparticles, it crosses a primary porcine in vitro blood-brain barrier model and 
reduces amyloid-β levels in the brain-representing compartment. Flurbiprofen mediates amyloid-β reduction by modifying the enzyme activity of 
γ-secretase.   
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ZUSAMMENFASSUNG 
Die Blut-Hirn-Schranke (BHS) trennt Peripherie und Zentralnervensystem voneinander um die fragile 
Hirn-Homöostase zu schützen. Allerdings scheitern daher viele potentiell effektive Neurotherapeutika 
in vivo – sie können die BHS oft nicht überschreiten. Nanopartikel können den Transport ins Gehirn 
vermitteln indem sie als Trojanische Pferde die physikochemischen Eigenschaften der Substanzen 
maskieren und einen zielgerichteten Transport erlauben. Dies vergrößert die Anzahl potentieller 
Neuropharmaka, z.B. gegen die Alzheimer Krankheit (AD). Flurbiprofen (FBP) gehört zu den nicht-
steroidalen Antirheumatika, die Amyloid beta (Aβ) und die AD-Prävalenz bei hoch dosierter 
Langzeitgabe verringern können. Dennoch verliefen klinische Studien mit AD Patienten enttäuschend, 
wahrscheinlich, weil FBP die BHS nur schlecht passiert. Diese Arbeit greift FBP wieder auf, indem die 
Substanz in Polymilchsäure-Nanopartikel (PLA-FBP NP) verpackt wird. PLA-FBP NP konnten ein in vitro 
BHS Modell (basierend auf primären porzinen Hirnkapillarendothel-Zellen (pBCEC) auf Transwell® 
Einsätzen zur Teilung in Blut- und Hirn-Kompartiment) überwinden. Darüber hinaus konnten die 
Nanopartikel Aβ42 im Hirn-Kompartiment (produziert von AD Modell-Zellen) reduzieren – ohne dabei 
die Barriere-Integrität zu zerstören. Diese vielversprechenden in vitro Daten unterstreichen das 
Potenzial Nanotechnologie-basierter Ansätze zur Überwindung der BHS für die Therapien und 
Prävention neurodegenerativer Erkrankungen. 
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ABBREVIATIONS  
 
°C Degrees Celsius 
µ Micro 
AChE Acetylcholine esterase 
AD Alzheimer’s disease 
AEBSF 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride 
AIDS Acquired immune deficiency syndrome 
ALS Amyotrophic lateral sclerosis 
ApoE3 Apolipoprotein E3 
APP Amyloid precursor protein 
ATP Adenosine triphosphate 
BACE1 β-secretase 1 (also known as β-site amyloid precursor protein cleaving enzyme 1, β-site APP 
cleaving enzyme 1, membrane-associated aspartic protease 2, memapsin-2, aspartyl 
protease 2, and ASP2) 
BBB Blood-brain barrier  
BSA Bovine serum albumin 
Cld-3 Claudin 3 
Cld-5 Claudin 5 
CLSM Confocal laser scanning microscopy 
CNS Central nervous system 
COX-1,-2 Cyclooxygenase-1,-2 
CSF Cerebrospinal fluid 
CYP  Cytochrome P450 
DAPI  4',6-diamidino-2-phenylindole 
DHA Docosahexaenoic acid 
DMEM Dulbecco's modified Eagle medium 
DMSO Dimethyl sulfoxide 
dpm Decays per minute 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
Em Emission 
EMA European medicines agency 
ESAM Endothelial selective adhesion molecule 
Ex Excitation 
FBP Flurbiprofen 
FBS Fetal bovine serum 
FCS Fetal calf serum 
FDA Food and drug administration 
g Gravity 
g Gram 
GI Gastrointestinal  
GPC Gel permeation chromatography 
GTP Guanosine triphosphate 
h Hour 
HAART Highly active antiretroviral therapy  
HD Huntington’s disease  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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HIV Human immunodeficiency virus 
HPLC High-performance liquid chromatography 
HRP Horseradish peroxidase 
HSA Human serum albumin 
JAM  Junctional adhesion molecules 
LDLR Low density lipoprotein receptor 
LRP1 Low density lipoprotein receptor-related protein 1 
LRP2 Low density lipoprotein receptor-related protein 2 (also known as Megalin) 
MAO  Monoamine oxidase 
MEM Minimum essential medium 
MES 2-(N-morpholino)ethanesulfonic acid 
MHC Major histocompatibility complex  
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRI Magnetic resonance imaging 
MS Multiple sclerosis  
NaCl Potassium chloride  
NCS New born calf serum 
NEAA Non-essential amino acids 
NRG1  Type III neuregulin 1  
NSAID Non-steroidal anti-inflammatory drug 
O/W Oil/water  
Occl Occludin 
PBCA Poly(butyl cyanoacrylate) 
PBS Phosphate buffered saline 
PD Parkinson’s disease  
PDI Polydispersity index 
PEG Poly(ethylene glycol) 
Pen/Strep Penicillin streptomycin solution 
PFA Paraformaldehyde 
PLA Poly(lactic) acid 
PLGA Poly(lactic-co-glycolic acid) 
PSEN 1, PSEN 2 Presenilin 1, Presenilin 2 
PVA Poyvinyl alcohol 
Resazurin  7-Hydroxy-3H-phenoxazin-3-one 10-oxide 
ROS Reactive oxygen species  
RT Room temperature 
RXR Retinoid X receptor 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
TER Transendothelial electrical resistance 
TJ Tight junction 
UK United Kingdom 
US United States of America 
VD Vascular dementia 
W/O/W Water/oil/water  
ZO-1 Zonula occludens 
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1 INTRODUCTION  
A strong barrier surrounds the human brain, rigorously and reliably shielding off most substances and 
pathogens to protect the fragile central nervous system (CNS) homeostasis. However, this barrier also 
often prevents successful drug treatment in case of brain-associated diseases.    
1.1 The blood-brain barrier: Obstacle in brain drug development 
Disorders of the brain are a significant problem today, including depression, schizophrenia, dementia, 
Alzheimer’s and Parkinson’s disease, epilepsy, cerebrovascular disease and brain tumors [1], but 
research and development for CNS disease drugs is highly complex. Substances may often show 
promising in vitro results in preclinical testing, but they often fail to benefit in vivo. Although the 
number of drugs for CNS treatment has steadily grown, too few drugs acting on the CNS have entered 
the market [2] – even though treatment tactics with small molecule drugs often may exist (Figure 1A). 
The limiting factor is the delivery to the brain. For example, in the early stage of the acquired immune 
deficiency syndrome (AIDS), the human immunodeficiency virus (HIV) infects the brain [3]. HIV can be 
significantly reduced by highly active antiretroviral therapy (HAART) in the periphery, but the cocktail 
of small molecule drugs partially cannot penetrate the brain parenchyma,  hampering HIV treatment 
if the virus settles down in the CNS of the patient [3, 4].  
1.1.1 The shortage of brain medications  
Transport of drugs to the brain is an exception rather than a rule: nearly 100 % of large molecule drugs 
and more than 98 % of small molecule drugs cannot gain access to the brain, leading to a very limited 
number of potential neuropharmaceuticals. Generally, only substances with a molecular mass less 
than 400-500 Da that form less than 8-10 hydrogen bonds in solvent water can diffuse to the brain in 
relevant amounts if no specific transport molecule is available. Also, the drug must not avidly bind to 
plasma proteins or be a substrate to the brain’s efflux transporters [5]. Only very few CNS disorders 
(depression or schizophrenia) respond to drugs of this category (Figure 1A).  
The brain seems to be fenced off from the rest of the body (as illustrated in Figure 1B). In the whole 
body autoradiogram of a mouse, sacrificed after intravenous injection of radiolabeled histamine, the 
CNS appears completely white; the overall rest of the body appears black and grey representing the 
amount of infused histamine (white areas in the abdomen represent air-filled intestinal loops). 
Whereas histamine (which only is approximately 100 Da in mass) perfused all capillaries in the 
periphery, it does not appear in the entire brain and spinal cord.  
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More than a century ago, Paul Ehrlich laid the foundation for the experiments leading to the discovery 
of the blood-brain barrier (BBB) by using trypan dyes [6, 7] that he originally developed in search of 
drugs against protozoa of the species Trypanosoma, which cause sleeping sickness (African 
trypanosomiasis). Peripheral injections of trypans lead to staining of the whole body of laboratory 
animals – with exception of the brain (Figure 1C).  
Edwin Goldman, systemically refined the experiments [7–9] and injected trypan blue in different 
animals (mice, rats, frogs, guinea pigs, rabbits, dogs and monkeys), and he also observed the same 
phenomenon. The dye distributed rapidly to the complete body with exception of the CNS. To rule out 
that this effect was due to a poor brain affinity, Goldmann performed the correct verifying experiments 
and injected the dyes not only to the periphery, but to the cerebrospinal fluids of the animals’ brains 
(Figure 1D). Vice versa, the CNS was stained, but not the body of the animal. He therefore proved that 
the distribution was independent from the dyes’ affinity, but that the dyes were caught in either the 
blood or the brain compartment of the body – dependent on the injection site. The actual structures 
responsible for separating the blood and the brain could only be proved to exist by Reese and 
Karnovsky with the introduction of scanning electron microscopy in the 1960s [10].  
 
  
 
Figure 1: The blood-brain barrier restricts body distribution of substances. (A) Drug therapy for brain disorders is difficult, even with small 
molecule drugs (adapted and modified from Pardridge [2]). Exceptions: L-dopa for Parkinson’s disease and cytokines for multiple sclerosis 
can enter the brain. (B) Autoradiogram of a mouse 30 minutes after intravenous injection of radiolabeled histamine. No signal was detected 
in the central nervous system, but everywhere else in the periphery (adapted and modified from Pardridge [2]). (C) Scheme of first 
experiment that hinted at the existence of such a barrier. Ehrlich developed trypan dyes that stained the periphery if injected into animals 
[6, 7]. (D) Goldmann systematically refined the experiments [7–9]. Not only staining the periphery by intravenous dye application was 
feasible, but also the inversion of the experiment. Injecting dyes into the CNS only stained the brain and cerebral fluids. These data proved 
the existence of a barrier between blood and brain parenchyma.  
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1.1.2 The structure of the blood-brain barrier  
Today we know that all higher organisms possess a blood-brain barrier (BBB) to maintain the unique 
and fragile homeostasis of a complex nervous system. A tight network of over 600 km of microvessels 
provides the human CNS with nutrients and exports toxic metabolites – nearly the linear distance 
between Hamburg and Munich (Figure 2A). Endothelial cells, growing on a basal lamina composed of 
collagen and laminine, line these cerebral microvessels and hence represent the barrier’s 
cornerstones. Astrocytes (which cover more than 90 % of the capillary’s surface), pericytes and 
neurons provide biochemical support via release of growth factors [11]. Together they are often called 
the “neurovascular unit” (Figure 2B).  
The very specialized brain endothelial cells – distinct from most other endothelia in the body – connect 
with each other and form a physical barrier (Figure 2C). The foundations are transmembrane tight 
junction (TJ) proteins that seal the paracellular pathway and play a key role in maintaining barrier 
function. Without accurate tight junction protein expression, the cellular barrier lacks appropriate 
resistance and is permeable to various substances. The first identified tight junction protein was zonula 
occludens [12]. Later, occludin and the very important claudin group were shown to block the aqueous 
pathway and force most molecules to take the transcellular route [13, 14]. Claudin derives from the 
Latin word “claudere”, meaning “to shut, to block”.  
Transcellular transport is highly regulated, thus resulting in a transport barrier (Figure 2C). 
Transporters on both sides of the endothelial layer import valuable nutrients and export noxious 
metabolites. Examples are glucose and amino acids that have their own transport system to maintain 
brain homeostasis: the brain only constitutes 2 % of body weight, but requires up to 20 % of the basal 
metabolism. Other valuable molecules are transported by receptor-mediated transcytosis: insulin, 
transferrin or apolipoproteins bind to their specific receptor protein at the BBB and are imported by 
clathrin-mediated endocytosis. This pathway leads to the formation of endosomes that are later 
acetated by proton pumps (and then are called lysosomes) before degradation. Another import 
process is adsorptive transcytosis: plasma proteins fuse with the plasma membrane of the endothelial 
cells due to their specific surface charge and are also transported across the barrier and released at 
the brain site.  
Different enzymes in the brain parenchyma contribute to the metabolic barrier (Figure 2C) function: 
peptidases and nucleotidases outside of the cell can degrade peptides and adenosine triphosphate 
(ATP); monoamine oxidase (MAO) and members of the cytochrome P450 (CYP) family inside the cell 
inactivate many neuroactive and toxic compounds [15]. 
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Figure 2: Simplified structure of the blood-brain barrier. (A) Schematic human brain that is lined with billions of blood capillary vessels, 
resulting in a remarkable large network. Brain data in the box from [2, 16–18]. (B) The neurovascular unit is composed of brain endothelial 
cells, basal lamina, pericytes, astrocytes and neurons. (C) Tight junctions seal the gaps between endothelial cells and represent the physical 
barrier. Efflux transporters (P-glycoprotein) possess many substrates that are exported if they cross the blood-brain barrier. Extra- and 
intracellular enzymes degrade a plethora of substances if they enter the brain parenchyma. JAM = Junctional adhesion molecules, ESAM = 
endothelial selective adhesion molecule, MAO = monoamine oxidase, CYP = cytochrome P450 (CYP1A and CYP2B). Modified after Abbott 
et al. [11]. 
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1.1.3 In vitro models try to predict in vivo success  
The BBB represents one of the most challenging hindrances in the body and therefore needs to be 
taken into account when trying to develop new CNS drugs. Today most of these studies are performed 
in laboratory animals, and consequently are expensive, labor intensive and under debate concerning 
ethical legitimation. Furthermore, it is often hard to choose or develop an appropriate animal model 
(transgenic or inbred strains, species variants). Generally, a robust, relatively simple, but still widely 
useable model is needed. Consequently, numerous in vitro models of the BBB emerged in order to 
complete and accelerate in vivo and human studies and to simplify the overwhelming complexity of 
this structure [19–21].  
In vitro approaches have various advantages compared to animal studies:  
• Less expense,  
• High throughput for drug permeability experiments, 
• Simplified working environment, 
• Less variability,  
• Higher reproducibility, 
• Higher versatility (manipulating possibilities). 
However, in vitro cellular models that aim at predicting permeability of drugs across the BBB need to 
fulfil certain criteria (summarized from Gumbleton and Audus [21]): First of all, the model must 
represent the permeability data for low (e.g., inulin or sucrose) and high (e.g., diazepam or 
propranolol) brain-penetrating substances, which can be set as an internal reference for the potential 
new CNS drug in debate. Secondly, the model must reflect the limited paracellular pathway, which 
forces substances to take the transcellular route across the BBB. Monitoring transendothelial electrical 
resistance (TER) indicates BBB integrity, but still provides only limited information regarding 
paracellular restriction. Thus, permeability studies with marker solutes are recommended. Thirdly, the 
model should possess a cell architecture that resembles the in vivo conditions, including morphology, 
cell-cell contacts, and expression of BBB relevant receptors, transporters and proteins. For 
nanoparticle-mediated drug transport studies, the expression of receptors that are capable of 
transcytosis is of upmost importance. Also, efflux pumps, most importantly P-gp, may have an 
enormous impact on BBB transit capacitance and therefore should be expressed accurately in an in 
vitro BBB model. Finally, a model ideally should allow easy handling and culturing, as well as high yield 
of cells for screening or high-throughput experiments. An immortalized cell line that stably expressed 
all abovementioned features would therefore be the optimal BBB model. However, until today, all 
brain endothelium cell lines failed to depict a realistically restricted paracellular pathway, drawing 
attention to primary cells as BBB model.    
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Immortalized brain endothelial cell lines are a very basic tool to mimic the BBB in vitro, advantages 
mainly comprise time and cost efficacy as well as low variability in experiments. Commonly used cell 
lines for BBB research are the murine bEnd3 [21, 22] and HBMEC [23], derived from human material. 
HBMEC was described as the most suitable human BBB model cell line, compared to 3 other cell lines, 
although HBMEC only expresses crucial proteins like claudin-5 or zonula occludens on a very low level 
[23]. Another disadvantage of cell lines is their low TER: bEnd3 cells exhibit TER values lower than 
60 Ω*cm2 in general [21]; HBMEC display TER values lower than 50 Ω*cm2 in cell cultures [23].  
Primary capillary endothelial cell cultures are a compromise between in vivo experiments and cell line 
based in vitro models, since BBB characteristics are generally better than in simple models (like bEnd3), 
but the experiments are not defined as animal studies. However, since yields of brain capillary 
endothelial cells from rodents are relatively low (e.g. 1-2 million cells per rat brain), large experimental 
setups need a vast amount of animals to be sacrificed, raising ethical concerns. Bovine (first described 
by Bowmann et al. [24]) and porcine species gained more and more attention as an alternative source 
for brain capillary endothelial cells, since cell yields are higher: for bovine material ~50 million viable 
cells per brain are reported [21]; the preparation protocol for porcine material used in this study 
usually results in 20-30 million cells per brain. Bovine models were widely neglected in Europe after 
bovine spongiform encephalopathy (BSE) appeared in the nineties, and the generation of porcine 
models was focused on, pioneered by the group of Galla [25]. TER of porcine BBB model used in this 
study can exceed 500 Ω*cm2 depending on the surface grown on [26, 27].    
In vitro models were continually refined, and today range from static horizontal cell culture systems to 
advanced three dimensional (3D), flow-based cocultures [28–31]. For example, NDIV-BBBr [28, 29], 
µBBB [30] and SyM-BBB [31] take into account the blood flow through a 3D vessel construct to induce 
shear stress and limit sedimentation of samples to depict realistic local concentration of drugs, leading 
to better predictability of drug transport in vivo.  
But all in all, regardless of all efforts made to optimize in vitro BBB models, mimicking the BBB on a 
cellular level is a challenging task and is associated with serious drawbacks as it is for any in vitro cellular 
model: cells cultivated ex situ lose their natural environment and lack external stimuli and physiological 
factors. They may modify expression of organ-specific, relevant features such as transporters, proteins 
and ligands which can lead to altered characteristics in vitro. Thus, in vitro findings always need to be 
verified within in vivo experiments.  
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1.1.4 Strategies for blood-brain barrier circumvention 
Strategies to deliver drugs to the brain in vivo are rare and often appear rather harsh: One common 
invasive approach is, for example, to inject hyperosmolar mannitol solution within the carotid artery. 
The osmotic shock shrinks the cells and disrupts the intercellular connections, so that co-applied drugs 
can pass the endothelial cell layer. Also, ultrasonic sound waves are used to forcibly break down the 
blood-brain barrier [32]. These techniques are not specific and allow uncontrolled passage of drugs; 
adverse side effects may comprise changes in neuropathology, brain vasculopathy and seizures [33–
37]. Even more radical is intraventricular injection of drugs or implantation of depots (Figure 3). Ipso 
facto, these are brain surgery procedures with all associated risks like intracranial infections [38] or 
brain edema [39]. Furthermore, in the brain parenchyma the drug concentration decreases 
logarithmically with the diffusion distance, leading to a very low bioavailability even close to the 
injection site [2, 40, 41].  
Non–invasive methods improve the treatment procedure, but they are rarely successful. The 
modification of drugs to improve blood-brain barrier crossing can lead to loss of function, whereas the 
intranasal application via the nervus olfactorius (a window in the blood-brain barrier) drastically 
decreases bioavailability [42]. Inhibition of efflux transporters (like P-glycoprotein) [43] allows some 
drugs to penetrate into the brain parenchyma, but entails severe, mostly intolerable adverse effects. 
A promising approach to combine the beneficial characteristics of non-invasive techniques is to use 
nanoparticles as drug carriers. Various studies showed that intravenous injection of drug-loaded 
nanoparticles can lead to drug release in the brain (for review see [39], also see 1.2.2): The 
nanoparticles can be transcytosed at the BBB by receptor-mediated pathways. The incorporated or 
adsorbed drug itself is not modified and can perform its original task after the particle matrix releases 
it into the brain. 
 
 
Figure 3: Invasive strategies for blood-brain barrier circumvention. (A) Intracerebral implant (2 mm disc with 125I-labeled nerve growth factor 
(NGF)) releases the drug only at the local depot site (autoradiogram of rat brain). Adapted from Pardridge [44]. (B) Implantation of GLIADEL® 
wafers (polymer loaded with chemotherapeutics for the treatment of recurrent gliomas) during human brain surgery. Adapted from Lesniak 
and Brem [45]. (C) Ommaya reservoir allows intraventricular injection of drugs. Adapted and modified from Mehta et al. [46]. 
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1.2 Nanotechnology: Promising approach for brain delivery  
Pharmacology today faces the challenge of efficient drug transport and distribution to desired organs. 
The advantages are seductive compared to classical, non-targeted administration of drugs: Specific 
transport allows a higher therapeutic value at the desired site of action and reduces adverse side 
effects in the periphery, therefore being advantageous compared to classical, non-targeted 
administration of drugs. For the treatment of brain disorders, nanomaterials represent an interesting 
pharmacological tool to overcome the otherwise insurmountable structure of the blood-brain barrier. 
In brief, nanoparticles can act as molecular Trojan horses [47]. 
1.2.1 What are nanoparticles? 
Nanotechnology is a versatile, advantageous and fast emerging biomedical field and a plethora of 
nano-sized formulations is being developed right now. For pharmaceutical purposes, nanoparticles are 
defined as solid, biodegradable colloids, with diameters ranging from 1 to 1,000 nm, and bearing drugs 
or other biologically active substances [48, 49]. Usually, nanoparticles intended for therapeutic 
approaches consist of at least two components: a basis polymer to form the particles and one 
pharmaceutically active substance that can be incorporated, adsorbed or chemically bound [49]. The 
preparation method depends on the basis material and can either be achieved by polymerization or 
dispersion processes. Natural macromolecules as basis material include human serum albumin (HSA), 
sodium alginate, chitosan or gelatin (for review of nanoparticle preparation see [50]). Common 
examples for synthetic, biocompatible polymers for nanoparticle preparation are poly(lactic acid) (PLA) 
and poly(glycolic acid) (PGA), or a copolymers from PLA and PGA, resulting in poly(lactic-co-glycolic 
acid) (PLGA) (Figure 4A), which are approved by the United States food and drug administration (FDA) 
[51–53] and frequently serve as basis material for nanoparticle preparation [54]. The human body 
metabolizes these polyesters into glycolic acid and lactic acid. These acids then are decomposed within 
the citric acid cycle to form water (H2O) and  carbon dioxide (CO2), which explains their excellent 
biocompatibility [55]. Current examples of approved drugs that utilize PLA and PLGA as material for 
implants or microparticles are Trenantone [56] , Profact [57] or Zoladex [57].  
 
For successful application in clinic, therapeutic nanoparticles are expected to be at least [39, 47, 49]: 
• non-toxic 
• non-immunogenic 
• non-inflammatory  
• preferentially biodegradable 
• functionally targeted to desired bio-structures  
• capable of prolonged circulation in the bloodstream  
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Regarding biomedical applications, the usage of nanoparticles may differ strongly despite preparative 
similarities. The desired function can either be a therapeutic effect of transported substances, the 
diagnosis of a disease state or molecular imaging in clinic or research. Drugs can be incorporated or 
conjugated to the surface of nanoparticles; detection molecules (contrast agents, radionuclides or 
fluorophores) can be added; and targeting structures (antibodies or ligands) can be coupled to the 
surface (Figure 4B) (for review see [58]). The biological stability of the biodegradable nanoparticles 
influences pharmacokinetics [54]: the drug release from nanoparticles can be altered by variation of 
size, basis material composition or coatings to allow a broad release profile ranging from immediate 
to retarded. 
 
 
 
Figure 4: Nanoparticle basis materials and modifications for biomedical application. (A) Chemical structure of poly(glycolic acid) (PGA), 
poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA). (B) A multi-functionalized nanoparticle can carry: Ligands for imaging (contrast 
agents for magnet resonance spectroscopy, radionuclides for positron emission tomography (PET) or single-photon emission computed 
tomography (SPECT)), shell coating for enhanced circulation time in the bloodstream (e.g. with poly ethylene glycol (PEG)), fluorescent 
markers for in vitro application, ligand-modification for targeted transport (e.g. peptides, antibodies). Drugs and proteins for therapeutic 
purposes can be bound to the surface of the nanoparticles or incorporated. Image adapted and modified from Re et al. [58]. (C) Nanoparticles 
can be targeted to bio-structures: mouse brain slice in electron microscopy, arrows indicate endocytosed nanoparticles in brain endothelial 
cells and nanoparticles in the blood stream after intravenous injection, scale bar 2 µm, reprinted from Zensi et al. [59]. 
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1.2.2 Targeting nanoparticles to bio-structures  
Body distribution 
Nanoparticles are often injected intravenously to avoid the biological barriers of the gastrointestinal 
tract. However, after entering the bloodstream, they usually accumulate in organs of the reticulo-
endothelial system (liver, spleen, lungs and bone marrow), and are thereby hindered in fulfilling their 
original purpose. Fortunately, targeting strategies to bio-structures exist. The next sections summarize 
the success of nanoparticles for brain targeting.  
Brain targeting options 
Nanoparticles are an elegant way to overcome the challenging blood-brain barrier with minimal 
invasive damage. By masking the original physic-chemical properties of a drug, nanoparticles allow 
transporting substances that could not enter the brain by themselves. The fundamental idea is that 
ligand-modified nanoparticles mimic biomolecules that have a specific receptor at the blood-brain 
barrier. 
Guiding drug-loaded nanoparticles to the brain was first achieved by surfactants. Kreuter et al. [60, 61] 
and Schroeder et al. [62, 63] tested more than a dozen different surfactant coatings for nanoparticles 
that influenced BBB transit capability. Interestingly, incubating nanoparticles with polysorbate 80 
(Tween®80) or poloxamer 188 (Pluronic® F-68) causes anchoring of lipoproteins from blood plasma [64, 
65] or serum of the culture medium [39, 49, 66–68]. These lipoproteins, for example apolipoproteins 
E and/or A-I, adsorb to the nanoparticles’ surface and can interact with receptors at the BBB, resulting 
in cellular uptake of the drug-loaded nanoparticles in vitro and in vivo [26, 47, 69–75].  
A tangible example is loperamide, an opioid drug that cannot enter the brain and therefore has no 
analgesic effect. When loperamide-loaded nanoparticles are injected into mice, these animals become 
less sensitive in nociceptive experiments, proving drug transport to the brain. Kreuter et al. showed an 
analgesic effect of apolipoprotein-modified nanoparticles in nociceptive experiments in 2002 [66]. 
Later, Chen et al. [76] investigated the differences in brain transport capacity comparing loperamide-
loaded PLGA-PEG-PLGA nanoparticles coated with either Tween®80 or Pluronic® F-68. Direct coupling 
of apolipoprotein onto the nanoparticles’ surfaces to enable BBB crossing (Figure 4C), can even 
increase the effect compared to Tween®80-coated nanoparticles [77, 78].  
The mechanism of nanoparticle uptake was proposed to be endo- and transcytosis mediated by 
receptors of the low density lipoprotein (LDL) receptor family [49, 60] (that is also expressed on BBB-
forming endothelia [79, 80]). For example, Tween®80-coated PBCA nanoparticles were shown to be 
taken up by neuronal cells in in vitro primary cells, and the uptake could be blocked by LDLR antibodies 
[72].  
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Wagner et al. [81] further investigated the endocytosis processes and confirmed that ApoE-modified 
nanoparticles are actively transported via LDL receptor family members in in vitro experiments by using 
the receptor-associated protein (RAP). RAP blocks binding sites of most LDL receptor family members 
and after co-incubating RAP with ApoE-modified nanoparticles, binding capacity to BBB model cells 
was drastically reduced [81]. The prominent role of the LDL receptor related protein (LRP1) was 
highlightened by adding soluble purified LRP1 fragments when ApoE-modified nanoparticles were 
incubated on BBB model cells [81]. Binding to the cells was inhibited when fragments expressing the 
binding domain II or IV of LRP1 were added, verifying LRP1 involvement [81], because the domains 
(which are capable of binding numerous LPR1 ligands [82]) sequester the nanoparticles before they 
can bind to the cellular LRP1 receptors expressed on the BBB cells.  
Present-day examples for compound-loaded nanoparticles for brain delivery are listed in Table 1, many 
of them focusing on brain tumors or pain management. Another hot topic is the treatment of 
neurodegenerative disorders. 
Nanoparticles for Alzheimer’s disease   
Nanotechnology offers the chance to rethink drug treatment strategies that are ineffective due to their 
inability to transit the BBB. It suddenly seems possible to choose from a larger variety of substances in 
the anti-neurodegeneration drug development- but how could we use this new pharmacological tool? 
Which substances would stand a chance against dementia and Alzheimer’s disease? Are there any 
treatment options right now that nanoparticles could improve? To answer these questions, we need 
to take a closer look at the nature of these diseases.  
 
Table 1: Selected examples of drugs and substances bound to nanoparticles for brain delivery in in vivo studies. Adapted and modified 
from Li and Sabliov [83] and Wohlfart et al. [39].  
Compound Purpose Basis material# Surface modification§ Reference 
Campthotecin  Anticancer drug SLN Pluronic® F 68 [84] 
Dalargin  Analgesic drug PBCA Tween®80 [61, 84] 
Dexamethasone  Steroidal drug PLGA Alginate hydrogel [85] 
Doxorubicin Anticancer drug PBCA Tween®80 [86] 
Etoposide Anticancer drug Tripalmitin Without coating [87] 
FITC  Fluorescent marker PLA Tween®80 [88] 
Gemcitabine  Anticancer drug PBCA Tween®80 [89] 
Kyotorphin Analgesic drug PBCA Tween®80 [62] 
Loperamide Opiate receptor agonist PBCA, HSA, PLGA Tween®80, ApoE3, ApoA1, ApoB100, (R)-g7 peptide [78, 90, 91] 
Methotrexate  Anticancer drug PBCA Tween®80 [92] 
Rivastigmine  Anti-Alzheimer's drug PBCA Tween®80 [93] 
Sulpiride Atypical antipsychotic drug PLA Maleimide PEG [94] 
Tacrine Anti-Alzheimer's drug PBCA Tween®80 [95] 
Tubocurarine  Muscle relaxants PBCA Tween®80 [96] 
 
#Abbreviations: SNL=solid lipid nanoparticles, PBCA=poly(butyl cyanoacrylate), PLGA=poly(lactic-co-glycolic acid), PLA=poly(lactic acid), 
HSA=human serum albumin.  §Trade names: Tween®80=polysorbate 80, Pluronic® F 68=poloxamer 188.  
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1.3 Dementia and Alzheimer’s disease: A rapidly growing problem   
A long life expectancy accompanies an increased risk to develop dementia of the Alzheimer’s disease 
type. On the one hand, the obstacle of the blood-brain barrier complicates treatment of 
neurodegenerative disorders. On the other hand, often the etiology and neuropathological processes 
are far from being understood - preventing the development of causal approaches. 
1.3.1 Case numbers, prognosis and treatment options  
Dementia is not a specific disease itself, but rather a collective term to depict symptoms like memory, 
communication and cognitive deficiencies [97] that are often responsible for disabilities in the elderly. 
The name derives from the Latin word dementia meaning irrationality.  
Today, more than 46 million people in the world suffer from dementia (population numbers in 2015 
for comparison: Colombia 48.2 million, Spain: 46.4 million [98]). The World Alzheimer Report 2015 
predicts that these numbers will almost double every 20 years [99] due to demographic changes 
(Figure 5A) and even corrected the estimates to be more than 10 % compared to the World Alzheimer 
Report 2009. Regarding global incidence, in 2015 over 9.9 million new cases will occur, meaning one 
new case every 3.2 seconds [99]. Up to 80 % of dementia cases are supposed to be caused by 
Alzheimer’s disease (Figure 5B). The situation is expected to rapidly aggravate, because life expectancy 
immensely increased during the last century (Figure 5C) and age is the main risk factor for Alzheimer’s 
disease [100, 101]. 
 
 
Figure 5: Dementia and Alzheimer’s disease facts. (A) Estimated number of people suffering from dementia worldwide at different time 
points (data from World Alzheimer Report 2015 [99]). (B) Causes and types of dementia displayed in percent of all dementia cases (data from 
Alzheimer’s Association [97]). DWL=dementia with Lewy bodies, FTLD= frontotemporal lobar degeneration, PD= Parkinson’s disease, CJD= 
Creutzfeldt-Jakob disease, NPH=normal pressure hydrocephalus, VD= vascular dementia. (C) Mean life expectancy for Europe and the world, 
data from Riley [102].  
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Mortality and Morbidity  
Some Alzheimer’s disease cases are not recognized for years, but once diagnosed, patients only live 
for an additional four to eight years on average [103, 104]. They do not die of the Alzheimer’s 
symptoms themselves, but of the on-going loss of body functions as well as secondary infections like 
pneumonia. Death certificates often listed these acute conditions as the primary cause of death rather 
than the underlying Alzheimer’s disease – even though later disease stages directly contribute to death 
by drastically promoting terminal conditions. Tinetti et al. reported that dementia was the second most 
important contribution to death after heart failure in the elderly [105]. Therefore, Alzheimer’s disease 
is likely to cause more deaths than officially recorded, but already nowadays, it is the sixth-leading 
cause of death in the United States. Compared to other major diseases, deaths attributed to 
Alzheimer’s disease drastically increased in recent years [97], reflecting various facts: a rise in the 
actual number of deaths attributed to Alzheimer’s disease, better survival chances for other life 
threatening diseases and an improved reporting pattern for causes of death [97].  
Are there any treatment options? 
Unfortunately, nothing prevents or cures the cognitive degradation and constantly proceeding 
helplessness of Alzheimer’s disease patients. Today, no causal therapy exists. Patients may only receive 
moderate symptomatic relief from three different acetylcholine esterase (AChE) inhibitors (donepezil, 
galantamine and rivastigmine) and one N-Methyl-D-aspartate (NMDA) receptor inhibitor (memantine) 
[106] that are on the market. Whether patients really benefit from these substances is highly 
controversial [107–109]. Attendant symptoms for cognitive impairment (like depression, 
schizophrenia and aggression) are commonly treated either pharmacologically or 
psychotherapeutically [106, 110, 111]. 
Recently, the development of causal, disease-modifying strategies has been in the focus of attention 
and many substances have advanced to clinical trials. Unfortunately, they failed eventually and did not 
stop or slow down cognitive decline in patients (for example [112]). In contrast to symptomatic 
improvement, these drugs are not expected to be efficient in a few months, complicating and 
increasing costs of clinical trials. Many believe that these drugs will not be beneficial to patients after 
the disease has already been recognized. Upon diagnosis of Alzheimer’s disease, neuronal damage and 
synaptic dysfunction have already occurred and are unlikely to be reversible.  
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1.3.2 Discovery and neuropathology of Alzheimer’s disease 
What happens in the brain of an Alzheimer’s disease patient? More than 100 years ago, Dr. Alois 
Alzheimer (Figure 6A) gave a remarkable lecture at a Psychiatrists Meeting in Tübingen, Germany 
[113]. He presented a case report of his former patient Auguste Deter (Figure 6B): she was severely 
demented and died at the early age of 55 at the Frankfurt Psychiatric Hospital. When Dr. Alzheimer 
autopsied her brain, he noticed aggregated plaques and neurofibrillary tangles. Surprisingly, the 
chairpersons and audience gave little attention to Alzheimer’s topic. The next year, he published an 
article about Deter’s case, called “Über eine eigenartige Erkrankung der Hirnrinde” [113–115]. His 
former mentor, Emil Kraepelin, noticed the significance of Alzheimer’s findings, published a report in 
the 8th edition of his famous textbook Psychiatrie [116] and proposed the name Alzheimer’s disease 
for the illness.  
Today, pathologists reconfirm the two primary cardinal lesions that Alois Alzheimer found in Auguste 
Deter’s brain. Firstly, extracellular plaques (Figure 6C, D) consisting of amyloid-β peptide (Aβ) that 
evolve after proteolytic cleavage of the amyloid precursor protein (APP) (described in detail in 1.3.3) 
and secondly, intracellular neurofibrillary tangles (NFTs) that consist of hyperphosphorylated τ protein 
leading to loss of synaptic function and eventually neuronal death [117]. Release of τ also triggers 
further neurodegeneration since it is neurotoxic itself [118]. During the course of the disease, neurons 
and synapses progressively perish (especially in the cortex and sub-cortex) [119]. Furthermore, the 
innate immune system responds with the activation of inflammatory processes in the diseased brain 
(for review see [120]) that can be advantageous in early stages, but promotes further neuronal cell 
death in late stages. Loss of brain mass compared to a non-diseased brain (Figure 6E, F) often is 
reported in the advanced disease stages of Alzheimer’s disease [121]. It is very challenging to 
determine if one pathological structure described above “drives the disease, is a natural bystander or 
just represents an unsuccessful repair attempt” [122], especially in end stages of Alzheimer’s disease 
when numerous biochemical pathways change and result in altered gene expression and protein levels 
compared to the healthy brain. 
These massive alterations in severe Alzheimer’s dementia obviously influence mental and physical 
health of affected patients. Deter’s symptoms were typical for a late disease stage: She lost track of 
time and space, and could not remember where she put things. She could not remember details from 
her own history and gave answers that had no connection to the question. She increasingly lost 
language, visuospatial (“where-am-I”) and behavioural skills [123] as well as became unsocial in her 
family life. Like the majority of patients in the advanced stages of the disease [124], she became 
completely helpless and lost muscle mass and mobility. Around 1905, Deter’s condition worsened and 
she became confined to bed, was confused, incontinent and unable to feed herself [125]. 
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Figure 6: The discovery of Alzheimer’s disease. (A) Alois Alzheimer, German neuropathologist and namesake of Alzheimer’s disease, 
reprinted from Hippius and Neundörfer [113]. (B) The first person diagnosed with Alzheimer’s disease, Auguste Deter, reprinted from Maurer 
et al. [126]. She died early (55 years old) after a secondary infection in 1906. Alzheimer post mortem investigated her brain and noticed 
severe abnormalities. (C-D) Schematic differences between a brain of a (C) healthy person and a (D) patient suffering from severe Alzheimer’s 
disease. Notice the two cardinal findings that are characteristic for Alzheimer’s disease: neurofibrillary tangles and senile plaques composed 
of Aβ peptide. Also, activated microglia release pro-inflammatory molecules, such as chemokines, interleukines and reactive oxygen species 
in the diseased brain. (E) Normal brain compared to a (F) brain from an Alzheimer’s disease patient with diffuse atrophy in the cortex and 
enlargement of the ventricle. Brain atrophy indicates a dementia of the Alzheimer’s type, but is not a clear diagnostic tool, images copied 
from Bird [127]. 
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1.3.3 Etiology hypotheses of Alzheimer’s disease 
Why exactly people develop Alzheimer’s disease is not elucidated up to today (except for an inherited 
variant with causal gene mutations [128–132]). Most likely, the disease is a consequence of multiple 
factors rather than one deciding cause. Age is the main risk factor as well as genetic predisposition 
exists, but many questions remain. Scientists continue to try to understand and explain Alzheimer’s 
disease etiology. The first hypothesis was based on the loss of cholinergic activity in 1982 [133]. Today, 
the most common hypothesis, suggested by John Hardy and colleagues in 1991 [134], blames 
aggregated amyloid-β peptide plaques as a causal event in Alzheimer’s disease. George Bartzokis 
questioned the amyloid hypothesis as the actual cause of Alzheimer’s disease and proposed his myelin 
breakdown hypothesis [135, 136] in 2004 as a response (see below).  
The cholinergic hypothesis  
In Alzheimer’s disease, levels of choline acetyltransferase (ChAT) and acetylcholine (ACh) (synthesized 
by ChAT) are low [133], which promotes the downfall of cholinergic neurons. This is expected to 
contribute to the disease, but is likely not a primary event in Alzheimer’s disease development. It rather 
appears that deposition of amyloid plaques negatively affects cholinergic neurons and consequently 
lowers ACh synthesis, then (as a secondary event) resulting in further damages of cholinergic neurons 
and lower ACh receptor expression [133, 137–139]. Acetylcholine esterase (AChE) inhibitors target this 
effect in Alzheimer’s disease therapy. By inhibiting the degrading enzyme, ACh concentration and 
duration are elevated, thereby easing the patients’ symptoms in early and moderate disease stages.  
The amyloid hypothesis  
According to the widely postulated amyloid-β hypothesis [134, 140, 141], the accumulation of the 
neurotoxic Aβ plaques causes Alzheimer’s disease, caused by either elevated Aβ42 production in the 
diseased brain or by decreased physiologic Aβ42 clearing processes. Aβ plaques derive from the 
amyloid precursor protein (APP) that is naturally expressed in the brain (Figure 7).  
Special proteases – so-called α-, β- and γ-secretases - sequentially cleave the transmembrane APP and 
different APP fragments evolve. In the non-amyloidogenic pathway, α-secretase cleaving results in a 
soluble APPα fragment, which will not form plaques (Figure 7A). In the amyloidogenic pathway, 
consecutive cleaving of β- and γ-secretases occurs (Figure 7B). Firstly, β-secretase (also called BACE1) 
cuts off a soluble APPβ fragment and leaves a 99 amino acid long fragment in the plasma membrane. 
Secondly, the γ-secretase cleaving leads to the neurotoxic peptide composed of 42 amino acids (Aβ42), 
which is highly hydrophobic and tends to form complexes – resulting in the characteristic extracellular 
plaque formation (Figure 7B). Regulating secretase activity can therefore influence Aβ42 burden: 
γ-secretase blockers reduce Aβ42 level by complete enzyme inhibition, whereas γ-secretase 
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modulators elegantly promote a switch from Aβ42 to Aβ38 without affecting other important pathway, 
such as Notch (Figure 7C), a highly conserved, evolutionary ancient cell signaling pathway present in 
most multicellular organisms (for review see [142]). 
The myelin breakdown hypothesis 
Another model was postulated by Bartzokis in 2004 [135, 136]. He criticized that the amyloid 
hypothesis does not explain recent failures in clinical trials, when Aβ burden reduction failed to reduce 
cognitive decline. Bartzokis proposed that myelin (produced by oligodendrocytes) is involved in 
essential circuit functions and is especially vulnerable to damage, thereby promoting Alzheimer’s 
disease. Hardy countered that the amyloid hypothesis was accurate, but that the damage after Aβ 
deposition already occurred, was irreversible [128]. 
 
 
Figure 7: The molecular generation of Aβ plaques. (A) Aβ plaques derive when the amyloid precursor protein (APP), which is expressed in 
the healthy brain, undergoes a specific proteolytic pathway. Most of the APP is cleaved by α-secretase, leading to a non-toxic, solvable 
fragment (sAPPα) and a smaller fragment in the membrane (non-amyloidogenic). (B) The other cleaving pathway results in neurotoxic Aβ 
species: APP is first cleaved by β-secretase, which leaves a 99 amino acid long fragment in the membrane. In the next step, the γ-secretase 
complex cuts off the upper 38-43 amino acids, leading to the amyloidogenic Aβ42. This Aβ species is highly hydrophobic and hence forms 
complexes (Aβ plaques). Flurbiprofen (FBP) and other non-steroidal anti-inflammatory drugs can modulate γ-secretase activity and therefore 
might be beneficial for Alzheimer’s disease therapy. Adapted and modified from LaFerla et al. [143]. (C) γ-secretase activity can be 
pharmacologically regulated: while γ-secretase blockers result in decreases of Aβ38, Aβ40 and Aβ42 production and a down regulated Notch 
pathway, γ-secretase modulators switch the preference from Aβ42 to Aβ38 without affecting Aβ40 levels or Notch signaling (for further 
information see [144]). 
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1.3.4 Alzheimer’s disease variants 
Two variants of Alzheimer’s disease exist: A rare, early onset familial variant caused by gene mutations 
and a much more common sporadic variant with no obvious cause:  
Familial Alzheimer’s disease 
In the familial variant, causal mutations in APP processing genes facilitate the formation of neurotoxic 
Aβ species (Figure 7). Either the APP gene itself or γ-secretase-encoding genes (PSEN-1 or -2) are 
mutated – both resulting in elevated Aβ42 production. In the Swedish APP mutation variant 
(N/L670/671K/M), more Aβ42 is produced because the β-secretase prefers the mutated APP variant, 
thereby favoring the amyloidogenic pathway [128–132]. Causal gene mutation cases only comprise up 
to 10 % of patients. A recent article reported that Auguste Deter was one of them. After exhumation 
of her body for genome analysis, a mutation associated with familial Alzheimer’s disease was found 
[145].  
Sporadic Alzheimer’s disease 
Far more patients (90-95 %) suffer from the sporadic variant with no obvious cause. The main risk 
factor is aging, but various other factors may have an impact (e.g., infections or cardiovascular 
diseases). In terms of genetics, genome-wide association studies revealed risk correlations [128], like 
variations in endosomal vesicle recycling genes [146, 147]. Also, altered cholesterol homeostasis can 
lead to AD, especially apolipoprotein E (ApoE) variations play a major role in incidence: People carrying 
one or two copies of the E4 allele of apolipoprotein E (ApoE4) have an increased risk compared to 
other isoforms (such as the most common variant ApoE3) [148]. In the central nervous system, ApoE 
serves as the major carrier for cholesterol, playing a key role in synaptogenesis and repair mechanisms, 
which may directly cause faster AD progression. Interestingly, the different ApoE isoforms differ in 
their cholesterol transport capacity – and ApoE4 is the least efficient. Other interesting relationships 
between cholesterol and Alzheimer’s disease exists: intracellular cholesterol has been found to 
interfere with Aβ production [149] and Aβ can modulate cholesterol metabolism in the brain [150]. 
ApoE4 expressing cells also seem to be less effective in Aβ clearance and degradation and a negative 
effect in immunomodulation is suspected [151–154]. Furthermore, altered innate immune system 
responses [155] can increase the risk for AD [156, 157]: For example, fibrillary amyloid can bind to the 
complement factor C1 that activates the classical complement cascade [158, 159] promoting an 
inflammatory response. In addition, astroglia and microglia bear Toll-like receptors that recognize 
fibrillary amyloid. The role of these activated microglia can at the same time be beneficial (involved 
brain repair) and harmful (pro-inflammatory) [160–162]. Furthermore, variants in innate immunity 
genes can be a risk factor for Alzheimer’s disease [155].   
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1.3.5 Alzheimer’s disease risk reduction factors 
A minority of people seems to have a considerably lower risk of Alzheimer’s disease than the rest of 
the population: For example, a recent study reported of a natural APP gene mutation in a cohort of 
Icelanders that is associated with a lower risk for Alzheimer’s disease and dementia [163]. Also 
nutrition factors, such as intake of long-chain Ω-3 polyunsaturated fatty acids, are debated to protect 
from Alzheimer’s disease, but so far failed to be effective in clinical trials [164–167]. Even psychosocial 
factors (higher education, sports) are discussed to potentially lower the disease risk (for review see 
[168]). Remarkably, retrospective epidemiologic studies revealed that patients suffering from 
rheumatoid arthritis actually are less likely to develop Alzheimer’s disease [169]. Apparently, their pain 
medication evokes a protective effect.  
Painkillers against Alzheimer’s disease? 
Patients affected with rheumatism receive high doses of non-steroidal anti-inflammatory drugs 
(NSAIDs) for a long period. Numerous epidemiologic studies suggested that a sustained intake of 
NSAIDs during the therapy of rheumatoid arthritis reduced the risk of developing Alzheimer’s disease 
[169]. Consequently, NSAIDs were proposed for the treatment and prevention of Alzheimer’s disease 
nearly 25 years ago [170]. Scientists believed that NSAIDs either were beneficial due to their anti-
inflammatory properties or because they might directly target the amyloid processing [171–173]. In 
fact, NSAIDs are able to lower neurotoxic Aβ species [174, 175] by modulating γ-secretase activity 
(Figure 7C). For example, sulindac sulphide, ibuprofen and indomethacin were shown to lower 
neurotoxic Aβ42 production in vitro and in vivo rodent models [174, 175].  
The flurbiprofen failure 
Another promising NSAID candidate for Alzheimer’s treatment was flurbiprofen (FBP). The enantiomer 
of the racemic mother molecule R-flurbiprofen (Tarenflurbil, FlurizanTM) can lower Aβ42 species in vitro 
[176–178] (Figure 7C), but elegantly lost its influence on the cyclooxygenases (COX) 1 and 2. This 
feature was sought for in order to reduce the classical severe side effects mediated by COX activity 
alteration during high dose NSAID therapy.  
For several years, Myriad Genetics (an American molecular diagnostic company) conducted research 
and clinical trials to investigate R-flurbiprofen’s potency for Alzheimer disease therapy, but 
discontinued the development in 2008 [179–181]. R-flurbiprofen still showed some benefits in a phase 
II clinical trial for patients with mild Alzheimer’s disease, but failed in a phase III clinical trial, because 
it did not significantly improve patients’ thinking ability or influenced daily activities [182–184]. 
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Flurbiprofen (like many other NSAIDs) only poorly distributes to the brain parenchyma and hence may 
have failed to reduce Aβ42 in a satisfactory quantity in vivo. Although the substance is fairly lipophilic 
and consequently is expected to readily cross the BBB, distribution in the CNS is limited, because 
flurbiprofen tightly binds to plasma proteins [185]. Therefore, availability of flurbiprofen in the brain – 
if applied in low to moderate doses - is very restricted, potentially prohibiting a neuroprotective effect 
regarding Alzheimer’s disease pathology. In fact, only >5 % of applied acidic NSAIDs (ibuprofen, 
flurbiprofen, ketoprofen, naproxen) reach the brain or the cerebrospinal fluid (CSF) [177, 185–188].  
In vitro experiments suggest that flurbiprofen efficiently decreases amyloid burden in cellular 
Alzheimer’s disease models at concentrations of 50 µM and higher [68, 172]. In contrast, less than 
1.5 µM of ibuprofen or flurbiprofen is achieved at normal plasma concentration in in vivo experiments 
[185–188]. Higher doses (as given in rheumatoid arthritis) would be required to achieve a desired 
NSAID effect in the brain in patients, but the severe gastrointestinal side effects and toxicity rules out 
high dose treatment. 
Therefore, it is desired to improve the NSAIDs’ bioavailability in the brain in order to increase a 
potential therapeutic effect while reducing peripheral doses and associated side effects. Packing 
flurbiprofen into nanoparticles is expected to increase brain distribution by reducing plasma protein 
binding and masking the physicochemical characteristics of the drug. Nanoparticle-mediated brain 
transport has been shown to be effective in various cases, and can be further optimized by specific 
ligand coupling to even increase active nanoparticle uptake mechanisms.  
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2 AIM OF THIS THESIS 
Brain drug development is a highly complex task, regarding that the vast majority of substances cannot 
cross the blood-brain barrier (BBB) in vivo. Unfortunately, many of the in vitro models of the BBB –
originally intended to facilitate brain drug development – actually rather confuse the situation, 
because they often do not reflect the insurmountable obstacle of the BBB. By being more permeable 
than the in vivo BBB, unsuited in vitro BBB models lead to a plethora of false positive brain drug 
candidates. Therefore, a great need exists for reliable in vitro screening methods in order to predict 
BBB crossing capacity. Thus, substances that show little promise for in vivo success could be better 
identified and the enormous expenses of further investigation could be restricted. 
This thesis aims at identifying and investigating an in vitro model that displays excellent barrier 
qualities. Nevertheless, the in vitro model is supposed to be only moderately complex in order to allow 
high-throughput approaches for pharmaceutical industries in the long term. Here, primary 
brain material from the domestic pig Sus scrofa was selected, because it is expected to be 
advantageous for BBB model formation compared to a cell-line based approach for various reasons, 
including high genetic comparability to humans and large availability from slaughter processes 
intended for food production. The suitability of the model was intended to be assessed by state-of-
the-art techniques, such as investigating the expression of essential tight junction proteins and BBB-
relevant receptors, defining transendothelial electrical resistance and determining the permeability 
capacitance of radiolabeled marker substances across the barrier. 
After verifying a proper barrier function of the in vitro model, this thesis intends to address the 
question: Are nanoparticles a potential tool to allow transport of drugs that could not enter the brain 
by themselves? Specifically, this work should focus on the non-steroidal anti-inflammatory drug 
(NSAID) flurbiprofen. Flurbiprofen was proposed as an anti-Alzheimer’s disease drug, because it 
showed promising results in Aβ42 reduction in vitro and in vivo experiments and nevertheless failed in 
clinical trials, probably due to its poor distribution to the CNS. This study aims at revisiting the drug by 
incorporating it into nanoparticles for BBB transit. Various nanoparticular characteristics, such as 
influence on the barrier formation, the viability or integrity of BBB model cells should be investigated 
in this thesis. The actual drug transport capacity of the nanoparticles and, eventually, the ability to 
reduce Aβ42 should be assessed, and possibly increased by optimizing the nanoparticular formulations 
by surface modifications or adjusting the choice of basis material to influence drug release profiles. 
In addition, this work aims at discussing to what extend other diseases could profit from NSAID-loaded 
nanoparticles and which other pathways could causally be targeted in Alzheimer’s disease pathology, 
benefitting from nanotechnology. 
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3 EXPERIMENTAL PROCEDURES   
3.1 Materials  
Utensils and consumables 
Item Supplier 
CELLSTAR® aspirating pipettes Greiner Bio-One, Frickenhausen, Germany 
CELLSTAR® cell culture flasks Greiner Bio-One, Frickenhausen, Germany 
CELLSTAR® multiwell culture plates  Greiner Bio-One, Frickenhausen, Germany 
CELLSTAR® serological pipettes, div. sizes Greiner Bio-One, Frickenhausen, Germany 
Culture slides, glass, div. sizes BD Bioscience, Heidelberg, Germany 
FACS tubes (Polystyrene, Round-Bottom Tube)  Becton Dickinson, Heidelberg, Germany 
Microscopy chamber ibidi, Martinsried, Germany 
Plastic scintillation vials PerkinElmer, Boston, USA 
Storage bottles, polystyrene, div. sizes  Corning, Wiesbaden, Germany 
Transwell® inserts (3 µm and 0.4 µm pore size) Corning, Wiesbaden, Germany 
VACUETTE® EDTA Tubes Greiner Bio-One, Frickenhausen, Germany 
Vacuum filtration system TPP, Trasadingen, Switzerland 
VerexTM HPLC vials Phenomenex, Aschaffenburg, Germany 
Antibodies 
Primary antibodies  
Name Antigen  Host Supplier   
Anti-ApoA4 Apolipoprotein A4 (ApoA4) Mouse Cell Signaling, Boston, USA 
Anti-ApoE3 Apolipoprotein E3 (ApoE3) Mouse Cell Signaling, Boston, USA 
Anti-ApoER Apolipoprotein E Receptor (ApoER) Mouse Acris, Herford, Germany 
Anti-Cld-3 Claudin 3 (Cld-3) Rabbit  abcam, Cambridge, UK, 
Anti-Cld-5 Claudin 5 (Cld-5) Rabbit  abcam, Cambridge, UK 
Anti-LDLR LDL Receptor (LDLR) Rabbit  abcam, Cambridge, UK 
Anti-LRP1 Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Mouse  Kind gift from C. Pietrzik, Mainz 
Anti-LRP2 Low Density Lipoprotein Receptor-related Protein 2 (LRP2) Mouse abcam, Cambridge, UK 
Anti-Occl Occludin (Occl) Rabbit  abcam, Cambridge, UK 
Anti-ZO-1 Zonula occludens (ZO-1) Rabbit  ZYTOMED, Berlin, Germany 
    
Secondary antibodies 
Name Conjugation Isotype Supplier  
Goat Anti-Mouse  Alexa Fluor® 488 IgG Invitrogen, Molecular Probes, 
Eugene, USA 
Goat Anti-Rabbit  Alexa Fluor® 488 IgG Invitrogen, Molecular Probes, 
Eugene, USA 
Rabbit-Anti-Mouse Horseradish peroxidase IgG Santa Cruz, Dallas, USA 
Spectra data of dyes and conjugates 
 Excitation [nm] Emission [nm] 
Alexa Fluor® 488  495 519 
CellTracker™ Blue CMAC  353  466 
CellTracker™ Red CMTPX  577 602 
DAPI 358 461 
Lumogen® F Orange 240 524  539  
PromoFluor-488 Premium  490 516 
PromoFluor-633 635 658 
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Chemicals, biologicals and kits 
Item Supplier 
14C-diazepam  Hartmann Analytic, Braunschweig, Germany 
14C-inulin  PerkinElmer, Boston, USA 
Acetonitrile Sigma-Aldrich, Steinheim, Germany 
AEBSF  Sigma-Aldrich, Steinheim, Germany 
alamarBlue® cell viability assay reagent Invitrogen, Karlsruhe, Germany 
ApoE3 human recombinant, expressed in E. coli Sigma-Aldrich, Steinheim, Germany 
Aqua ad iniectabilia Berlin-Chemie, Berlin, Germany 
Aβ42 human ELISA Kit Life Technologies, Darmstadt, Germany 
BD Cytofix/Cytoperm™ Kit BD Biosciences, San Diego, USA 
Bovine Serum Albumin  PAA Laboratories, Pasching, Germany 
Carboxy-(PEG)4-amine Thermo, Langenselbold, Germany 
CellTrackerTM Blue CMAC and Red CMTPX  Invitrogen, Karlsruhe, Germany 
Collagen from human placenta, type IV Sigma-Aldrich, Steinheim, Germany 
Collagenase Biochrom, Berlin, Germany 
Dichloromethane Sigma-Aldrich, Steinheim, Germany 
Dispase® II (neutral protease, grade II) Roche Diagnostics, Mannheim, Germany 
Coomassie Brilliant Blue R-250 Bio-Rad Laboratories, Munich, Germany 
Divinylsulfone Sigma-Aldrich, Steinheim, Germany 
DMEM/F-12  Invitrogen, Karlsruhe, Germany 
DNAse Roche Diagnostics, Mannheim, Germany 
Easycoll Separating Solution Biochrom, Berlin, Germany 
EDC AppliChem, Darmstadt, Germany 
Ethyl acetate Sigma-Aldrich, Steinheim, Germany 
FACS-Flow, -Clean, -Rinse Becton Dickinson, Heidelberg, Germany 
Fetal Bovine Serum   Sigma-Aldrich, Steinheim, Germany 
Fetal Bovine Serum Gold  PAA Laboratories, Pasching, Austria 
Flurbiprofen Sigma-Aldrich, Steinheim, Germany 
Geneticin®  Invitrogen, Karlsruhe, Germany 
Gentamicin  Invitrogen, Karlsruhe, Germany 
HEPES  Invitrogen, Karlsruhe, Germany 
Hydrocortisone solution Sigma-Aldrich, Steinheim, Germany 
L-glutamine  Invitrogen, Karlsruhe, Germany 
Lumogen® F Orange 240  BASF, Ludwigshafen, Germany 
M199 Invitrogen, Karlsruhe, Germany 
MANNIT 20 %, mannitol solution Serag-Wiessner, Naila, Germany 
MEM NEAA Invitrogen, Karlsruhe, Germany 
MEM Vitamins Invitrogen, Karlsruhe, Germany 
Newborn Calf Serum  Biochrom, Berlin, Germany 
N-hydroxysulfoxuccinimide Sigma-Aldrich, Steinheim, Germany 
Nu-Serum™ IV  BD Biosciences, Heidelberg, Germany 
Ovalbumin from hen egg white Sigma-Aldrich, Steinheim, Germany 
Paraformaldehyde  Sigma-Aldrich, Steinheim, Germany 
Penicillin-Streptomycin  Invitrogen, Karlsruhe, Germany 
Phosphate buffered saline  Invitrogen, Karlsruhe, Germany 
Phosphate buffered saline, pH 7.2 Invitrogen, Karlsruhe, Germany 
Poly(lactic acid) (PLA) Sigma-Aldrich, Steinheim, Germany 
Polyvinyl alcohol (PVA) Sigma-Aldrich, Steinheim, Germany 
Potassium chloride solution (0.075 M) Sigma-Aldrich, Steinheim, Germany 
PromoFluor-488 Premium Labeling Kit PromoCell, Heidelberg, Germany 
PromoFluor-633 Labeling Kit PromoCell, Heidelberg, Germany 
Protein Assay Bio-Rad Laboratories, Munich, Germany 
RESOMER® RG502H and RG752H Evonik Industries, Essen, Germany 
Sodium chloride  Sigma-Aldrich, Steinheim, Germany 
SolvableTM PerkinElmer, Boston, USA 
Trifluoroacetic acid  Sigma-Aldrich, Steinheim, Germany 
Trypsin EDTA Invitrogen, Karlsruhe, Germany 
Tween®80  Sigma-Aldrich, Steinheim, Germany 
Ultima Gold, Scintillation fluid  PerkinElmer, Boston, USA 
VECTASHIELD® Hard SetTM mounting medium (+/- DAPI)  Vector Laboratories, Burlingame, USA 
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Software 
Software  Provider 
CellQuest Pro Becton Dickinson, Heidelberg, Germany 
cellZscope® 2.1.2 nanoAnalytics, Münster, Germany 
ChemStation® 1.7 Agilent Technologies, Waldbronn, Germany 
CorelDRAW® Graphics X6 Corel Corporation, Ottawa, Canada 
Leica Application Suite X (LAS X) Leica Microsystem, Heidelberg, Germany 
Microsoft Office 2010 & 2013 Microsoft Corporation, Redmond, USA 
OriginPro 9.1G OriginLab Corporation, Northampton, USA 
QuantaSmart software  PerkinElmer, Boston, USA 
Zeiss ZEN 2009 Zeiss, Jena, Germany 
 
Hardware 
Item Supplier 
Agilent 1200 and 1260 Infinity HPLC device Agilent Technologies, Waldbronn, Germany 
Analytical balance CP64 Sartorius, Göppingen, Germany 
Biofuge stratos Heraeus, Hanau, Germany  
CASY® Cell Counter + Analyzer System OLS OMNI Life Science, Bremen, Germany 
CC-12 camera Soft imaging systems, Münster, Germany 
cellZscope® device  nanoAnalytics, Münster, Germany 
Centrifuge 3K18 Sigma Laboratory Centrifuges, Osterode am Harz, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Centrifuge Biofuge Pico Thermo Scientific, Langenselbold, Germany 
Centrifuge Biofuge R Thermo Scientific, Langenselbold, Germany 
Dispersion tools S25N-10G and S25NK-19G Ultra Turrax®, IKA, Staufen, Germany 
Excitation light source, mercury lamp X-Cite®, series 120 Lumen Dynamics Group Inc., Mississauga, Canada 
Flow cytometer FACS Calibur Becton Dickinson, Heidelberg, Germany 
Gemini® NX 250-C18 column Phenomenex, Aschaffenburg, Germany 
Heraeus® BBD6220 Incubators  Thermo Scientific, Langenselbold, Germany 
Leica TCS SP8 confocal microscope Leica Microsystem, Heidelberg, Germany 
Microscopes CKX31 and IX70 Olympus, Hamburg, Germany 
Mini centrifuge Biozym Scientific, Hessisch Oldendorf, Germany 
Poroshell 120 EC-C18 column  Agilent Technologies, Waldbronn, Germany 
Poroshell 120 UHPLC Guard EC-C18 Pre-column  Agilent Technologies, Waldbronn, Germany 
TECAN infinite® 200 microplate reader Tecan Group, Maennedorf, Switzerland 
Tri-Carb 2910TR, liquid scintillation counter PerkinElmer, Boston, USA 
TSKgel Super SW3000 column Tosoh Bioscience, Stuttgart, Germany 
Ultra Turrax® device T25 digital Ultra Turrax®, IKA, Staufen, Germany 
Zeiss LSM 510 confocal microscope Zeiss, Jena, Germany 
Zetasizer PN3702 Malvern Instruments, Malvern, UK 
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Origin of cell lines and primary cells 
Cells Type Biological source Provider 
    
7WD10 Human APP gene transfected cell line Cricetulus griseus Kind gift from Claus Pietrzik, Institute 
for Pathobiochemistry, Mainz 
University, Germany 
bEnd3 Polyoma middle T antigen transformed brain 
endothelioma cells 
Mus musculus LGC Promochem, Wesel, Germany 
HBMEC SV-40 transfected human brain microvascular 
endothelial cells 
Homo sapiens Kind gift from Kwang Sik Kim, Division 
of Pediatric Infectious Diseases, Johns 
Hopkins University School of 
Medicine, Baltimore, USA 
pBCEC Primary porcine brain capillary endothelial cells Sus scrofa domestica Freshly prepared from primary 
material from local slaughterhouse 
(Zweibrücken, Germany) 
Media composition & coatings for cell culture 
Medium stocks were prepared in a maximum volume of 500 ml, only small volumes were pre-heated 
to 37 °C prior to use in cell culture. All basis media were obtained from Gibco®, Life Technologies. Fetal 
calf serum was obtained from PAA or Sigma-Aldrich. 
Growth surfaces for endothelial cells (pBCEC, bEnd3, HBMEC) were pre-coated with 0.1 mg/ml 
collagen type IV from human placenta in 0.25 % acetic acid / PBS (1:4). A total of 180 µl/cm2 of this 
solution was incubated for 2 hours at 37 °C, washed with PBS and cells were seeded when the growth 
surfaces were still moist. 
 
Cell type Basis (Cat. No. Gibco®) medium Sera Antibiotics Additives 
     
7WD10 MEM α (22571)  10 % FCS 1 % Pen/Strep 
400 µg/ml Geneticin®  
 
 
bEnd3 DMEM (41965) 10 % FCS  
 
 
HBMEC RPMI 1640 (21875) 10 % FCS 
10 % Nu-Serum 
1 % Pen/Strep 2 mM L-glutamine 
1 mM sodium pyruvate 
1x MEM NEAA 
1x MEM Vitamins 
 
pBCEC 1st  M199 (31150) 10 % NCS 1 % Pen/Strep 
1 % Gentamycin 
 
0.7 mM L-glutamine 
pBCEC 2nd DMEM/F-12 (11039) 0 or 5 % FCS 1 % Pen/Strep 
1 % Gentamycin 
1.5 mM L-glutamine 
550 nM hydrocortisone  
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3.2 Methods 
3.2.1 Cell culture 
All cell culture work was performed under sterile conditions to avoid contamination with bacteria, 
fungi or other microorganisms. Consumable materials and reagents were either sterilized by the 
supplier or autoclaved, ethanol-sterilized or sterile-filtered prior to use. All applied chemicals were of 
highest purity. Mycoplasma contamination of cell lines was tested for in frequent intervals. 
Cultivation of cell lines 
Endothelial cell lines of murine and human origin (bEnd3, HBMEC) were cultured at 37 °C, 5 % CO2 and 
95 % relative air humidity in an incubator. For splitting, cells were washed with PBS and incubated with 
trypsin-EDTA (0.5 %) until more than 90 % of the cells detached. Addition of culture medium inhibited 
the trypsin effect and rinsed off the remaining cells. After centrifugation, the cell sediment was 
resuspended in medium and cultured accordingly to further application. bEnd3 and HBMEC were 
allowed to reach confluence before splitting and seeding.  
Isolation and cultivation of primary porcine brain capillary endothelial cells  
Primary porcine brain capillary endothelial cells (pBCEC) were dissected following a protocol of Wagner 
et al. [26]. Directly after slaughtering fresh porcine skulls from Sus scrofa domestica (Figure 8A) were 
kindly provided by the local slaughterhouse in Zweibrücken, Germany. Slaughtering occurred in 
accordance with the guideline 93/119/EC of the European Community on the protection of animals at 
the time of slaughter or killing from 22.12.1993. At the Fraunhofer IBMT, skulls were sprayed with 
disinfecting agent and the skullcap was removed (Figure 8B) to prepare cerebral tissue. The outermost 
layers of the meninges (Dura mater and Arachnoidea mater) were removed. The brain was carefully 
detached from the brainstem (Truncus encephali) and transferred to a transport buffer. All following 
steps were performed under sterile conditions in an airflow hood. The remaining meningeal 
membrane (Pia mater) and major blood vessels were stripped off (Figure 8C) and the grey matter was 
collected and minced into pieces (Figure 8D). For homogenization and release of capillary fragments, 
the gray matter was digested with the same volume of dispase II solution at 37 °C for 70 minutes under 
stirring. Afterwards, the capillary fragments were divided from the connective tissue with the aid of a 
discontinuous density gradient (30 min, 4 °C, and 822 g, without brake) (Figure 8E). The fatty 
supernatant was removed after centrifugation and capillary fragments were transferred to fresh 
medium. After centrifugation (20 min, 4 °C, 235 g) to wash out remaining percoll, the cells were 
digested in collagenase II solution (20 min, 37 °C, 150 rpm on a shaking incubator) with frequent 
resuspensions. This step allows separation of brain capillary cells from non-endothelial tissue, because 
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collagenase II segregates intercellular connections and the basal lamina. Subsequently, DNAse was 
added at 37 °C for 3 minutes to prevent clumping of capillary fragments due to unleashed DNA. Next, 
the cell suspension was filtered with the aid of a cell strainer (70 µm pore size) in order to discard larger 
undigested microvascular capillary fragments and to singularize cells. After centrifugation (10 min, 
4 °C, 376 g) the cell pellet was resuspended in 1 ml DMEM and transferred onto a continuous density 
gradient (20 min, 10 °C, 312 g, no brake), that was freshly prepared (45 min, 21 °C, 14,500 g, no brake). 
This second density gradient allowed separation of brain capillary endothelial cells from other cells and 
permitted a homogenous, pure cell culture. The upper fraction containing the pBCEC was collected 
and transferred to PBS for centrifugation (10 min, 4 °C, 258 g). To remove remaining erythrocytes, the 
pellet was resuspended twice in 1 ml erythrocyte lysis buffer and subsequently centrifuged (5 min, 
4 °C, 165 g) (Figure 8F). Finally, the cells were washed two times in DMEM and resuspended in a 
medium containing 10 % newborn calf serum (pBCEC 1st) for counting and seeding.  
After Isolation, pBCEC were plated at a density of 3.5x106 cells/cm2 on collagen IV-coated surfaces. To 
remove unattached cells and debris, a medium exchange was performed 1 hour after the initial 
seeding. Approximately 24 hours after seeding, the medium was changed to hydrocortisone-
containing medium (pBCEC 2nd) in order to support transendothelial electrical resistance (TER) 
development of the confluent monolayer, unless otherwise stated. pBCEC were not passaged and used 
for further experiments within 1 week after isolation, usually after 4 to 5 days in culture. 
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Figure 8: Selected steps of pBCEC preparation. (A) Sculls obtained from the local slaughter house. (B) Removal of skullcap after opening with 
a hatchet. (C) Isolated brain before removal of meningeal membranes. (D) Homogenization of the grey matter and preparation for dispase II 
digestion. (E) Digested brain tissue transferred to discontinuous gradient for removal of fatty supernatant. (F) Final pBCEC pellet after various 
enzymatic digestion and centrifugation steps. 
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3.2.2 Measurement of transendothelial electrical resistance of cell layers  
In the body, epithelial and endothelial cells form barriers to regulate diffuse permeation of solutes. A 
direct correlation between permeability and transendothelial electrical resistance (TER) exists as tight 
cell layers show high TER values [189]. Therefore, TER measurement is suitable for quantifying leakage 
of barrier forming tissue. 
In this work, pBCEC were plated on human collagen IV-coated (131 µg/cm2) Transwell® inserts and 
subsequently placed in the cellZscope® device, which allows non-invasive real-time monitoring of TER 
development. Transwell® controls consisted of a collagen IV-coated insert without cells. Except for 
sample applications and medium exchanges, the module stayed in an incubator (37 °C, 5 % CO2, 95 % 
relative air humidity) and was connected to an external controller and computer, allowing automated, 
long-term measurements. A cellZscope® device can monitor TER and capacitance (CCl) of cell layers that 
grow on porous membranes between two electrodes and form an interface between two 
compartments. When small alternating current voltage (Vac) is applied, the electrical impedance of the 
cell system can be measured. Ideally, the cell layer limits ion current in this setup.  
Principle of measurement 
Barrier properties can be evaluated by extracting data from equivalent circuits and corresponding 
mathematical models that allow separating the total impedance (Z) spectrum from the impedance 
spectrum of the cells. Although cell layers are complex systems, their electronic features can be 
modelled by basic elements. 
The relevant components for a cell layer’s total impedance are the ohmic resistance TER and the 
capacitance Ccl (Figure 9). The TER describes the parallel connection of the paracellular paths while the 
capacitance Ccl of the cell layer comprises both apical and basolateral membranes. Rmed is 
approximated and models the culture medium’s ohmic resistance in the apical (Rmed1) and basolateral 
((Rmed2) compartment (Figure 9). The interface between the electrodes’ metal and the cell culture 
medium is called constant phase element (CPE) and displays a complex impedance behaviour. It is 
empiric and based on the two parameters Acpe, ncpe. The cellZscope® software uses CPE as a 
mathematical model to describe the frequency-dependence of the electrode-medium interface's 
impedance. Total impedance of the system is calculated by the applied equivalent circuit and the 
corresponding mathematical models that are based on the five parameters TER, Ccl, Rmed, Acpe and ncpe.  
Obtained data from the cellZscope® device is fitted by resulting algorithms to extract the parameters 
TER and Ccl.  
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Figure 9: Schematic measurement of transendothelial electrical resistance (TER) and capacitance (Ccl) of a cell layer. Frequency dependent 
impedance is recorded and an electric equivalent circuit is used to analyze the data. Adapted and modified from nanoAnalytics [189].  
 
3.2.3 Permeability of radiolabeled model substances 
The quality of in vitro BBB model systems cannot only be monitored by measurement of the TER, but 
also by determination of the permeability of different marker substances, which is more sophisticated 
and sensitive.  
The permeability of a BBB model is expressed by the percentage of measured decays per minute (dpm) 
values of a radiolabeled substance from apical (blood-representing) and basolateral (brain-
representing) Transwell® compartments. Although Becquerel (Bq) is the Système international d’unités 
(SI)-derived unit of radioactivity, the unit Curie (Ci) is still widely used in scientific publications and 
industry and was therefore also calculated in this study. 
For the evaluation of the obtained data, the following conversion factors are essential: 
 
1  = 60 	
 
1 	
 = 0.016  
1 	
 = 1.67× 10  
1  =  2.7027 × 10  
1  =  27.027  
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For permeability assays pBCECs were isolated and prepared as described (see 3.2.1) and seeded on 
Transwell® inserts (Figure 10A) placed in a cellZscope® device. Permeability experiments occurred 
during maximum TER plateau, usually at day 4 to 5 post seeding. As a paracellular marker 14C-inulin 
was chosen (Figure 10B). Inulin is not able to cross the BBB in vivo and therefore its low permeability 
represents a good indicator for intact barrier integrity. To verify physiological conditions, a transcellular 
marker was also applied (Figure 10B). For this purpose, 14C-diazepam was selected. Diazepam is also 
known as Valium® and can diffuse through endothelial cell in vivo. For barrier characterization 
experiments, 0.35 µCi/Transwell® of 14C-inulin or 14C-diazepam (DZP) were added to the apical 
compartment. After 2 hours incubation, medium from the apical and basolateral Transwell® 
compartment was transferred to a plastic vial containing 6 ml scintillation fluid and placed into a liquid 
scintillation counter (LSC). The decay per minute (dpm) and counts per minute (cpm) data were 
calculated by the QuantaSmart software with program settings for a single dpm assay and a measured 
energy level from 0 to 156 keV.  
In order to further verify physiological conditions, the BBB model was opened by adding hyperosmotic 
1.1 M mannitol solution. In this case, permeability experiments were performed with the radiolabeled 
markers solved in 1.1 M mannitol solution (Figure 10C) with an approximate osmolality of 
1,100 mOs/ml.  
After the marker incubation, Transwell® membranes were solubilized in 1 ml SolvableTM for 4 h at 60 °C, 
transferred to scintillation fluid and also measured in LSC analysis equally like samples from basolateral 
or apical compartment.  
 
 
 
Figure 10: Schematic experimental design for permeability assays. (A) pBCEC on Transwell® inserts were incubated with radiolabeled marker 
substances when TER values were appropriate (4-5 days after preparation). After 2 hours, medium was analyzed for radioactive decays per 
minute (dpm) in a liquid scintillation counter. (B) 14C-inulin served as a paracellular marker, tight junctions should largely prohibit diffusion 
across an intact barrier. 14C-diazepam (DZP) passes the BBB transcellularly in vivo and should be detected in the basolateral compartment of 
the in vitro model. (C) When mannitol is added, pBCEC osmotically shrink, and 14C-inulin should be able to pass by the disrupted tight 
junctions. 
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3.2.4 Characterization of the in vitro models by immunocytochemistry 
For the characterization of the in vitro BBB models, primary cells or endothelial cell lines were stained 
with different antibodies for relevant markers and subsequently analyzed either by confocal laser 
scanning microscopy (CLSM) (qualitative) or flow cytometry (quantitative). Primary and secondary 
antibodies used for characterization are listed in section 3.1.  
Qualitative immunocytochemistry 
Primary pBCECs were stained with various antibodies against tight junction proteins (Cld-3, Cld-5, ZO-1, 
Occl). Cells were fixed with 1 % paraformaldehyde or acetone for 5-10 minutes and blocked by 
5 % fetal calf serum (FCS) or bovine serum albumin (BSA) for 20 minutes. The primary antibody was 
diluted in PBS and incubated at room temperature for 1 hour or at 4 °C overnight. Cells were washed 
twice with PBS before applying the secondary antibody for 1 hour. After washing with water or PBS, 
cell culture slides were allowed to dry for up to 1 hour. Cover glasses and VECTASHIELD® Hard SetTM 
mounting medium (with DAPI) were added and again left to dry in a refrigerator for at least two hours. 
Samples were then analyzed with the aid of a confocal laser scanning microscope (CLSM).  
Quantitative immunocytochemistry  
For determination of the receptor status of the in vitro BBB model, flow cytometry analysis was 
performed after immunostaining for receptors of the low density lipoprotein receptor family (LDLR, 
LRP1, LRP2, ApoER). The pBCEC, bEnd3 or HBMEC were detached from growth surface by trypsin-EDTA 
incubation (0.5 %, 37 °C, 5-10 min). After washing, 3x105 – 1x106 cells were transferred to FACS tubes 
and incubated with BD Cytofix/Cytoperm solution for 20 min at 4 °C and subsequently with blocking 
solution (5 % FCS in PBS) for 30 min at 4 °C in order to prevent unspecific antibody binding. Then, 
blocking solution was removed and cells were incubated with 50 µl primary antibody (0.5-1 µg in PBS) 
for at least 1 hour at 4 °C. Afterwards, cells were washed again and incubated with the secondary 
antibody (0.5-1 µg in 50 µl PBS) for 30 min at 4 °C in the dark, washed again and resuspended in FACS-
Fix solution before further analysis. Washing was performed with BD Perm/Wash solution and PBS. 
Samples were analyzed by flow cytometry with a FACS Calibur device. An electronic gate was set for a 
mother population of adequate control cells (treated identically, but without primary antibody 
incubation). 10,000 cells were recorded for each investigated sample and analyzed with the CellQuest 
Pro software. For analysis, a threshold was set for fluorescence intensity of the control population. 
Sample signals exceeding the threshold were counted as “positive” for the respective staining, 
(expressed either as “% positive”).  
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3.2.5 Nanoparticle preparation and characterization  
All nanoparticles used in this study were prepared at the Institute for Pharmaceutical Technology and 
Biopharmacy (IPTB) at Münster University by Dr Iavor Zlatev and Bastian Raudszus. 
Drug-loaded human serum albumin (HSA) nanoparticles 
To prepare drug-loaded human serum albumin (HSA)-based nanoparticles two protocols were used. 
For the solvent displacement technique 0.5 ml aqueous HSA solution (40 mg/ml; pH 8) and 0.4 ml FBP 
(10 mg/ml) in water (pH 8) were added to 0.1 ml of water and were incubated for 2 h in a 
Thermomixer® (20 °C, 650 rpm). Afterwards, 4 ml ethanol 90% (m/m) were added dropwise in a 
velocity of 1 ml/min under constant stirring. After centrifugation (10 min, 16,000 g) and washing, the 
synthetized nanoparticles were collected and the amount of incorporated FBP was detected by HPLC 
analysis. Solvent displacement with PEG4000 was performed the like solvent displacement technique 
above, but instead of ethanol, 4 ml PEG4000 (300 mg/ml) in water (pH 5.5, 5.8 or 6.1) were added.  
The inverse solvent displacement technique was similar to the solvent displacement technique, but 
instead of adding ethanol to a HSA solution, the process was inversed, resulting in addition of the 
aqueous HSA-FBP solution (described above) to 4 ml ethanol 90% (m/m). Next, 11.6 µl glutaraldehyde 
(80 mg/ml) in water were added and stirred overnight.  
Drug-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
For preparation of poly(lactic-co-glycolic acid) (PLGA) nanoparticles two different techniques and two 
different PLGA polymers (differing in proportions of lactide and glycolide) were used. For oil/water 
(o/w) emulsion diffusion technique, either 100 mg RESOMER® RG502H (lactide : glycolide 50:50 ) or 
100 mg RESOMER® RG752H (lactide : glycolide 75:25) and 10 mg FBP were dissolved in 1 ml ethyl 
acetate (organic phase). Then, 2 ml polyvinyl alcohol (PVA) in water (10 mg/ml) was added (aqueous 
phase). For O/W emulsion, the sample was homogenized in an UltraTurrax® device (30 min, 
21,000 rpm, dispersion tool S25N-10G). The emulsion was then transferred to 8 ml PVA in water 
(10 mg/ml) and magnetically stirred in an exhaust hood for at least 3 hours for ethyl acetate 
evaporation. The thereby produced nanoparticles were centrifuged and redisperged five times in PBS 
(pH 8) or water for washing. For detection of incorporated FBP, 20 µl nanoparticle suspension were 
added to 980 µl acetone and mixed for 5 min at 20 °C with a Thermomixer® device (20 °C, 700 rpm). 
After centrifugation (20 min, 20,000 g), FBP content was analyzed by HPLC.   
For water/oil/water (w/o/w) emulsion evaporation technique, 0.5 ml FBP (20 mg/ml in water, 
pH 12.3) and 2.5 ml RESOMER® RG502H in dichloromethane (40 mg/ml) was homogenized by 
UltraTurrax® (1 min, 18,000 rpm, dispersion tool S25N-10G), resulting in a pre-emulsion. For w/o/w 
double emulsion, the pre-emulsion was added to 14 ml PVA in hydrochloric acid (10 mg/ml, pH 2.2) 
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and again homogenized by UltraTurrax® (5 min, 18,000 rpm, dispersion tool S25NK-19G). The pH was 
adjusted to 5.8 by NaOH. For dichloromethane removal, the sample was stirred on a magnetic stirrer 
(220 rpm) overnight under an exhaust hood. The produced nanoparticles were centrifuged and 
redisperged five times in PBS (pH 8) or water for washing. The detection of incorporated FBP was 
performed by HPLC analysis as described above for o/w emulsion diffusion technique prepared PLGA 
nanoparticles.  
Drug-loaded poly(lactic acid) nanoparticles 
Nanoparticles based on poly(lactic acid) (PLA) were produced by an emulsion diffusion technique 
(Figure 11A) as previously described [68]. In brief, the organic phase (100 mg PLA and 10 mg FBP 
dissolved in 2 ml dichloromethane) and aqueous phase (12 ml polyvinyl alcohol (2%, w/v)) were 
homogenized with an Ultra Turrax® device (24,000 rpm, 30 min) in an ice bath. If visualization of the 
nanoparticles for flow cytometry and microscopy analysis was aimed for, the organic phase also 
contained 150 µg Lumogen® F Orange 240. Dichloromethane removal occurred by stirring overnight at 
room temperature under an appropriate exhaust hood. Nanoparticles were then collected by 
centrifugation and resdiperged and washed in purified water.  
For lyophilization, trehalose (3 % w/v) was added as a cryoprotective agent. Lyophilization steps were 
performed as indicated in Figure 11A. Lyophilized nanoparticles were freshly reconstituted in cell 
culture medium (40 mg/ml) and vortexed prior to experiments. 
For determination of flurbiprofen loading, high-performance liquid chromatography (HPLC) analysis 
was performed: 1 ml acetonitrile was added to 1 mg nanoparticles and incubated for 5 min at room 
temperature (RT). After centrifugation (20,000 g; 10 min), the 20 µl aliquots of the supernatant were 
measured with a HPLC device at a flow rate of 1 ml/min. The mobile phase consisted of acetonitrile 
and 0.1 % (v/v) trifluoroacetic acid (57.5 : 42.5, v/v), detection occurred at 245 nm wavelength.  
After preparation, particle diameter, polydispersity index (PDI), and zeta potential of drug-loaded 
nanoparticles (resdiperged in purified water) were analyzed with the aid of a Malvern Zetasizer 
Nano ZS. In this study, only nanoparticles with a PDI < 0.1 were used for further experiments, because 
the population distribution of the nanoparticles is then assumed to be monodisperse (Figure 11B, C). 
For surfactant coating, Tween®80 was added in a final concentration of 1 % to the freshly redisperged 
nanoparticles 30 min before incubation on cells and shacked at RT at 600 rpm.  
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Figure 11: Preparation and characterization of fluorescence-labeled, flurbiprofen-loaded poly(lactic acid) nanoparticles (PLA-FBP-Lum NP) 
by oil/water (O/W) emulsion diffusion technique. (A) Preparation overview. The organic phase (consisting of poly(lactic acid) (PLA), 
flurbiprofen and a Lumogen® dye, all solved in dichloromethane) was added to the aqueous phase (polyvinyl alcohol (PVA)) and was 
subsequently homogenized with an Ultra Turrax® device in an ice bath to avoid vaporization of the organic phase. Dichloromethane was 
removed by stirring overnight (220 rpm) under an exhaust hood. Nanoparticles were collected by centrifugation and redispersion in purified 
water. Before freeze drying in a lyophilization device as indicated, trehalose solution was added as a cryoprotective agent. After drying, the 
vials were sealed and stored at 4 °C until use. (B), (C) Scheme of two different nanoparticle populations that might display the same mean 
diameter. Notice that the particles in (B) share a common size distribution whereas the size and shape of the population in (C) strongly varies. 
These characteristics are important for cellular uptake and cytotoxicity. The polydispersity index (PDI) challenges this problem. If a particle 
population shows a PDI smaller than 0.1, a population of equal size and shape (=monodisperse) as shown in (B) can be assumed. 
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Ligand-modified poly(lactic acid)nanoparticles 
For apolipoprotein E3 (ApoE3) or ovalbumin modification, 15 mg PLA NP were mixed with a 5-fold 
molar excess of divinylsulfone for 5 minutes in 0.1 M NaOH (introducing amine-reactive 
vinylsulfonegroups to the particle surface). The nanoparticles were collected at 10,000 g and washed 
3 times with purified water. Afterwards nanoparticles were redisperged and incubated in 125 µl 
carboxy-(PEG)4-amine solution (4 mg/ml) overnight at room temperature and 700 rpm, resulting in 
PEGylated nanoparticles that were purified by centrifugation (10,000 g, 10 min) and redisperged in 
water. Afterwards, 80 µl of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) solution 
(30 mg/ml) and a N-hydroxysulfosuccinimide (Sulfo-NHS) solution (10 mg/ml) were added and 
incubated for 15 min at room temperature and 600 rpm, buffered by 2-(N-morpholino)ethanesulfonic 
acid (MES) at pH 4.6. The reaction leads to linking of an amine-reactive Sulfo-NHS ester to the 
PEGylated nanoparticles, allowing to covalently bind an amine-containing molecule (like a protein) to 
the nanoparticles’ surface. Excess reagent was removed by centrifugation (10,000 g, 5 min). 
Nanoparticles were redisperged in water, centrifuged a second time and then incubated with 5 mg/ml 
ApoE3 or ovalbumin in PBS (pH 7.5) for 3 hours. To determine the amount of unbound ApoE3 or 
ovalbumin, nanoparticles were centrifuged (15,000 g, 15 min) and the supernatant was analyzed in 
20 µl aliquots by gel permeation chromatography (GPC) at a flow rate of 0.35 ml/min. The mobile 
phase was PBS (pH 6.8) containing 0.1 % sodium dodecyl sulfate (SDS). Detection was performed at 
280 nm wavelength. 
As for drug-loaded nanoparticles, particle diameter, polydispersity index (PDI) and zeta potential of 
ligand-modified nanoparticles (redisperged in purified water) were analyzed with a Zetasizer device. 
Lyophilization of the ligand-modified nanoparticles was performed as described above for drug-loaded 
nanoparticles (Figure 11A).  
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3.2.6 Fluorescence labeling of proteins 
Lyophilized human, recombinant apolipoprotein E3 and the control protein ovalbumin were labeled 
with a fluorescent marker to allow detection in flow cytometry. A commercially available kit, 
PromoFluor-633 Labeling Kit was used according to the manufacturer’s instructions. Samples were 
lyophilized after preparation and freshly resolved prior to experimental use. The fluorescent label 
allowed detection at Ex 637/Em 657 nm. Protein labeling was performed at the IPTB at Münster 
University by Dr Iavor Zlatev. 
3.2.7 Nanoparticle plasma protein binding assay 
The investigation and analysis of the protein corona of PLA-FBP NP after incubation with human 
plasma was performed by Dr. Sabrina Meister of the Johannes Gutenberg University, Mainz, Germany 
as described [68, 190].  
Human blood plasma from 15 apparently healthy donors was collected at the Otorhinolaryngology, 
Head- and Necksurgery (ENT) department at the Medical University Mainz in EDTA-coated tubes to 
prevent blood clotting. The samples were anonymized in order to be untraceable back to a specific 
donor. Studies were performed according to the local ethics committee of the Medical University 
Mainz and in accordance with the Declaration of Helsinki.  
For protein corona investigation, PLA nanoparticles were incubated with an equal volume of human 
plasma sample for a defined period of time (5, 15, 30 and 60 min). Afterwards, the mixture was loaded 
onto a sucrose cushion (0.7 M in PBS) and centrifuged through cushion (12,000 rpm, 20 min, 4 °C), 
thereby allowing a separation of plasma from the nanoparticle-protein complexes. After washing the 
nanoparticle-protein pellet three times with PBS, the proteins were eluted from the nanoparticles by 
adding an equal amount of sodium dodecyl sulfate (SDS) buffer (62.5 mM Tris-HCl pH 6.8; 2 % w/v SDS, 
10 % glycerol, 50 mM DTT, 0.01 % w/v bromophenol blue) at 95 °C for 5 min (also see [68]).  
The proteins were separated by gel electrophoresis on a 12 % SDS-polyacrylamide gel that was stained 
with Coomassie Brilliant Blue R-250. Quantitative analysis of proteins was performed by using a 
commercially available protein assay kit from Bio-Rad Laboratories. Qualitative analysis of proteins 
was performed by immunochemistry. Proteins from the nanoparticles’ corona were relocated to 
polyvinylidene difluoride (PVDF) membranes, which were blocked with 5 % non-fat dry milk in tris-
buffered saline (TBS) containing 0.01% Tween® 20, before performing primary antibody staining with 
anti-ApoA4 and anti-ApoE3 and a horseradish peroxidase-coupled secondary antibody (antibodies are 
listed in section 3.1, also see [68]).  
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3.2.8 Cellular binding studies 
Different endothelial cell lines and primary cells were seeded on multi-well culture plates, previously 
coated with human collagen IV (131 µg/cm2). Samples and controls were incubated for 4 hours at 
37 °C. Nanoparticular formulations were added in a final concentration of 105.3 µg/cm2 growth 
surface. Fluorescence-labeled ApoE3 was added in a concentration of 1.053 µg/cm2 growth surface to 
simulate the approximate concentration of ApoE3 on ApoE3-modified nanoparticles (10 µg 
ApoE3/1 mg nanoparticle). After incubation, the cells were washed twice with PBS, detached from the 
growth surface by trypsin-EDTA (0.5 %) incubation and transferred into FACS tubes. Cells were again 
washed two times with PBS and subsequently fixed with FACS-Fix solution. For flow cytometry analysis, 
at least 10,000 cells per sample were counted and evaluated with the aid of CellQuest Pro software. 
Untreated control cells were used for population gating (Figure 12). Lumogen® F Orange 240 labeled 
PLA nanoparticles were detected in fluorescence channel FL-1 (Ex 488/Em 530), PromoFluor-633 
labeled ApoE3 was detected in FL-4 (Ex 633/Em 661). 
 
Figure 12: Exemplary analysis of flow cytometry data. (A) First, a cellular population is gated as control (Forward-scattered light (FSC) vs. 
sideward-scattered light (SSC)). (B) To quantify events, the threshold can be set by including approx. 1 % of the untreated control cells. (C) All 
fluorescence events above the threshold are counted as positive cells. (D) Alternatively, the parameter Y Geo Mean (reflects binding intensity) 
can be analyzed. It describes the shift of the histogram (represents signal intensity in the relevant fluorescence channel, here FL1-H). 
 
3.2.9 Cellular uptake studies 
Cellular uptake of nanoparticles can be monitored by confocal laser scanning microscopy (CLSM). For 
this purpose, primary pBCEC or the human BBB model cell line HBMEC were seeded on human collagen 
IV-coated glass cover slides and incubated with 105.3 µg/cm2 of nanoparticular formulations for 37 °C 
for 4 or 24 hours. After washing with PBS, cells were incubated with CellTrackerTM Blue CMAC according 
to the manufacturer’s instructions to stain the cytosol. Then, samples were fixed with 
1 % paraformaldehyde for 10 minutes at room temperature, dried and embedded in VECTASHIELD® 
Hard SetTM mounting medium, which either contained DAPI or not. Microscopy analysis was performed 
with a Zeiss LSM 510 or a Leica TCS SP8 confocal microscope. PLA nanoparticles were labeled with 
Lumogen® F Orange 240 for detection at 524/539 nm wavelength.  
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3.2.10 Determination of cytotoxic potential of nanoparticles 
Influence on transendothelial electrical resistance 
Transendothelial electrical resistance (TER) alteration after nanoparticle exposure was taken as an 
indirect indicator for cellular integrity and viability. TER values directly before sample incubation were 
defined as “original TER” and normalized to 100 %. After 4 hours, TER measurements were stopped 
and the latest values recorded by the cellZscope® device were averages and converted to “% of original 
TER” of each Transwell® insert. If possible, controls and sample solutions were applied in equal droplet 
size to assure comparable influence on vibration shock induced TER alteration. 
Influence on marker permeability 
To investigate the nanoparticles’ influence on barrier integrity, 0.35-0.67 µCi of 14C-inulin was directly 
added to each Transwell® after nanoparticles and controls were applied. After 2 hours of incubation, 
the medium from each compartment was collected and transferred to 6 ml scintillation fluid for 
analysis with a liquid scintillation counter. The decay per minute (dpm) and counts per minute (cpm) 
data were calculated by the QuantaSmart software with program settings for a single dpm assay and 
a measured energy level from 0 to 156 keV. 
Cellular viability  
Cellular viability can be assessed by incubation of resazurin (the active compound of alamarBlue®), 
which is blue in color, practically non-fluorescent and crosses cell membranes. Viable cells reduce 
resazurin continuously to resorufin, which is red in color and highly fluorescent, whereas non-viable 
cells loose metabolic capacity necessary for resazurin reduction. Therefore, it can be used as an 
oxidation-reduction and proliferation indicator in cell viability assays in order to measure aerobic 
respiration [191]. In this study, the cytotoxic potential of nanoparticles and other samples was 
investigated. For this purpose, freshly prepared pBCEC were seeded in 96-well plates and cultivated 
for 4 days. Subsequently, cells were incubated with different concentrations of ApoE3, flurbiprofen or 
flurbiprofen-loaded nanoparticles. Ethanol incubation served as positive control for cellular toxicity. 
After 4 hours, a medium exchange was performed and alamarBlue® solution was added according to 
the manufacturer’s instructions and incubated for another 4 hours. Fluorescence intensity was 
measured with a common plate reader at Ex/Em 560/610 nm. The intensity of the fluorescent signal is 
proportional to the number of vital cells; untreated cells were set as 100 % vital. The assay was 
controlled for effects of medium and flurbiprofen-loaded nanoparticles in order to exclude false 
positive responses. Intern replicas of experimental or no-cell control samples were performed to 
minimize experimental errors.   
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3.2.11 Nanoparticle-mediated drug transport experiments 
For drug transport experiments across an advanced in vitro BBB model, the following setup was 
chosen: Primary porcine brain capillary endothelial cells (pBCEC) were prepared from fresh skulls and 
seeded on Transwell® inserts in a cellZscope® device to monitor TER development as a quality control 
(also see 3.2.1). Four days later, when TER reached a plateau phase or was still rising, pBCEC were 
incubated with nanoparticles and other samples for 4 hours (Figure 13A). 
To assess the flurbiprofen-loaded nanoparticles’ capacity of transporting the drug across the in vitro 
BBB model, the following experiments were subsequently performed (Figure 13A-D):  
 
  
Figure 13: Overview of experimental setup for nanoparticle transport studies. (A) After isolation and cultivation, pBCEC were incubated 
with nanoparticles or control samples for 4 hours. Then, medium from the apical (blood-representing) and basolateral (brain-representing) 
compartment were either analyzed for flurbiprofen content in (B) HPLC analysis or (C) transferred to the Alzheimer’s disease model cell line 
7WD10 for 72 hours in order to perform an Aβ42-detecting ELISA with the supernatants. (D) The cellular viability of the 7WD10 cells was 
afterwards checked for in a cellular viability (alamar®Blue) assay to exclude that an Aβ42-reducing effect was caused by impaired viability. 
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Quantification of flurbiprofen by high performance liquid chromatography  
For quantitative detection of flurbiprofen, cell culture samples from basolateral compartments were 
harvested after 4 hours of incubation in the pBCEC BBB model and transferred to high performance 
liquid chromatography (HPLC) analysis (Figure 13A, B). Medium from the apical compartment was 
harvested; mixed with 0.8 ml acetonitrile to precipitate proteins and disintegrate remaining 
nanoparticles [192]. After centrifugation (10,000 g, 10 min), 500 µl of the supernatant was transferred 
to fresh vials and investigated in HPLC analysis. 
Transwell® membranes were dissolved by adding 1 ml DMSO (also described to precipitate 
proteins[193]) and centrifuged (10,000 g, 10 min) to remove polycarbonate residues.  
All supernatants were transferred to fresh vials for HPLC analysis, performed by either Dr Iavor Zlatev 
and Mr. Bastian Raudszus at IPTB at Münster University or at Fraunhofer IBMT (Table 2) with the aid 
of Ms. Linda Elberskirch. Calibration of flurbiprofen measurement was performed by DMSO-dissolved 
drug standard (IPTB: 1.5-150 µg FBP, 7 concentrations or IBMT: 0.031-250 µg FBP, 14 concentrations). 
Calculation of the calibration curve from standard served as reference for sample analysis.  
 
Table 2: Parameters for flurbiprofen detection via HPLC analysis performed at IPTB in Münster, Germany or at IBMT in Sulzbach, Germany. 
 IPTB IBMT 
HPLC device Agilent 1200 Infinity  Agilent 1260 Infinity  
Column  Gemini®-NX-C18  Poroshell 120EC-C18 
Mobile phase 57.5 % acetonitrile  
42.5 % trifluoroacetic acid (0.1 % in H2O) 
57.5 % acetonitrile  
42.5 % trifluoroacetic acid (0.1 % in H2O) 
Flow rate 1 ml/min 0.5 ml/min 
Column compartment temperature  30 °C 40 °C 
Detection Diode array detector, 245 nm Diode array detector, 247 nm 
Injection volume  20 µl  10 µl 
Runtime 8 min 8 min 
 
Functional assay for detection of Aβ42 species  
Aβ42 reducing potential of nanoparticles and control samples was assessed with a commercially 
available Aβ42 detecting ELISA (Figure 13C). Again, pBCEC were incubated with samples for 4 hours in 
the apical, blood-representing compartment of the Transwell® model when TER was sufficient. Then, 
800 µl of the medium from the basolateral, brain-representing compartments was transferred to 
24 well plates, previously seeded with 3x104 7WD10 cells/cm2. 7WD10 are Chinese hamster ovary 
(CHO) cells that stably express APP751wt for the secretion of Aβ peptide [194]. After three more days 
without further medium exchange, the supernatant of the 7WD10 cells was analyzed in an Aβ42 
detecting ELISA according to the manufacturer’s instructions. In the first step, standards of known 
Aβ42 concentration (15.63 – 1,000.00 pg/ml), samples and controls were co-incubated with an 
antibody specific for the COOH terminus of the 1-42 Aβ sequence in a microtiter plate coated with an 
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antibody specific for the NH2 terminus of the Aβ peptide. As recommended in the manufacturer’s 
instructions, the protease inhibitor cocktail 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride 
(AEBSF) was added in a final concentration of 1 mM. Bound antibody was detected by adding a 
horseradish peroxidase (HRP)-labeled antibody that recognizes the species origin of the anti-Aβ42 
peptide antibody. Next, the HRP substrate (stabilized chromogen) was added and converted to a bluish 
color by HRP (directly proportional to the amount of Aβ42). The reaction was stopped by a stop 
solution that changes color from blue to yellow and enabled detection at 450 nm with a common plate 
reader. Negative controls included chromogen blanks. All samples and standards were performed at 
least in duplex per assay. Untreated 7WD10 cell controls were set as 100 % Aβ42 level.  
Cellular Viability of the Alzheimer’s disease model cells 
In order to exclude cytotoxic effects on the Alzheimer’s disease model cells that could falsify the 
outcome of Aβ42 reduction, the cellular viability assay was performed after transport experiments 
across the pBCEC in vitro BBB model (Figure 13D) as described earlier. In brief, samples and controls 
were added to Transwell® inserts seeded with pBCEC as described earlier. After 4 hours of incubation, 
the basolateral medium was transferred to 7WD10 cells and after 72 hours, the supernatant was 
analyzed for Aβ42 species and flurbiprofen content. The 7WD10 cells were washed with PBS and 
provided with fresh medium containing alamarBlue® overnight in an incubator and analyzed for 
fluorescence intensity (excitation 560 nm, emission 610 nm).  
3.2.12 Experimental definitions and visual display of data 
Unless otherwise stated, the term independent experiment was defined as the following: For primary 
cells, one preparation from one porcine brain, which was treated with nanoparticles from different 
lots (usually prepared on different days or in different batches). For cell lines, an independent 
experiment also was performed with different nanoparticle lots. Furthermore, cells from different 
passages were used.  
Error bars represent the standard error of the mean (SEM) calculated with Microsoft Excel. Data was 
plotted with OriginPro 9.1 and the resulting graphs were customized and standardized with 
CorelDRAW® Graphics X6 without altering the original data. Fluorescent images were contrasted and 
modified in the same manner for all samples and controls.  
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4 RESULTS & DISCUSSION 
This study investigates the transport capacity of poly(lactic acid) nanoparticles loaded with a potential 
anti-Alzheimer’s disease drug across an advanced blood-brain barrier (BBB) model based on freshly 
isolated primary porcine brain capillary endothelial cells (pBCEC). It was examined whether application 
of flurbiprofen-loaded nanoparticles on the blood-representing compartment of the in vitro BBB model 
could reduce neurotoxic Aβ42 peptide (expressed by 7WD10 cells) in the brain-representing 
compartment. Due to its physicochemical properties, flurbiprofen itself only poorly crosses the BBB in 
vivo and was therefore discontinued as an anti-Alzheimer’s disease drug in clinical trials.  
4.1 Characterization of the in vitro blood-brain barrier model*  
In order to prove that the porcine in vitro blood-brain barrier model fulfils the expectations for drug 
transport studies, a number of quality tests were performed (Figure 14). After pBCEC isolation from 
primary material (also see 3.2.1), immunostaining for tight junction (TJ) proteins was performed as a 
first indicator for accurate barrier formation of the endothelial cell layer. Furthermore, the 
transendothelial electrical resistance (TER) of pBCEC cultured on Transwell® membranes was 
continuously monitored with the aid of a cellZscope® device, allowing impedance measurements 
across a cellular layer. Moreover, the permeability of 14C-labeled marker substances inulin and 
diazepam across the in vitro barrier was assessed by using a liquid scintillation counter (LSC). 
 
 
 
Figure 14: Flow chart of the experimental design. The blood-brain barrier model (pBCEC) was tested for its suitability as an appropriate 
model. After preparation and seeding of cells, tight junction (TJ) proteins were stained for. Next, transendothelial electrical resistance (TER) 
measurements were perfomed with the aid of a cellZscope® device that automatically monitores impedance. Furthermore, the permeability 
of radioactive tracers (14C-inulin and 14C-diazepam) was evaluated with the aid of a liquid scintillation counter (LSC).   
                                                          
* Parts of this section were published in [195]. 
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4.1.1 Tight junction protein expression 
Tight junction (TJ) proteins play a key role in maintaining barrier function in brain endothelial cells. 
Literally, they seal the gaps between the cellular monolayer (see Figure 2C). Without accurate tight 
junction protein expression, the cellular barrier lacks appropriate resistance and is permeable for 
various substances. To prove that pBCECs express the main TJ proteins, antibody staining was 
performed and evaluated by confocal laser scanning microscopy (CLSM). Claudin 5 (Cld-5) and 
claudin 3 (Cld-3), occludin (Occl) and zonula occludens (ZO-1) antibody staining (green) revealed a 
characteristic pericellular expression of tight junction proteins (Figure 15), implying that the 
connecting function between adjacent cells can be performed without restriction. Therefore, the 
pBCEC in vitro BBB model fulfils one of the fundamental requirements of a suitable barrier integrity.  
 
Figure 15: Tight junction protein expression in primary pBCEC. Claudin 5 (Cld-5) and claudin 3 (Cld-3), occludin (Occl) and zonula occludens 
(ZO-1) antibody staining displayed in green, DAPI-stained nuclei displayed in blue. Scale bar as indicated. Data published in [195].  
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4.1.2 Measurement of transendothelial electrical resistance  
Different methods to determine endothelial barrier function exist. One convenient way is following 
barrier characteristics in real time with the automatized measurement of impedance (Figure 16A). For 
this purpose, pBCEC were isolated and seeded on Transwell® inserts in a cellZscope® device. Especially 
on small pore-sized membranes (0.4 µm polycarbonate membranes), transendothelial electrical 
resistance (TER) values are excellent and comparable to in vivo measurements of approximately 
2,000 Ω*cm2 (data not shown, compare Figure 36C). However, 0.4 µm sized pores might hamper the 
transport of nanoparticles, which in this study are approximately up to 0.25 µm in diameter. 
Consequently, for all transport experiments, pBCEC were cultured on polycarbonate membranes with 
larger pores (3 µm diameter). TER values are generally lower on larger pore sized membranes, but a 
hindrance for nanoparticle transport is less likely to occur.  
An averaged example of TER development of pBCEC from one primary preparation displays that TER 
increased approximately two days after preparation and reached a plateau or slower escalating phase 
after four to five days (Figure 16B). During this phase in TER development, all further experiments were 
initialized, because it was assumed that TJ protein connections (disrupted during primary cell 
preparation) were reformed between endothelial cells. As a quality criterion, only pBCEC displaying 
>300 Ω*cm2 were included. Transwell® controls, consisting of identically treated inserts without cells 
(“No cells” in Figure 16B) never displayed TER development, thereby ruling out that the polycarbonate 
membrane or collagen IV coating affected a barrier formation.  
 
 
Figure 16: Transendothelial electrical resistance (TER) development of pBCEC on large pore-sized Transwell® membranes. (A) Schematic 
drawing of experimental design. (B) Transendothelial electrical resistance (TER) was measured in a Transwell® system and averaged by the 
cellZscope® software. Data from 3 independent Transwell® inserts, displayed with error bars. 
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4.1.3 Permeability of radiolabeled model substances  
The quality of an in vitro blood-brain barrier model can also be described by the permeability of specific 
marker substances. Here, the pBCEC Transwell® model was incubated with radiolabeled 14C-inulin, and 
radioactive decays were detected in the apical and in the basolateral compartment of the Transwell® 
insert (Figure 17A). The experiments were performed on 3 µm pore-sized membranes in order to 
validate barrier tightness, despite lower TER compared to smaller-pored membranes. For pBCEC grown 
on 3 µm pores, only about 0.2 % of the applied 14C-inulin was detected in the basolateral compartment 
after two hours of incubation (Figure 17B). To validate that the low permeability is determined by the 
cellular barrier function (e.g. unrelated to inulin accumulation on the membrane), 20 % mannitol 
solution was added to prove for physiological function. Hyperosmolar mannitol is supposed to 
osmotically shrink the cells and therefore loosen the tightly packed endothelial cells. This technique is 
also used in patients in vivo for supporting drug transport across the blood-brain barrier. In the pBCEC 
model, mannitol application increased the low permeability for 14C-inulin up to 3.5 % (Figure 17B). The 
physiological properties in terms of osmotic opening were therefore assumed to be confirmed. Next, 
the permeability of a transcellular marker was investigated. 14C-diazepam is able to cross cellular 
membranes. Diazepam is a tranquilizing, anxiolytic (fear easing) and anti-epileptic drug that is highly 
lipophilic and works when applied orally for it crosses the blood-brain barrier in vivo. In the pBCEC 
Transwell® model, 6.1 % of the applied 14C-diazepam was found in the basolateral compartment after 
2 hours. As expected, the permeability for 14C-diazepam rose drastically when mannitol addition forced 
the barrier to open. In this case 13.3 % of 14C-diazepam was retrieved in the brain-representing, 
basolateral compartment. 
 
Figure 17: Verification of appropriate barrier characteristics in vitro. (A) Schematic drawing of experimental design. When TER was 
sufficiently high, 14C-labeled markers were added to the pBCEC BBB model. (B) Permeability of radiolabeled marker substances 14C-inulin and 
14C-diazepam in a pBCEC blood-brain barrier model was assessed by liquid scintillation counter (LSC) measurements. Hyperosmolar mannitol 
was applied to simulate an osmotic shock. For comparison, Transwell® inserts without pBCEC (No cells) were also measured for marker 
permeability. Data from at least 3 independent experiments with 3 internal replicas (=Transwell® inserts). Error bars indicate SEM. Data 
published in [195].   
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4.1.4 Concluding remarks on characterization of the in vitro blood-brain barrier model 
All in all, this section closely characterized the quality of the in vitro primary pBCEC BBB model using 
various methods in order to verify the suitability of the pBCEC model for drug transport studies. 
Firstly, tight junction (TJ) protein expression was analyzed. Tight junction proteins seal the intercellular 
gaps of the endothelial layer and therefore play a key role in blood-brain barrier integrity. The 
expression and right cellular localization of the most important tight junction proteins in pBCEC was 
confirmed by antibody staining and confocal laser scanning microscopy (CLSM) analysis. The pBCEC in 
vitro BBB model strongly expresses claudins 3 and 5, zonula occludens and occludin, being 
advantageous to commonly used cell lines that either do not express all of these TJ proteins or the 
expression level is very low [23].  
Secondly, the development of transendothelial electrical resistance (TER) of the cellular layer was 
measured by impedance spectroscopy with the aid of a cellZscope® device. TER is a commonly used 
parameter for a non-invasive determination of a BBB model quality. Earlier studies showed that small 
pore sizes of 0.4 µm in diameter facilitate high TER values. However, the small pores might hamper 
nanoparticle transport. Hence, for transport experiments membranes with larger pores of 3 µm were 
used in this study. In general, a good model is expected to display TER values in the order of magnitude 
of hundreds Ω*cm2 [19]. For comparison, in vivo fetal rats develop TER around 300 Ω*cm2, adult rats 
up to 1,400 Ω*cm2 [196]. In this study, pBCEC grown on 3 µm pore-sized membranes usually reached 
TER values up to 300 Ω*cm2 and higher, thereby by far exceeding cell line-based BBB models like 
HBMEC (~25 Ω*cm2) or bEnd3 (~40 Ω*cm2) [19–21, 68].  
Thirdly, to assure that the cells grown on 3 µm pore-sized membranes are also a suitable model with 
good barrier integrity, a permeability assay with transcellular and paracellular radiolabeled markers 
was established. The measurement of radioactive tracers is one of the most sensitive assays to monitor 
permeability today. A proper model should be impermeable for inulin, which is neither actively 
transported via the blood-brain barrier, nor diffuses to the brain in vivo. High permeability is therefore 
always a sign of a leaky model. 14C-labeled inulin and diazepam were applied to the pBCEC model 
during the ascending phase of TER development. Only 0.2 % of the applied 14C-inulin was detectable 
in the basolateral (brain-representing) compartment. This finding implies a strong barrier function of 
the cells. In contrast, when the BBB model was forced to open by mannitol addition, 14C-inulin 
permeability drastically increased, which proves a good comparability to in vivo conditions, since 
mannitol-based opening of the BBB is also used in experimental animals and patients. Another 
indicator of physiological conditions is the good permeability for diazepam. This drug, also known by 
its trade name Valium®, easily crosses the BBB in vivo. The pBCEC models also is permeable for 
14C-labeled diazepam in in vitro experiments.   
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4.2 Nanoparticle preparation and characterization* 
The first result and discussion section introduced a suitable in-house in vitro blood-brain barrier model 
usable for drug transport studies. This second section deals with preparation of nanoparticles for BBB 
crossing and their characterization. An overview of the experimental setup is shown in Figure 18. After 
preparation of different polymer-based flurbiprofen-loaded nanoparticles quality parameters like size, 
surface charge and poly dispersity index were determined with the aid of a Zetasizer® device. 
Flurbiprofen-loading of the nanoparticles was assessed by high-performance liquid chromatography 
(HPLC) analysis.  
Usually, the pBCEC in vitro BBB model reacts very sensitively to external stimuli and consequently, 
several experiments were performed to further investigate the nanoparticles’ cytotoxic potential. The 
cellular viability of the pBCEC BBB model was evaluated after nanoparticle incubation in a resazurin-
based, color changing (alamarBlue®) assay. Furthermore, the influence of nanoparticles on the 
transendothelial electrical resistance (TER) in short- and long-term exposure was investigated in 
impedance measurements with the aid of a cellZscope® device. Finally, the influence on barrier 
integrity was assessed by determining the permeability of radiolabeled marker substances after 
nanoparticle incubation with the aid of a liquid scintillation counter (LSC).  
 
 
 
Figure 18: Flow chart of the experimental design. Nanoparticular formulations based on different basis materials were prepared and 
investigated for various quality features. Also, they were tested for their cytotoxic potential regarding the BBB-forming pBCEC in a cellular 
viability assay. Furthermore, the nanoparticles’ influence on transendothelial electrical resistance (TER) development after short-and long-
term exposure was investigated in impedance measurements with a cellZscope® device. Intact barrier integrity after nanoparticle application 
was checked for in permeability studies with radiolabeled marker substances.  
 
.  
                                                          
* Parts of this section were published in [68, 195, 197].  
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4.2.1 Choice of basis material, synthesis and characterization of nanoparticles 
Different basis materials are possible to take into account when preparing nanoparticles capable of 
drug transport across the BBB. During the course of the project, various nanoparticular formulations 
were prepared and tested for their drug transport capacity and interaction with BBB model cells (see 
[197]).  
HSA-based nanoparticles were prepared by a well-established desolvation technique that allows 
ApoE3-modification [197], but requires chemical precipitation with ethanol. Flurbiprofen is hardly 
soluble in aqueous media and tends to dissolve in the alcohol that is dropped into the aqueous phase 
for nanoparticle formation. The loading consequently was too inefficient for further experiments [197]. 
For three different preparation techniques, more than 80 % of the originally used drug were 
redetected in washing supernatants and not incorporated in HSA nanoparticles [197].  
PLGA-based nanoparticles loaded with flurbiprofen during the preparation process (PLGA-FBP NP) 
failed in in vitro experiments and did not lower Aβ42 levels in the brain representing compartment of 
the pBCEC BBB model (data not shown). The drug was not detected in expected amounts in HPLC 
analysis after transport, and PLGA-FBP NP did not evoke cytotoxic effects (data not shown). Most of 
the flurbiprofen was likely released from the PLGA-FBP NP during further wash steps in the preparation 
protocol, and therefore the theoretical loading efficacy did not reflect the actual flurbiprofen content 
during the cell culture experiments. This effect is in accordance with other recent data, describing that 
PLGA-FBP NP very quickly release flurbiprofen [197]. Neither oil/water (O/W) emulsion diffusion nor 
water/oil/water (W/O/W) emulsion evaporation technique improved FBP-loading of PLGA NP if they 
were dissolved in media with pH >7, which is essential for biological applications. PLGA is consequently 
not suited for this application.  
PLA-based nanoparticles were prepared by an emulsion-diffusion method as described in 3.2.5 and 
also a recent publication [68]. For PLA nanoparticle tracking in microscopy and flow cytometry 
experiments, an optional fluorescent substance (Lumogen® F Orange 240) was added for visualization 
(also see 3.2.5). During the preparation process, flurbiprofen was added and incorporated into the 
nanoparticles (PLA-FBP NP). The main characteristic features of PLA-FBP NP were determined with the 
aid of a Zetasizer Nano ZS and by HPLC analysis (Table 3).   
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Table 3: Characterization of flurbiprofen-loaded poly(lactic acid) (PLA) nanoparticles (PLA-FBP NP) and unloaded control nanoparticles 
(PLA NP). Table of NP characteristics according to data sheets provided by the Institute for Pharmaceutical Technology and Biopharmacy 
(IPTB) at Münster University. Diameter and dispersity index were measured with the aid of a Zetasizer Nano ZS. Flurbiprofen loading was 
determined by HPLC analysis. 
 Lots (n) Diameter (nm) Poly dispersity index 
(PDI) 
FBP loading 
(µg/mg NP) 
PLA NP 6 250.0 (±19.6) 0.089 (±0.036)  
PLA-FBP NP 10 239.9 (±11.2) 0.070 (±0.026) 52.27 (±11.3) 
 
 
The mean nanoparticle diameter settled at < 250 nm for drug-loaded or control particles; the poly 
dispersity index of less than 0.1 indicates a monodisperse, meaning homogeneous particle population 
(Table 3). The mean loading of the drug into PLA-based nanoparticles leveldoff at around 52 µg 
flurbiprofen per 1 mg nanoparticle formulation (Table 3). Reconstitution of the lyophilized PLA-FBP NP 
in saline resulted in a quick release of the drug. After 6 hours, more than three quarters of the initially 
incorporated flurbiprofen appeared in the supernatant of redisperged nanoparticles (Figure 19 and 
[68, 197]). 
 
 
 
  
  
Figure 19: Flurbiprofen released from PLA-FBP NP over time. Nanoparticles were dissolved in aqueous solution at pH 7.5, before drug 
content was measured by HPLC analysis at different time points as indicated. Release of flurbiprofen is displayed as percent of the originally 
incorporated drug. Figure copied from [68]. 
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4.2.2 Cellular viability of model cells after nanoparticle application  
To test for nanoparticles’ cytotoxic potential on the in vitro BBB cellular model, different viability tests 
are possible. Here, an alamarBlue® cellular viability assay was performed that quantifies the reduction 
from a non-fluorescent (resazurin) to a highly fluorescent dye (resofurin), which can only be performed 
by living cells (see 3.2.10). The pBCECs were incubated with increasing concentrations of DMSO-
dissolved flurbiprofen (FBP) and a corresponding solvent control (DMSO) (Figure 20). In order to 
compare the cytotoxic potential of drug-loaded nanoparticles and the free drug, the equal 
concentration of flurbiprofen incorporated in flurbiprofen-loaded nanoparticles (PLA-FBP NP) was 
added to the cells.  
FBP application strongly influenced cellular viability, reducing it to less than 50 % in higher 
concentrations, whereas (in equivalent concentrations) the solvent DMSO itself did not alter cellular 
viability, ruling out a solvent-mediated effect. FBP-incorporation in nanoparticles abolished the 
cytotoxic potential of the drug: PLA-FBP NP did not reduce cellular viability of pBCEC. On the contrary, 
especially higher concentrations seemed to slightly elevate resazurin conversion compared to control 
cells. For the PLA-FBP NP were intended for BBB crossing purposes and coatings with surfactants were 
shown to enable and enhance BBB transit [37, 49, 64–67], the nanoparticles were pre-incubated with 
1 % Tween®80, which was reported to enable brain uptake of PLA-based nanoparticles before [88]. 
However, coating PLA-FBP NP with 1 % Tween®80 in this experimental setup reduced cellular viability 
and appeared to be toxic to pBCEC in high concentrations (Figure 20).  
 
    
 
Figure 20: Cellular viability of in vitro blood-brain barrier model cells (pBCEC) after incubation of dissolved flurbiprofen (FBP) or 
flurbiprofen-loaded poly(lactic acid) nanoparticles (PLA-FBP NP). The pBCECs were incubated with increasing amounts of FBP or PLA-FBP NP 
and corresponding controls for 4 hours at 37 °C. Error bars as indicated, n is at least 3 from independent experiments with multiple internal 
replicas. Data partly published in [195].   
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4.2.3 Influence on transendothelial electrical resistance development 
As transendothelial electrical resistance (TER) is a strong indicator for BBB integrity and pBCEC viability, 
the nanoparticles’ influence on TER was checked for with the aid of a cellZscope® device.  
Regarding short-term TER development, even low concentrations of the free drug FBP drastically 
decreased TER by more than 70 % in low concentrations, even by 90 % in high concentrations, 
therefore completely abolishing TER (Figure 21A, B). In contrast, PLA-FBP NP only caused minor, 
reversible drops in TER that rapidly recovered again. Although application of PLA-FBP NP forced a 
concentration dependent drop in TER, pBCEC nearly completely recovered during the following 
4 hours. After PLA-FBP NP application, TER never dropped by more than 15 %, even in highest 
concentrations. Cells incubated with lower concentrations of PLA-FBP NP showed no major difference 
in further TER development (Figure 21A, B). The co-incubation of Tween®80 negatively impacted on 
TER development, but did not decrease TER by more than 50 % compared to original values. Control 
cells were treated with PBS to simulate the droplet-induced cellular stress. 
 
 
Figure 21: PLA-FBP NP influence on short-term development of transendothelial electrical resistance (TER). (A) After preparation, pBCEC 
were cultured on Transwell® inserts as described earlier and TER was monitored by a cellZscope® device. Nanoparticles (±Tween®80) or free 
drug were added (indicated by black arrow) when TER was still increasing. Lines represent representative measurements of pBCEC on 
Transwell® inserts treated with different drug concentrations or PBS as control. (B) Mean influence on TER after sample incubation is plotted 
for different concentrations of flurbiprofen, either applied as free drug or PLA-FBP NP ((±Tween®80). Error bars represent SEM, n > 3. Data 
partly published in [195].   
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To investigate if nanoparticles influenced TER in the long term, PLA-FBP NP and the free drug FBP were 
applied to pBCEC and incubated for several weeks during which TER measurements were continuously 
performed automatically every hour in a cellZscope® device.  
Cells treated with dissolved FBP reacted with a dramatic TER impairment that did not fully recover 
during the following weeks (Figure 22A). Furthermore, TER value development of FBP-treated cells did 
not compare to PBS-treated control cells (Figure 22A). In contrast, application of PLA-FBP NP barely 
affected the long-term development of TER in the in vitro pBCEC BBB model: although TER values did 
not always reach TER of the control cells during the next weeks, the general time course of TER 
development appeared similar for PLA-FBP NP-treated and PBS-treated control cells (Figure 22B). 
Pre-coating of nanoparticles with Tween®80 generally decreased TER values, but the time course of 
TER development appeared to be comparable to PLA-FBP NP-treated cells and controls (Figure 22B).  
 
 
Figure 22: Influence of flurbiprofen (FBP), flurbiprofen-loaded nanoparticles (PLA-FBP NP) with or without Tween®80 on long-term 
transendothelial electrical resistance (TER). (A) Exemplary measurements of pBCEC treated with either 29 µg FBP (black filled curve) and 
corresponding DMSO control (dashed line). (B) Same experimental setup, this time 29 µg flurbiprofen from PLA-FBP NP with (white filled 
curve) or without (red filled curve) prior 1 % Tween®80 coating of the nanoparticles was applied. Light grey filled curve represent control cells 
treated with PBS. Black arrows indicate time point of sample addition.   
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4.2.4 Influence on marker permeability and barrier integrity of the in vitro BBB model 
The reversible decrease in TER (Figure 21) after PLA-FBP NP application might symptomize a short-
term barrier disruption for pBCEC. This would be fatal, because it would mimic a transport process of  
PLA-FBP NP when actually the barrier became leaky.  
To rule out a permeable barrier after nanoparticle application, freshly isolated pBCEC were grown on 
3 µm pore Transwell® membranes as described in 3.2.1 and incubated with the free drug FBP and 
PLA-FBP NP (Figure 23A) while TER was still rising. In this experimental setup, the paracellular marker 
14C-inulin was simultaneously applied in order to identify fenestration or impairment of the pBCEC BBB 
model. As shown earlier in Figure 17, again pBCEC control cells were highly impermeable and only 
allowed less than 0.2 % of the apically applied 14C-inulin to pass (Figure 23B). Increasing concentrations 
of flurbiprofen-loaded nanoparticles (PLA-FBP NP) did not increase permeability of 14C-inulin, 
suggesting unaffected barrier integrity. Incubation with DMSO-dissolved flurbiprofen on the other 
hand had a drastic effect on barrier integrity (Figure 23B). Even the lowest concentrations of FBP 
increased 14C-inulin permeability to more than 3.5 %, which compares to simultaneous mannitol 
application (see also Figure 17). Higher concentrations of FBP resulted in a drastic increase of 14C-inulin 
permeability to over 15 %, indicating that the barrier function of the pBCECs was destroyed. The 
solvent DMSO itself negatively impacted 14C-inulin permeability, but not as drastically as dissolved FBP 
(Figure 23B).  
 
 
Figure 23: Influence of flurbiprofen and flurbiprofen-loaded nanoparticles on the permeability of the paracellular marker 14C-inulin. 
(A) Schematic drawing of experimental design. Increasing concentrations of DMSO-dissolved flurbiprofen (FBP) or flurbiprofen-loaded PLA 
nanoparticles (PLA-FBP NP) were applied to pBCEC cultured in a cellZscope® device when transendothelial electrical resistance (TER) was 
sufficient. Simultaneously, the paracellular marker 14C-inulin was added and incubated for 2 hours at 37°C. (B) Analysis of 14C-inulin content 
in the basolateral compartment after sample addition, measured with the aid of a liquid scintillation counter (LSC). Error bars represent SEM, 
n is at least 3 from independent experiments with multiple internal controls. Data published in [195].   
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4.2.5 Concluding remarks on nanoparticle preparation and characterization 
In this study, the basis material PLA was chosen for nanoparticle preparation for various reasons. 
Firstly, PLA itself is a common basis material used for nanoparticle preparation and displays excellent 
biocompatibility [55]. The human bodies’ capability to degrade PLA  was first described nearly 50 years 
ago [198] and explains why PLA was approved by the US Food and Drug Administration (FDA) for 
contact with biological fluids and a vast number of other applications, ranging from wrapping and 
catering material, agricultural use to medical technology, e.g. surgical implants.  
Secondly, compared to HSA and PLGA, PLA in this study showed the most efficient flurbiprofen loading 
capacity. However, freeze-dried PLA-FBP NP quickly released the incorporated drug after redispersion. 
More than 75 % of flurbiprofen exits the nanoparticles during the first 6 hours in phosphate buffer [68, 
197], which could be optimized in future preparation protocols. 
Other basis matrices for nanoparticle preparation incorporating flurbiprofen could comprise alginate, 
gelatin or poly(butylcyanoacrylate) (PBCA) (for a review on nanoparticle preparation see [50]). 
To investigate the nanoparticles’ influence on the in vitro BBB model, several experiments were 
performed. Firstly, a cellular viability assay (alamarBlue®) revealed that pBCEC tolerated PLA-FBP NP 
application. In contrast, the free drug flurbiprofen (FBP) drastically decreased cellular viability in high 
concentrations. Coating the nanoparticles with Tween®80 reduced cellular viability in high 
concentrations.  Secondly, the development of the pBCEC’s transendothelial electrical resistance (TER), 
which represents an indicator for barrier function, was barely influenced by PLA-FBP NP application – 
neither in short-term, nor in long-term TER monitoring. Again, the free drug FBP drastically (and 
irreversibly) impaired TER, even in low concentrations. Coating the nanoparticles with Tween®80 
negatively impacted on short- and long-term TER development, but not as drastically as the incubation 
of the free drug FBP. Thirdly, PLA FBP NP application did not increase 14C-inulin (a paracellular marker) 
permeability across the BBB model, which proves for an unimpaired barrier integrity. Application of 
free FBP caused a major increase of 14C-inulin permeability and therefore massively weakened the 
barrier function. All in all, the PLA-FBP NP used in this study are characterized by a very low cytotoxic 
potential and therefore suitable for further examination.  
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4.3 Nanoparticle-mediated drug transport across the in vitro barrier*  
After characterizing the flurbiprofen-loaded, PLA-based nanoparticles (regarding physicochemical 
parameters and cytotoxic or barrier-disrupting potential) in the last section (see 4.2), this part of the 
study deals with the actual drug transport capacity of the nanoparticular formulation across the pBCEC 
in vitro BBB model, which displays excellent barrier characteristics (also see 4.1). 
In brief, the following experiments were performed in order to investigate if the nanoparticles 
effectively convey the incorporated drug across the cellular barrier and if the transported drug is still 
biologically active and able to reduce Aβ42 levels in the brain-representing compartment of the in vitro 
model (Figure 24). First, the cellular binding and uptake capacity of the drug-loaded nanoparticles was 
investigated in flow cytometry and confocal laser scanning microscopy (CLSM), for these processes are 
required for a successful transcytosis across the BBB. Next, the drug content in the different 
compartments of the in vitro pBCEC BBB model was analyzed by high-performance liquid 
chromatography (HPLC). The medium from the brain-representing compartment was subsequently 
transferred to a cellular in vitro Alzheimer’s disease model (7WD10), which expresses a mutated 
amyloid precursor protein (APP) variant. Aβ42 levels after incubation with the medium from 
nanoparticle-treated BBB model was assessed by an Aβ42-recognizing enzyme-linked immunosorbent 
assay (ELISA). To rule out that a possible Aβ42-reducing outcome was mediated by cytotoxic effects, 
the Alzheimer’s disease in vitro model was investigated in a cellular viability assay (alamar®Blue) after 
application of nanoparticle-treated medium.  
 
Figure 24: Flow chart of experimental design. Cellular binding and uptake of nanoparticles was checked for in flow cytometry and high 
resolution CLSM analysis. Drug transport capacity of the nanoparticles across the cellular barrier was assessed by HPLC analysis. Verification 
of preserved biological efficiency of the drug after nanoparticle packing was achieved by a functional Aβ42 species ELISA. To ensure that a 
potential Aβ42-lowering effect was not due to cytotoxicity, the Alzheimer’s disease model cells were finally investigated in a cellular viability 
assay. 
  
                                                          
* Parts of this section were published in [68, 195]. 
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4.3.1 Cellular binding of nanoparticles 
When nanoparticles are intended to be used as carrier systems to overcome the blood-brain barrier 
by receptor-mediated transcytosis, the first step is binding to the cellular surface. Here, cell lines of 
different species (human HBMEC and murine bEnd3) as well as freshly isolated primary porcine brain 
capillary endothelial cells (pBCEC) were investigated for their ability to bind to drug-loaded poly(lactic 
acid) nanoparticles in flow cytometry analysis. For detection, a Lumogen® Orange label was introduced 
during the nanoparticle preparation process that allowed visualization at 539 nm. The fluorescent, 
flurbiprofen-loaded PLA nanoparticles (PLA-FBP-Lum NP) were applied to different blood-brain barrier 
model cells and incubated for 4 hours at 37 °C. Data was analyzed either by counting % positive cells 
or by measuring the binding intensity (displayed as Y Geo Mean) of nanoparticles. Nearly 100 % of the 
different endothelial model cells were positive in flow cytometry experiments after nanoparticle 
incubation, meaning that nearly all cells bound PLA-FBP-Lum NP (Figure 25A). This result was 
independent from the cellular model and equally true for HBMEC, bEnd3 or the primary pBCEC model 
systems. Binding intensity peaks (labeled as “Y Geo Mean”) shifted from cell type to cell type, whereas 
the human-derived BBB modell cell line HBMEC most extensively bound PLA-FBP-Lum NP (Figure 25B). 
This data is in accordance with analysis concerning the expression of BBB relevant receptors (also see 
Table 4), revealing that (of the three cellular BBB models used in this study) HBMEC most extensively 
express receptors of the low density lipoprotein (LDL) receptor family. The LDL receptors (especially 
LRP1) were shown to play a key role in apolipoprotein-modified nanoparticle uptake in BBB model cells 
[81]. For PLA nanoparticles form a protein corona partially consisting of apolipoproteins [68] after 
incubation in plasma or serum-containing medium, the different LDL receptor expression of the various 
BBB model cell lines explains the altering binding capacity of the nanoparticles.  
 
Figure 25: Binding capacity of PLA-FBP-Lum NP to different blood-brain barrier model cells in flow cytometry experiments. (A) Binding 
characteristics of PLA-FBP-Lum NP after 4 hours of incubation analyzed as “% positive cells”, displaying quantitative evaluation. Data partly 
published in [195]. (B) Same experiments analyzed by “Y Geo Mean”, representing the binding intensity of PLA-FBP-Lum NP to the different 
endothelial cells as indicated. Data was obtained in at least 3 independent experiments with multiple internal replicas. 
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4.3.2 Cellular uptake of nanoparticles  
Cellular uptake of poly(lactic acid) nanoparticles was investigated in confocal laser scanning 
microscopy (CLSM). After incubating HBMEC with flurbiprofen-loaded, fluorescent poly(lactic acid) 
nanoparticles (PLA-FBP-Lum NP) and staining for the cytosol with CellTrackerTM Blue afterwards, a 
correlation between the cytosolic staining (blue in Figure 26) and the signal for PLA-FBP-Lum NP 
(yellow) was detectable in effectively every cell. It appeared that the nuclei of the cells were not 
infiltrated with the fluorescent labeling molecules of the nanoparticles (Figure 26). 
To strengthen this data, similar experiments were performed with primary porcine brain capillary 
endothelial cells (pBCEC) incubated with PLA-FBP-Lum NP. As shown for the cell line HBMEC, the 
cytosolic staining of pBCEC (blue in Figure 27) correlated with the fluorescent signal of the 
nanoparticles (yellow in Figure 27) when PLA-FBP-Lum NP were incubated for 4 hours at 37 °C.  
In untreated control cells (upper panel in Figure 27), no nanoparticle signal was detected. Furthermore, 
nanoparticle incubation at 4 °C instead of 37 °C, completely abolished PLA-FBP-Lum NP uptake (lower 
panel in Figure 27).  
Another experiment used confocal microscopy imaging to obtain pictures not only in x and y direction, 
but additionally in z coordinates (Figure 28) in order to reconstruct 3D images of PLA-FBP-Lum NP-
treated pBCEC and rule out that scattered signals from the cellular surface might be mistaken for 
cellular uptake. Again, when incubation occurred at 4 °C, samples lacked cell associated nanoparticle 
signals (Figure 28A). In contrast, incubation at 37 °C provoked a correlation of the cytosol signal (blue) 
and the signal for the nanoparticles (yellow) (Figure 28B). The effect becomes particularly apparent 
when images are cropped (Figure 28C), underlining the cellular uptake of the nanoparticles by allowing 
insight into the cytosol (Figure 28C-F). 
 
 
Figure 26: HBMEC uptake of fluorescent PLA-FBP NP. Confocal laser scanning microscopy (CLSM) revealed a clear correlation of the yellow 
fluorescent signals (nanoparticles) with the blue-stained cytosol of HBMEC cells (right image). In contrast, no yellow fluorescence signal was 
detected in control samples that were incubated with PBS instead of nanoparticles (left image) after 4 hours of incubation at 37 °C. Scale bar 
as indicated.   
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Figure 27: Primary pBCEC uptake of fluorescent PLA-FBP NP analyzed by confocal laser scanning microscopy (CLSM). Nanoparticles were 
incubated on pBCEC for 4 h either at 37 °C (middle panel) or 4 °C (lower panel). Cells without PLA-FBP-Lum NP incubation served as control 
(upper panel). After nanoparticle incubation, cells were stained with CellTrackerTM Blue for 30 min; mounting medium for CLSM analysis 
contained DAPI. At 37 °C, PLA-FBP-Lum NP signals (yellow) correlated with the cytosol staining (blue), whereas for 4 °C incubation or control 
cells, no yellow signals were detectable in the cytosol. Scale bar as indicated.  
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Figure 28: 3D projection of confocal laser scanning microscopy (CLSM) analysis of pBCEC after nanoparticle incubation. (A) Untreated 
control cells, cytosol was stained with CellTrackerTM Blue, nuclei are DAPI stained. (B) Cells incubated at 37 °C with PLA FBP NP. Yellow signal 
for nanoparticles correlates with blue cytosol staining. (C) Magnification of cells positive for nanoparticle signals. Red and green line represent 
level for optical cutting in x and y direction. Front quarter was cropped to allow in insight into the cytoplasm. Nanoparticle signal seems to 
be distributed to the cytosol. Nuclei appear not to be infiltrated by nanoparticles. Scale bar as indicated. Data partly published in [195]. 
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4.3.3 Drug transport studies 
Total flurbiprofen transport across the barrier 
To check if flurbiprofen-loaded nanoparticles release the incorporated drug on the brain-representing 
compartment of the in vitro BBB model, the basolateral media of pBCEC grown Transwell® inserts was 
collected after sample incubation and analyzed for flurbiprofen in high-performance liquid 
chromatography (HPLC).  
Figure 29A displays single measurements for different concentrations of either the free drug or 
nanoparticle formulation and was used to calculate Figure 29B, which averages the transport rate of 
flurbiprofen across the barrier. More than 2/3 of apically applied flurbiprofen (FBP) was detectable in 
the basolateral (brain-representing) compartment (Figure 29A, B) after 4 hours of incubation in the in 
vitro pBCEC BBB model. When PLA-FBP NP were applied, less than 30 % of the incorporated drug 
passed the barrier, independent from Tween®80 coating of the nanoparticles. The large discrepancy 
between flurbiprofen transit when applied as free drug or incorporated in nanoparticles raised the 
question where PLA-FBP NP remained in the in vitro BBB model. Therefore, the model’s compartments 
were analyzed separately in the next experiment.  
 
Figure 29: Comparison of flurbiprofen transport across the pBCEC BBB 
model when applied either as free drug or incorporated in nanoparticles. 
(A) Drug amount detected in the basolateral compartment in the pBCEC BBB 
model. After adding flurbiprofen (FBP) or drug-loaded nanoparticles 
(PLA-FBP NP) with or without Tween®80 coating, the medium from 
basolateral site was harvested after 4 hours of incubation and analyzed by 
high-performance liquid chromatography (HPLC). Each symbol represents 
data from one independent measurement; linear fits (calculated with 
OriginPro 9.1G software) are displayed as lines. Data partly published in [195]. 
(B)  Drug transport rate to the basolateral compartment in %, calculated and 
averaged from all data points in (A). Data was obtained in at least 3 
independent experiments with multiple internal controls. Error bars as 
indicated. 
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Drug distribution within in the in vitro model 
In order to localize the remaining PLA-FBP NP within the in vitro BBB model, the different 
compartments of the model were analyzed by HPLC separately: 
To calculate the retrieval rate of the theoretically applied drug, medium from the apical, blood-
representing compartment (grey in Figure 30) was incubated with acetonitrile in order to precipitate 
proteins from cell culture medium on the one hand, and disintegrate remaining nanoparticles to 
release the drug payload on the other hand. Transwell® inserts (white in Figure 30), seeded with pBCEC, 
were treated with DMSO to disintegrate the polycarbonate membrane and solubilize the cells, ideally 
dissolving the incorporated drug into the solvent matrix. Medium from basolateral, brain-representing 
compartment (black in Figure 30) was analyzed in HPLC without further treatment. Whereas for FBP 
the entire drug amount could be retrieved, retrieval rates for PLA-FBP NP were about less than 90 % 
(Figure 30A). For nanoparticles, about half of the calculated drug crossed the BBB model and was 
detected in the basolateral compartment (independent from Tween®80 coating) (Figure 30B), for the 
free drug FBP, basolateral values exceeded 60 %. When the total amount of the samples was set as 
100 % (Figure 30B), nanoparticle samples had a higher retrieval rate (>6 %) in the Transwell® 
compartment than the free drug (<2 %). This data indicates that a proportion of PLA FBP NP could still 
be endocytosed inside the pBCEC and were not yet transcytosed across the in vitro BBB.  
Figure 30: Drug retrieval in different 
compartments of the BBB model 
analysed by HPLC. (A) Percentage of 
drug retrieved in apical (grey), 
basolateral (black) or Transwell® (white) 
compartment of the BBB model when 
applying one exemplary concentration  
(146 µg FBP/TW) flurbiprofen. (B) Total 
retrieved drug values from (A) were set 
as 100 % in each sample, in order to
quantitatively compare the different 
localizations of flurbiprofen. Data from 
at least 3 independent experiments 
with multiple internal controls. Error 
bars indicate SEM. Data partly 
published in [195]. 
 Results & Discussion 
63 
 
4.3.4 Aβ42 reduction by flurbiprofen-loaded poly(lactic acid) nanoparticles  
Drugs should keep their biological efficacy after transport across the BBB. In order to assess if the 
incorporated flurbiprofen from nanoparticles can still reduce Aβ42 levels in vitro, we designed an 
experimental setup with Aβ42 overexpressing cells 7WD10 (Figure 31A). 
After pBCEC (grown on Transwell® inserts as described) were incubated 4 hours with either 
flurbiprofen (FBP) or flurbiprofen-loaded nanoparticles (PLA-FBP NP), the basolateral medium was 
transferred to Aβ42 overexpressing 7WD10 cells and left there for 72 hours (Figure 31A). The 
subsequent Aβ42 ELISA revealed that the transported flurbiprofen from PLA-FBP NP can reduce the 
Aβ42 levels to less than 70 % of the control level (Figure 31B). Nanoparticle coating with Tween®80 did 
not seem to enhance the effect. Similar concentrations of FBP reduced Aβ42 to 30 % of the original 
level. The more pronounced Aβ42 reducing effect of FBP was expected, because (as shown before in 
Figure 29) more drug was detected in the basolateral compartment after FBP incubation, compared to 
PLA-FBP NP application. However, FBP appeared to be toxic for pBCEC in higher concentration (shown 
in (Figure 20-23), indicating that the barrier became leaky after FBP application.  
 
 
Figure 31: Flurbiprofen-loaded poly(lactic acid) nanoparticles (PLA-FBP NP) reduce Aβ42 levels after transport across the in vitro blood-
brain barrier (BBB) model. (A) Schematic drawing of experimental design: pBCEC were isolated and cultivated as described earlier. When 
transendothelial electrical resistance (TER) was adequate, samples were incubated for 4 hours. The apical compartment and pBCEC were 
then discarded and basolateral medium was transferred to culture plates seeded with Aβ42 producing 7WD10 cells. After 72 hours, the 
supernatants were harvested and analyzed in a human Aβ42-recognizing ELISA assay. (B) Increasing concentrations of applied 
flurbiprofen (FBP) gradually decrease Aβ42 levels. PLA-FBP NP application achieves reduction of Aβ42 levels to less than 70 % of the control 
samples, independent from Tween®80 pre-incubation. Grey rectangle indicates free FBP concentrations that showed a toxic effect on pBCEC 
in cellular Data from at least 3 independent experiments, error bars indicate SEM. Data partly published in [195].   
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4.3.5 Cellular viability of the Alzheimer’s disease model cells 7WD10  
In order to exclude that the transported flurbiprofen from apically applied drug-loaded nanoparticles 
may alter cellular viability of the Alzheimer’s disease model cell line in the basolateral compartment, 
cytotoxicity assays after transport studies were performed. A decrease in cellular viability could cause 
false positive results for Aβ42 reduction in the subsequent assay.  
FBP or PLA-FBP NP (± Tween®80) were first applied to the apical compartment of the in vitro blood-
brain barrier model for 4 hours. Then, the basolateral medium was transferred to the 7WD10 cells 
(Figure 32A). 7WD10 cells were not negatively affected by the samples. Even after 72 hours of 
incubation, all treated cells displayed viability values near 100 % compared to untreated control cells.  
 
 
Figure 32: Nanoparticles’ influence on the Alzheimer’s disease model (7WD10) cells’ viability after crossing the pBCEC BBB model. 
(A) Schematic drawing of experimental design: pBCEC were incubated with FBP or PLA-FBP NP (±Tween®80). After 4 hours, medium of the 
basolateral compartment was transferred to the 7WD10 cells for 3 days, before performing an alamarBlue® cell viability assay. (B) Data from 
cellular viability assay. 7WD10 cells treated with basolateral medium from control Transwell® inserts without drug application were set as 
100 % vital. Data from at least 3 independent experiments, error bars indicate SEM. Data partly published in [195]. 
 
4.3.6 Summary drug transport 
The first step in nanoparticle-mediated transcytosis for drug transport comprises binding of the 
particles to the cells’ surfaces at the blood-representing site, followed by an uptake into the cytoplasm 
of the BBB model cells and finally a release process at the brain-representing site.  
The binding characteristics of PLA-FBP NP were investigated by using the primary in vitro BBB model 
(pBCEC) as well as commonly used BBB model cell lines (bEnd3, HBMEC). Flow cytometry revealed that 
the nanoparticles strongly bound to the cells, although binding intensity differed from model to model, 
being strongest for the human-derived cell line HBMEC. However, flow cytometry data in this case 
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includes both surface-bound nanoparticle signal and intracellular signal, therefore confocal laser 
scanning microscopy (CLSM) was also performed to further investigate cellular uptake. CLSM analysis 
allowed optical sectioning by focusing on selected depths of samples and thereby provided insight 
access into the nanoparticle-treated cells. CLSM data revealed that the nanoparticle signal correlated 
with the cytosolic staining, verifying cellular uptake of PLA-FBP NP in endothelial cells.  
Next, the drug transport capacity of PLA-FBP NP was investigated in HPLC analysis. Flurbiprofen from 
PLA-FBP NP was detected in the brain-representing compartment of the primary in vitro BBB model 
after 4 hours incubation in the blood-representing compartment, verifying that the nanoparticular 
formulation and drug-loading efficacy is suitable for this purpose. In this study’s experimental setup, 
transit of free FBP was about twice as high as for PLA-FBP NP. However, the BBB crossing of FBP is 
rather due to barrier disruption than active transport for several reasons: As stated earlier, FBP 
performed poorly regarding cellular viability of the pBCEC, also TER and C14-inulin permeability were 
strongly influenced by FBP. Another disadvantage of FBP application was the low solubility of FBP in 
water, which required the use of solvents. In this study, FBP was dissolved in DMSO. However, DMSO 
is poorly compatible with the basis material (polycarbonate) of the Transwell® inserts, and can dissolve 
the actual membrane structure. Although a very low volume (>20 µl) of DMSO was applied to a total 
volume of 2.5 ml, an effect of the DMSO became apparent in 14C-inulin permeability assays, indicating 
that even the DMSO solvent destroys the barrier function of pBCEC grown on polycarbonate Transwell® 
membranes. FBP therefore is not a suitable control in drug transport experiments in this experimental 
setup.  
Finally, this study’s data verifies that drug transport from flurbiprofen-loaded poly(lactic acid) 
nanoparticles (PLA-FBP NP) is sufficient to evoke a biological effect and reduce Aβ42 levels in the brain-
representing compartment of the pBCEC model – most importantly, without impairing the barrier 
function of the barrier. HPLC analysis of flurbiprofen content in the brain-representing compartment 
verified this conclusion; supporting the promising binding and uptake experiments of the nanoparticles 
with endothelial cells.  
In a recent publication [68], we could already underpin this study’s data by showing that PLA-FBP NP 
successfully reduced Aβ42 levels by more than 25 %. Nevertheless, using a simpler, murine cell 
line-based BBB model consisting of bEnd3, the study had one major limitation. bEnd3 cells only develop 
low TER values (~40 Ω*cm2), not comparable to the in vivo situation (e.g. in fetal rats around 
300 Ω*cm2, in adult rats up to 1,400 Ω*cm2) [196]. Here, this gap was closed by using a more advanced, 
primary pBCEC-based model with higher TER values (300-1,200 Ω*cm2). Additionally, intact barrier 
integrity was verified by checking for permeability of radiolabeled, non-transportable tracers to 
minimize false positive results in drug transport studies.   
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This promising in vitro data suggests that PLA-FBP NP could also be used to transport flurbiprofen to 
the brain in vivo. The approach shows major benefits compared to the application of the drug alone. 
Flurbiprofen is indeed capable of lowering Aβ42 levels in an in vitro Alzheimer’s disease model, 
consisting of 7WD10 cells that secrete Aβ peptides. However - in contrast to PLA-FBP NP - the 
application of the dissolved drug is toxic to pBCEC (verified in cellular viability assays) and drastically 
impairs the BBB integrity (shown in transendothelial electrical resistance measurements and 
permeability assays with radiolabeled 14C-inulin). Since flurbiprofen destroys the barrier function of 
the in vitro BBB model, more drug crosses the pBCEC layer (verified in HPLC analysis and Aβ42 ELISA). 
In the first study, flurbiprofen also evoked cytotoxic effects on bEnd3 cells prohibiting application of 
corresponding concentrations of dissolved drug compared to PLA-FBP NP [68]. Here again, a cytotoxic 
effect in viability assays was observed. In addition, DMSO-dissolved flurbiprofen increased 14C-inulin 
permeability (even low concentrations) (Figure 23), making the dissolved drug an unsuitable control 
for drug transport studies.  
Furthermore, it was investigated if the pre-coating of nanoparticles with the surfactant Tween®80 
increased drug transport capacity across the in vitro pBCEC BBB model. Surfactants generally lower the 
surface tension between two liquids or between a liquid and a solid. For nanoparticles, it was widely 
proposed that surfactant (like Tween®80) coating of nanoparticles facilitates brain transport in in vivo 
experiments. Hypothetically, Tween®80 coating is expected to anchor lipoproteins from sera or 
plasma, thereby enhancing endocytosis processes at the BBB, because the bound proteins (like ApoE) 
from the blood or cell culture medium promote uptake by BBB specific receptors (for review see [47]). 
Other (less likely) hypotheses state that Tween®80 coatings could act either by inhibiting efflux pumps 
(especially P-glycoprotein) or by a general effect characterized by endothelial membrane fluidization 
and enhanced permeability (for review see [47]).  
Many brain targeting nanoparticles coated with Tween®80 show promising study outcomes (Table 1). 
For PLA-based nanoparticles, evidence exists that Tween®80 enhances brain uptake. For example, Sun 
et al. reported that for BBB crossing of their FITC-loaded PLA nanoparticles, Tween®80 coating was 
actually required in their in vivo experimental setup [88]. Interestingly, in this study’s experimental 
setup, the pre-incubation of PLA-FBP NP with Tween®80 did not enhance BBB crossing, indicated by 
unaltered Aβ42 reduction in the following functional experiments. This is in accordance with the HPLC 
data showing that Tween®80 coating of PLA-FBP NP did not enhance flurbiprofen concentration in the 
brain-representing compartment after application to the blood-representing compartment.  
Kreuter recently reviewed that for some nanoparticlular formulations (like PLGA-based nanoparticles) 
Tween®80 coating was not as efficient for BBB transit than other surfactants [47]. Therefore, other 
surfactant coatings that were shown to enhance crossing of the BBB (like Pluronic-F68®) could be tested 
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for PLA-FBP NP in the future. However, Meister et al. used the same PLA-FBP NP that were used in this 
study and applied them to a simpler BBB model consisting of bEnd3 cells [68]. The sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot data (Figure 33A, B) showed 
that a protein corona appeared on the surface of the nanoparticles – notably without prior surfactant 
coating of the nanoparticles. So, the PLA-FBP NP obviously adsorbed to apolipoproteins, regardless of 
surfactant coating. The protein corona appeared already after 5 min of plasma incubation (Figure 33A) 
and increased over time, rather quantitatively than qualitatively. Notably, the protein corona partially 
consisted of ApoE3 (Figure 33B). Apolipoproteins enable receptor-mediated uptake by lipoprotein 
receptors at the BBB, and ApoE-coupling to nanoparticles allows active endocytosis of the 
nanoparticles via the low density lipoprotein receptor-related protein 1 (LRP1) [81]. Here, it seems that 
in the case of PLA-FBP NP, Tween®80 coating does not seem to play a major role for drug transport in 
vitro (but should nevertheless be taken into account for possible in vivo studies). Alternatively, direct 
coupling of relevant ligands to the nanoparticles’ surface could be applied. Consequently, the next 
section of this thesis concentrates on further describing a potential ligand for PLA-FBP NP to improve 
BBB crossing. 
 
Figure 33: Protein corona of PLA-FBP NP after plasma incubation without surfactant coating. (A) Coomassie Blue-stained SDS-PAGE of 
nanoparticles incubated with human plasma for different periods as indicated. The nanoparticle-plasma protein complexes were separated 
from human plasma by sucrose cushion centrifugation before gel electrophoresis. Protein corona formation on nanoparticles is already visible 
after 5 min of plasma incubation and the amount of bound protein seems to increase over time. (B) Western blot data of the nanoparticle-
protein complexes stained for Apolipoprotein A4 (α-ApoA4) and E (α-ApoE). Image copied and modified from [68].  
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4.4 A suitable ligand for in vivo application: Apolipoprotein E3* 
For this study’s in vitro transport experiments (see 4.3), flurbiprofen-loaded nanoparticles without a 
surface modification were used. However, for in vivo application, a specific ligand modulation would 
be desirable to specifically target receptor-mediated transport across the blood-brain barrier.  
Coupling apolipoprotein E3 (ApoE3) to the nanoparticles’ surface targets the low density lipoprotein 
receptor (LDLR) family, in particular the low density lipoprotein receptor-related protein 1 (LRP1), for 
specific transport. This next section summarizes the preliminary experiments for specific ligand 
coupling. 
 
 
 
Figure 34: Flow chart of the experimental design. Different model cells (pBCEC, bEnd3, HBMEC) were tested for the expression of relevant 
blood-brain barrier receptors in flow cytometry after antibody staining. Next, cells were incubated with fluorescent ApoE3 or ApoE3-modified 
nanoparticles and analyzed in flow cytometry or confocal laser scanning (CLSM) experiments. The cytotoxic potential of ApoE3 was 
investigated considering permeability, viability and influence on transendothelial electrical resistance (TER).        
 
 
4.4.1 Verification of receptor expression  
The different in vitro BBB model cells (pBCEC, HBMEC and bEnd3) robustly express the surface 
receptors LDLR, LRP1 and LRP2 (also known as Megalin) (Table 4). The human-derived cell line HBMEC 
most extensively expresses the receptors compared to bEnd3 and pBCEC. Cells were stained with 
specific primary antibodies and fluorescent secondary antibodies and subsequently analyzed in flow 
cytometry measurements. The signal increased in a concentration-dependent manner when compared 
to control cells (incubated without the primary antibody). For clarity, only one antibody concentration 
per sample is displayed.  
  
                                                          
* Parts of this section were published in [195]. 
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Table 4: Expression low density lipoprotein receptor protein receptor (LDLR) family members. Different endothelial cells were antibody-
stained for receptors expressed at the BBB in vivo and analyzed in flow cytometry experiments. Data from at least 3 independent experiments 
with multiple replicas of >10,000 cells. Symbols represent proportion of % positive cells: (-) <10 %; (+) 11-49 %; (++) 49-90 %; (+++) >90 % 
 
4.4.2 ApoE binding to blood-brain barrier model cells  
To address the question if the planned ligand binds to in vitro BBB model cells, ApoE3 was fluorescently 
labeled with a commercially available kit (also see 3.2.8) and investigated in flow cytometry 
experiments. For this screening experiment, the human BBB model cell line HBMEC was used to avoid 
time and cost-consuming primary cell preparation of pBCEC. As shown in Table 4, HBMEC expresses 
the relevant receptors required for lipoprotein binding. 
Fluorescent ApoE3 (ApoE-633) in a concentration of 1 µg/cm2 showed excellent binding that was 
reduced by about 40 % when unlabeled ApoE3 (in a 10-fold excess) was applied for competitive 
displacement at the LRP1 receptor (Figure 35). A random protein of comparable molecular weight 
(ovalbumin) that was not expected to be specifically transported via the LRP1 receptor served as a 
negative control and was simultaneously fluorescently labeled. As expected, the basal binding of the 
fluorescent ovalbumin (Ov-633) was unaltered by co-incubation with 10-fold excess of free, unlabeled 
ApoE3 (Figure 35). The binding of ApoE3 therefore is assumed to be specific.  
Similar binding experiments were performed in a 4 °C environment, instead of 37 °C (Figure 35). As 
Wagner et al. showed in 2012 for ApoE3-modified nanoparticles, it was confirmed that also the uptake 
of free, fluorescently labeled ApoE3 is an active process that cannot be performed if the cell’s 
metabolism is reduced to a minimum. Values for the mean fluorescence intensity dropped by >95 % 
when cells were incubated at 4 °C instead of 37 °C for four hours.  
 
 
 
pBCEC bEnd3 HBMEC 
LDLR ++ +++ +++ 
LRP1 ++ ++ +++ 
LRP2 ++ ++ +++ 
Figure 35: ApoE binding to brain endothelial 
cells. The human cell line HBMEC was
incubated with fluorescence-labeled ApoE3 
(ApoE-633) or ovalbumin (Ov-633) for 
4 hours at 37 °C or 4 °C before analyzing 
binding intensity (described as Y Geo Mean) 
by flow cytometry. Untreated pBCEC served 
as control and threshold setting. Unlabeled 
ApoE3 in a 10-fold excess was added as 
indicated to check for competitive 
displacement at the specific receptors. Data 
from at least 3 independent experiments 
with multiple replicas of >10.000 cells.  
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4.4.3 ApoE influence on barrier integrity and viability of primary BBB model cells 
ApoE3 was tested for its potency to reduce cellular viability in vitro. ApoE3 showed no relevant 
reduction in viability when applied in concentrations up to 100 µg/cm2 (Figure 36A). After excluding a 
cytotoxic effect, ApoE3 was also investigated for its potential to alter the permeability of radiolabeled 
marker substances in the primary pBCEC BBB model. As described earlier, pBCEC were isolated from 
freshly slaughtered pig brains and cultivated in a cellZscope® device to monitor their barrier qualities. 
When the transendothelial resistance (TER) was still rising, permeability experiments with radiolabeled 
14C-inulin were performed. 
After exposure of 14C-inulin (0.4 µCi/ml) to the apical compartment, only about 0.2 % of the originally 
applied substance was detectable in the basolateral compartment - indicating good barrier integrity of 
the primary model system (see also 4.1.3). In contrast, addition of 1 µg ApoE3/cm2 growth surface 
promoted permeability of 14C-inulin, although data can only be interpreted as a trend, because 
statistical significance was not achieved. As a further control, hyperosmotic mannitol solution was 
applied together with the 14C-inulin. As expected, the permeability of the radiolabeled marker rose 
drastically (Figure 36B), implying physiological characteristics.  
Next, ApoE3 was tested for its influences barrier integrity by application to pBCECs during TER 
measurements in a concentration of 1 µg ApoE3/cm2 growth surface. While the TER values of control 
cells still increased after a comparable droplet of PBS was applied to the Transwell®, the TER of samples 
incubated with ApoE3 decreased (Figure 36C). The concentration was equivalent to the amount of the 
ApoE3 coupled to the nanoparticles when applied in the standard concentration of 100 µg NP/cm2 
growth surface. However, in terms of experiments with nanoparticles, these concentrations will not 
be attained at the cellular level, because the ApoE3 is coupled to the surface of the assumed spherical 
structure. The surface of a sphere is defined as   = 4 = . If the diameter of the nanoparticle 
is approximately 200 nm, surface area totals to 125250 nm2. This results in a very low actual 
concentration of ApoE3 at the cellular surface. In accordance with this assumption, ApoE3-modified 
nanoparticles show substantial milder effects on TER in the equivalent ApoE3 concentration per 
incubation surface: Wagner et al. reported in a study investigating uptake mechanisms for ApoE-
modified HSA-based nanoparticles a rapid, reversible drop in TER after incubation that appeared to be 
less drastic than the free ApoE3 in this study’s experiments [81]. Overall, ApoE3 appears to alter barrier 
integrity without being toxic to the primary in vitro BBB model pBCEC. 
 
  
 Results & Discussion 
71 
 
  
Figure 36: Cell – ligand interactions of ApoE3 and pBCEC. 
(A) Influence of ApoE3 on cellular viability of pBCEC was assessed 
in a cellular viability assay after cells were incubated with different 
concentrations of ApoE3. PBS-treated cells served as negative 
control and were assumed to be 100 % vital. (B) Influence of ApoE 
and ovalbumin (Ov) on barrier integrity of primary pBCEC. 
Mannitol was added to test for physiological characteristics of the 
BBB model. (C) Influence of ApoE3 on transendothelial resistance 
(TER) of pBCEC grown on 0.4 µm Transwell® membranes. One 
exemplary experiment out of at least 3, PBS-treated cells served as 
control. Data from >3 independent experiments with multiple 
internal controls. 
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4.4.4 Binding and uptake of ligand-modified nanoparticles  
The previously described drug transport experiments in section 4.3 were performed by using 
unmodified, drug-loaded nanoparticles. It was shown that, after human plasma incubation, these 
nanoparticles form a protein corona consisting of apolipoproteins [68]. For coupling of apolipoproteins 
to nanoparticles can increase BBB translocation [59, 66, 81, 199], the next step in this study comprised 
ligand modification of poly(lactic acid)-based nanoparticles.      
A PEGylation of the nanoparticles surface allowed coupling of the ligand ApoE3 (PLA-PEG-ApoE NP) or 
the control protein ovalbumin (PLA-PEG-Ov NP). The amount of covalently bound ApoE to the 
nanoparticles was 14.8 µg protein/mg NP, comparable to the amount of bound ovalbumin 
(11.48 µg/mg NP) (Table 5). The diameter of unmodified PLA NP was 244.1 nm, confirming previous 
data (see Table 3). Ligand-modification slightly increased the nanoparticles’ diameter to 266.9 nm for 
PLA-PEG-ApoE NP and 263.1 nm for PLA-PEG-Ov NP. Next, the preparation procedure of the PLA-PEG-
ApoE NP was slightly changed and lacked NaOH in the buffer composition (PLA-PEG-ApoE NP w/o 
NaOH). Thereby the ApoE3 binding reaction is expected to be diminished, representing a further 
control to verify specific, ApoE3-mediated uptake of the nanoparticles. The diameter of these control 
PLA-PEG-ApoE NP w/o NaOH was unexpectedly larger (285 nm) compared to PLA-PEG-ApoE or Ov NP.  
Similar to experiments in section 4.3.1 and 4.3.2, cellular binding and uptake of ligand-modified 
nanoparticles was checked for. Flow cytometry experiments revealed that incubating different 
endothelial cells (HBMEC, pBCEC) with PLA-PEG-ApoE NP drastically enlarged binding capacity, 
compared to unmodified control nanoparticles (PLA NP) (Figure 37A, B). Binding of PLA-PEG-ApoE NP 
w/o NaOH was similar to PLA NP. Coupling of the random protein ovalbumin (resulting in 
PLA-PEG-OV NP) also scaled down binding to pBCEC.  
CLSM analysis indicated that PLA-PEG-ApoE NP entered primary endothelial cells (Figure 36C, D). 
Primary pBCEC were incubated either with ApoE3-modified PLA nanoparticles for 24 hours at 37 °C. 
The blue signals for DAPI-stained nuclei and yellow nanoparticle fluorescence did not overlap 
indicating a cytosolic distribution. Untreated control cells lacked cell specific nanoparticle signals. 
 
Table 5: Characterization of ligand-modified poly(lactic acid) (PLA) nanoparticles and control nanoparticles. Table of NP characteristics. 
Diameter and dispersity index were measured with the aid of a Zetasizer Nano ZS. The amount of bound protein was calculated indirectly by 
detection of unbound protein in the supernatant after NP purification by gel permeation chromatography (GPC) analysis. For visualization, 
all NP were labeled with 1.5 µg Lumogen® F Orange 240/mg NP. 
 Diameter (nm) Poly dispersity index (PDI) Bound protein (µg/mg NP) 
PLA NP 244.1 0.064 - 
PLA-PEG-ApoE NP 266.9 0.075 14.8 
PLA-PEG-ApoE NP w/o NaOH 285.0 0.106 - 
PLA-PEG-Ov NP 263.1 0.132 11.5 
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Figure 37: Influence of ApoE3 modification on nanoparticles’ binding and uptake characteristics in endothelial cells. In pilot flow cytometry 
experiments, (A) HBMEC or (B) pBCEC cells were incubated with 105.3 µg NP/cm2 growth surface for 4 hours at 37 °C. ApoE3-modified 
nanoparticles (PLA-PEG-ApoE NP) strongly increased binding intensity, compared to unmodified control nanoparticles (PLA NP). If the 
preparation procedure of PLA-PEG-ApoE NP was modified and lacked NaOH in the buffer (PLA-PEG-ApoE NP w/o NaOH), binding capacity 
dropped drastically again. Nanoparticle modification with the control protein ovalbumin (PLA-PEG-Ov NP) did not seem to strongly alter 
binding compared to unmodified nanoparticles (PLA NP). The effect was also observed for other concentrations and incubations times (data 
not shown). n=1. Note different y axis increment. Data from (B) was published in [195]. Cellular uptake of PLA-PEG-ApoE NP was checked for 
in primary pBCEC analyzed by confocal laser scanning microscopy (CLSM): (C) In control samples, no cell specific nanoparticle signal was 
detectable; (D) after 24 h of incubation with PLA-PEG-ApoE NP, nanoparticular accumulation in the cytoplasm appears (yellow) was apparent. 
Pilot experiment, n=1. Nuclei are DAPI stained (blue). Scale bar as indicated.  
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4.4.5 Concluding remarks on ligand modification  
Previous studies demonstrated that modification of nanoparticles with apolipoproteins facilitates the 
transport across the BBB in vitro and in vivo [26, 59, 66, 77, 81, 200]. This effect was already reported 
for human serum albumin (HSA)-based nanoparticles and is especially important for in vivo application 
to promote targeted transport across the BBB in the body. Examples for successful brain targeting 
formulations are loperamide-loaded [78, 90, 91] and obidoxime-loaded [26] ApoE3-modified 
nanoparticles. Loperamide, for example, an opioid drug used against diarrhea, does not cross the BBB 
in vivo and consequently does not reduce pain. However, it shows analgesic effects if it is injected 
directly into the brain or loaded into ApoE3-modified HSA nanoparticles that are intravenously injected 
into mice. These animals react less sensitive in a tail-flick test, vividly demonstrating the elegant 
potential of nanoparticle-mediated drug transport to the brain [77].  
Here, nanoparticles that were coupled to apolipoprotein E3 or control ligands were used. Pilot 
experiments with these nanoparticles suggest that pBCEC take up ApoE3-modified PLA nanoparticles 
(PLA-PEG-ApoE NP). Furthermore, PLA-PEG-ApoE NP bind stronger to brain capillary endothelial cells 
than control nanoparticles. Elegantly, the control nanoparticles are in this case not just PEGylated 
nanoparticles, but particles that are prepared by the exact same procedure except for the lack of NaOH 
during the coupling phase (preventing the functionalization of free OH groups for coupling ligands). All 
in all, it is therefore likely that ApoE3-modification of flurbiprofen-loaded nanoparticles (PLA-FBP NP) 
also will enhance brain transport capacity of the incorporated drug in vivo. 
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5 OUTLOOK & SCIENTIFIC CONTEXT  
5.1 Optimization of nanoparticles for flurbiprofen transport 
Drug-loading capacity, release profile and surface modification  
Although flurbiprofen-loaded poly(lactic acid) nanoparticles (PLA-FBP NP) used in this in vitro study 
displayed very promising results in terms of low cytotoxic potential, crossing of the in vitro BBB model 
and capability to reduce amyloid burden in a subsequent in vitro Alzheimer’s disease model, many 
ways of further improving them exist.  
Firstly, the drug release profile of PLA-FBP NP used in this study is rather quick, meaning that the 
complete drug loading is released within a few hours after redisperging the freeze-dried nanoparticles. 
For the in vitro study, the release profile was sufficient, but for in vivo experiments, a retarded drug 
release profile of PLA-FBP NP is more desirable. In vivo, nanoparticles can be transported to the brain 
as fast as 15 min after intravenous injection [59], but a sustained drug release in the brain parenchyma 
would prolong treatment intervals for humans. Possibilities to produce “retard nanoparticles” in the 
future comprise coating with different guarding substances, such as chitosan or PEG (for review see 
[201]). It is also possible to produce multilayer nanoparticles that bear a PLA-based, FBP-loaded core 
with shells of different material in order to keep the drug inside the particle for a longer time. 
Secondly, the nanoparticle formulation for flurbiprofen transport should further be improved to allow 
a ligand-modification on the one hand, and an optimal drug-loading efficacy on the other hand. In this 
study, PLA served as a nanoparticle basis material due to its advantageous flurbiprofen-loading 
capacity (compared to HSA- or PLGA-based nanoparticles). Furthermore, coupling of the surface ligand 
ApoE3 to unloaded PLA nanoparticles was achieved (PLA-PEG-ApoE NP). In summary, one nanoparticle 
species with a ligand modification without drug loading (PLA-PEG-ApoE NP) and another nanoparticle 
without ligand, but with drug loading (PLA-FBP NP) were available for in vitro testing. In the future, 
one nanoparticle must possess these two critical key attributes: it must be capable of selectively 
crossing the blood-brain barrier (due to a surface modification) and must bear a sufficient amount of 
the drug flurbiprofen to evoke biological effects.  
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Nanoparticle trafficking and tracking in vitro and in vivo  
The question arises if the in vitro BBB model depicts realistic local in vivo concentrations. The pBCEC 
BBB model is based on a simple Transwell® system, meaning the endothelial cells grow horizontally on 
a porous membrane. Also, the system lacks any fluidic movements and is therefore a static system. 
This does not portray the realistic circumstances at the neurovascular unit since in human brains more 
than 600 ml of blood passes the capillaries per minute with a mean flow velocity of 1 mm/s [202]. 
Without question, the local concentration of nanoparticles that can interact with the BBB surface in 
vivo will be considerably lower. Therefore, the data obtained in this in vitro study cannot predict an 
outcome in humans, but rather serves as a proof of concept for future experiments. The data obtained 
from the pBCEC BBB model is less prone to be false positive results compared to weaker in vitro BBB 
models and confirms PLA-FBP NP as appropriate technology for transporting drugs to the brain.  
This study only indirectly suggests that drug-loaded nanoparticles crossed the in vitro BBB model, 
because detection occurred via analyzing the released drug at the brain-representing site by HPLC and 
biological efficacy of the released drug via an Aβ42-detecting ELISA assay and not the actual 
nanoparticles themselves. It would therefore additionally be interesting to track the nanoparticles in 
in vitro and in vivo experiments. Different strategies exist to label nanoparticles with radioactive tracer 
molecules since either incorporated or bound proteins can be labeled [203] or the nanoparticles’ basis 
material (e.g. PLGA) [204] can bear radioactive molecules. 
If nanoparticles consist of or bear proteins or peptides, iodination strategies [205] are a convenient 
way to add a radioactive tracer (depending on the amino acid that becomes labeled ). Commonly, the 
Bolton-Hunter reagent (125I, 131I) is used for iodination of proteins. It can be applied directly to peptide 
or protein samples and conjugates to terminal amino groups effectively introducing radioactive iodine. 
This technique is non-oxidative and less harsh to proteins than alternative methods. One disadvantage 
is that iodine isotopes have relatively short half-lives (60 days for 125I and 8 days for 131I) and need to 
be used very soon after labeling. Here, Bolton-Hunter iodination could be used to label either HSA-
based nanoparticles or ApoE3-modified PLA-based nanoparticles in order to monitor transport across 
the in vitro BBB model. Another way to achieve radiolabeled nanoparticles is to label one of the 
nanoparticles components before the actual nanoparticle preparation process. Various methods and 
isotopes exist that allow traceable nanoparticle formulations. Tritium (3H) (a radioactive isotope of 
hydrogen) can be used to label peptides [206]. The low energy β emitter has a half-life of 12.32 years, 
making it convenient for laboratories. Peptides can be easily tritium labeled by catalytic exchange, e.g. 
it would be possible to 3H-label the ApoE3 ligand before or after nanoparticle modification. Using 
N-succinimidyl [2,3-3H]propionate ([3H]NSP), the reaction is similar to using Bolton-Hunter reagent and 
labels free amino groups with less alteration of the protein structure, though with lower specific 
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activity compared to Bolton-Hunter reagent. Also, it is possible to tritium label the basis material as 
companies offer custom synthesized 3H-PLGA formulations [204] that can be further used to prepare 
nanoparticles respectively.  
Peptide labeling can also be achieved by 14C [207]. Theoretically, 14C-labeled amino acids can be 
incorporated in peptides or 14C can be added to the N-terminus of peptides by acetylation of free amino 
groups with 14C acetic acid. However, compared to tritium labeling, this approach is rather expensive 
and reduced in specific activity [208]. 
A further step to investigate nanoparticular trafficking routes in the body is to follow in vivo routes by 
high resolution imaging techniques, such as magnetic resonance imaging (MRI). For this purpose, the 
ferrimagnetic compound magnetite (Fe3O4) can be introduced to nanoparticles. We already showed 
that magnetite-labeled HSA nanoparticles can be detected in rats with clinical MRI scanners with 
limited sensitivity, although further investigations with ligand-modified, magnetite-labeled HSA 
nanoparticles are needed to reliably visualize brain uptake [209]. A magnetite labeling of PLA-based 
nanoparticles that carry a flurbiprofen loading would also be desirable to test in in vivo MRI trafficking 
experiments. Different groups already demonstrated that it is possible to prepare magnetic 
nanoparticles that consist of, or carry PLA [210, 211]. Further elucidation the potential of PLA-FBP NP 
as anti-Alzheimer’s disease drug would be possible by adapting the preparation protocol to produce 
magnetic PLA-FBP NP for MRI analysis. 
Nevertheless, past experiments have shown that even the best in vitro data cannot accurately reflect 
the in vivo situation, especially not for brain delivery. Since flurbiprofen already failed in clinical trials, 
the in vitro data of this study needs to be critically regarded and confirmed with great care, requiring 
verification in vivo. The study outcome is not yet confirmed in animal models, which would be essential 
to further promote PLA-FBP NP in anti-Alzheimer’s disease drug development. The body distribution 
of this nanoparticular formulation would be of utmost importance to correlate the in vitro data with 
in vivo trafficking and suitability as a brain drug.   
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5.2 Improving models: Can in vitro data predict in vivo outcome?  
“Animal experiments will remain necessary in biomedical research for the foreseeable future” [212] 
states the Basel Declaration, a document signed by scientists from Switzerland, Germany, the United 
Kingdom, France and Sweden to promote alternatives to working with laboratory animals. The basic 
3R principle (replace, reduce, refine) aims at avoiding and reducing animal tests and suffering of 
laboratory animals. One important cornerstone to achieve this goal are in vitro models. 
In drug development research, in vitro models are commonly used before testing promising 
formulations in in vivo animal studies or in clinical trials with healthy humans or diseased patients 
(strictly regulated by official institutions such as the US Food and Drug Administration (FDA) or the 
European Medicines Agency (EMA)). Especially advanced (close to in vivo) models can reduce false 
positive study outcomes and limit the number of candidates suited for in vivo studies and clinical trials 
– saving research money and decreasing ethical concerns.  
Alzheimer’s disease models 
In this study, 7WD10 cells (a widely reported cell line heterogeneously overexpressing amyloid 
precursor protein 751WT (APP751WT) prone to peptide aggregation) were used as an in vitro 
Alzheimer’s disease model. As for all simplified in vitro models, this cell line cannot replicate all 
characteristics of Alzheimer’s disease, but is rather used to explore the pharmacological efficacy in 
targeting the amyloid cascade in a controlled experimental setup.  
Generally, great effort has been made to improve in vitro cellular Alzheimer’s disease models. Israel et 
al. reprogrammed primary cells from patients suffering from either the familial or sporadic Alzheimer’s 
disease by using induced pluripotent stem cell (iPSC) technology [213]. They further characterized their 
model for pathological markers like amyloid-β levels and phosphorylated τ and treated purified 
neurons with β- and γ-secretase inhibitors to investigate phenotypes relevant to Alzheimer’s disease. 
In a recent Nature publication, Choi et al. introduced familial Alzheimer’s disease mutations (in APP 
and PSEN1) in a neural stem-cell-derived model cultured in a three-dimensional setup [214]. These 
cells produced amyloid-β (and also amyloid-β plaques) and aggregated phosphorylated and 
filamentous τ. Application of β- and γ-secretase inhibitors reduced amyloid-β pathology and also 
tauopathy [214]. 
A further step in testing anti-Alzheimer’s disease drug candidates are in vivo models, but the situation 
is complicated. As the most common animal model Mus musculus does not suffer from demented itself 
and so far no neurotoxin has been discovered that induces Alzheimer’s disease in mice (as the 
compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does for a Parkinson’s disease 
phenotype). Nevertheless, generation of genetically modified mouse models drastically increased the 
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understanding of Alzheimer’s disease pathology and improved preclinical testing of potential 
therapeutics [215]. However, it is vital to keep in mind that alterations in these transgenic animals can 
lead to potential confounding factors due to overexpression of Aβ or τ. Models based on the amyloid 
hypothesis (used to test Aβ reducing strategies) are, for example, Tg2576 [216]. These mice 
overexpress a mutant APP and show Aβ plaques comparable to those observed in humans, even 
though these animals lack neuronal tangles or neuronal loss. Analogously, τ transgenic models (e.g. 
Tg4510 [217]) overexpress a mutant τ form and display neurofibrillary tangles, functional deficits and 
brain atrophy. Furthermore, the elegant 3xTg Alzheimer’s disease mouse model combines three gene 
mutations (tauP301L, APPK670N/M671L and PS1M146V) and displays three of the Alzheimer’s-
associated characteristics: amyloid aggregation, fibrillary tangles and deficiencies in synaptic 
transmission.  
A very recent model uses Octodon degus, a rodent native to South America, as a sporadic Alzheimer’s 
disease model: apparently, these animals spontaneously develop pathological hallmarks associated 
with Alzheimer’s disease, such as amyloid-β plaques and τ deposits; also, they develop a decline in 
cognition with age [218]. All in all, the Octodon degu model seems to fulfil a plethora of Alzheimer’s 
characteristics found in humans, including molecular, cellular and even behavioral aspects, making it 
a unique natural rodent model for neurodegenration.    
Still, no currently established disease model can display all aspects that are reported for Alzheimer’s 
disease in humans. Therefore, it will always be necessary to reconfirm in vitro and in vivo animal data 
in clinical trials to prove efficacy in Alzheimer’s disease therapy in humans. 
Blood-brain barrier models 
Overall, this study suggests that the monoculture of the primary porcine in vitro model based on pBCEC 
represents a strong, physiologically comparable fort. This conclusion was also recently underpinned in 
[219]. Also, using swine primary material closely resembles human conditions regarding genome, 
anatomy and physiology [220] (unlike many other experimental animal species), but lacks ethical 
concerns compared to using primary primate cells. Nevertheless, there is a plethora of possibilities to 
further improve.  
As cells never grow isolated in a physiological system, advanced in vitro models focus on multiple cell 
type cultures and three dimensional setups. Literature bursts of studies concerning co-cultures of 
endothelial cells with astrocytes, pericytes and neurons or even aforementioned triple-cultures. 
Especially astrocytes, which in vivo cover more than 90 % of the endothelial cells’ surface, seem to play 
a major role. Many reports claim an increased blood-brain barrier integrity of model cells if astrocytes 
(or even astrocytoma cell lines like 1321N1) are cultured on the opposite side of the Transwell® 
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membranes, or if astrocyte-covered membrane disks or if sole astrocyte-conditioned media are added 
to endothelial cell cultures [19, 221–223].  
Other innovative in vitro cell culture models try to remodel the natural blood flow of the in vivo 
situation by expanding to a third dimension (3D models) or introducing dynamics and fluidics, because 
the lack of shear stress in static models (like Transwell® inserts) can influence barrier characteristics, 
like the expression of TJ proteins and BBB-relevant ion channels and transporters. Inducing shear stress 
at the endothelial cells’ surface alone can induce a convergence to in vivo situations and can improve 
barrier integrity, as well as the separation into compartments allowing co-culturing of different cell 
types (endothelial and neuronal cells, astrocytes, pericytes). Current microfluidic models that allow 
multiple cell cultures in different compartments comprise, for example, NDIV-BBBr [28, 29], µBBB [30] 
and SyM-BBB [31]. These systems mimic a blood flow through a vessel that is better suited for drug 
transport studies than the static, horizontal Transwell® system. In a 3D blood vessel model, 
sedimentation of substances is not possible and detection of the substances at the other side of the 
barrier is more likely due to active transport processes. This allows a better predictability for the 
transport of a drug in vivo. Nevertheless, in all three models the culture surface is rather small (e.g. in 
[30]: 10 x 10 mm2); making detection of substances with a low permeability in vivo rather difficult (due 
to detection range). 
Additionally, the increase in complexity in an in vitro BBB model makes it more and more difficult for 
pharmaceutical industries to transit the model to a high through-put variant for large scale research 
and development, and eventually for preclinical testing of promising drug candidates. Overall, simple 
BBB models that still display excellent barrier characteristics and moreover can be upgraded to high 
through-put techniques are most desirable for pharmaceutical drug development.  
Impairment of the blood-brain barrier in Alzheimer’s disease  
A further complicating factor for BBB modelling in the context of neurodegenerative disorders is the 
existing BBB dysfunction in Alzheimer’s disease. It was postulated that neurotoxic Aβ crosses an 
impaired BBB and induces neurodegeneration; the process of Aβ accumulation in the brain and BBB 
impairment are also believed to interact and reinforce each other, eventually promoting 
neurodegeneration [224–226]. 
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5.3 Further strategies and candidates profiting from nanotechnology   
This study proves that nanoparticle-mediated drug transport allows transit across an advanced in vitro 
blood-brain barrier model and therefore may be an excellent tool to treat life-threatening brain 
diseases, like brain tumors (glioblastoma multiforme) or others. The etiology and pathological 
processes associated with neurodegenerative disorders, like Alzheimer’s disease, are confusingly 
complex. Often it remains unclear if a certain hallmark is reason or cause of the disease development 
and progression, prohibiting reliable prognosis of effective drug treatment options in the future. 
Prevention or acute treatment?  
Experts on the Alzheimer’s disease topic are consent that the disease is not currently treatable and 
therapy will, if anything, only halt or slow down the disease’s progression. Of very large concern is the 
timing of the intervention, because by the time amyloid deposits and neurofibrillary tangles are 
present, treatment is expected to be past the point of efficacy [104]. However, imaging data suggests 
that amyloid plaques appear even before clinical decay [227]. The diagnosis of a very early stage 
Alzheimer’s disease is therefore essential - and justifies the great efforts in molecular biomarker 
development [228–230]. When the first symptoms become noticeable, patients have already lost a big 
part of the neural signaling capacity, meaning a large proportion of neurons already perished, and the 
remaining neurons tire while compensating the loss of the other neurons. The rigorous exhaustion 
again causes neural death and even more neurons perish. Furthermore, the lack of synaptic stimulation 
causes neurons to draw back their dendrites and reduce themselves to mainly soma. These altered, 
“sleeping” neurons fall into a passive condition and lose their capability in signal passaging.  
Screening for Alzheimer’s disease biomarkers in certain cases, like when tangible risk factors (such as 
familial Alzheimer’s disease history or APOE4 genotype) are given, therefore would be a step towards 
early intervention possibilities. From current research, anti-amyloid treatment can only be preventive 
and this must be taken into account when developing nanoparticle formulations. Advantages of 
nanoparticular formulations compared to conventional drug development comprise low doses and less 
side effects due to targeted transport (Figure 38). However, a long-term prevention of diseases by drug 
therapy should ideally be orally applied, cheap and should aim at good compliance and low side effects 
for the patients. A common example is secondary prevention of cardiovascular diseases with the 
antithrombotic drug acetylsalicylic acid (ASA, AspirinTM): a daily oral dose of >100 mg/day is sufficient 
for antithrombotic prevention [231, 232] (whereas for pain relief 500–1,500 mg are required) and 
people only suffer from an acceptable rate of side effects.   
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Figure 38: Overview of nanoparticle-mediated benefits and concerns for Alzheimer’s disease and other neurodegenerative disorders 
regarding NSAID- and other potential drug-loading for preventive approaches. NSAID-based drug application is only expected to work 
against Alzheimer’s disease if given at very early stage. But high doses required relevant in AD outcome do not justify NSAID-prevention 
therapy without further indications. Nanoparticles can be used to target NSAIDs to the brain to reduce peripheral side effects and enhance 
local drug concentrations, but at the moment, only intravenous injection of brain-targeted nanoparticles is feasible, raising ethical concerns 
and questions about patients’ compliance. Nevertheless, NSAID-loaded nanoparticles could not only be beneficial for Alzheimer’s disease 
patients, but also in context of other neurodegenerative diseases (like Parkinson’s or Huntington’s disease). Other disease modifying 
strategies in the battle against Alzheimer’s disease could comprise nanoparticles targeting causal mechanisms (like inflammation or amyloid 
production). Often these substances are not able to cross the blood-brain barrier themselves, which could be allowed by effectively using 
nanotechnology.   
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In the case of flurbiprofen, long-term high dose NSAIDs application for Alzheimer’s disease risk 
reduction (as shown in patients with rheumatoid arthritis) is not justifiable, because of the severe 
adverse side effects in these doses. Therefore, packing flurbiprofen into nanoparticles as Trojan horses 
in order to target transport to the brain is an elegant approach to reduce side effects by lower doses 
in the periphery. 
However, at present, nanoparticles that are intended to be given orally and to treat brain diseases are 
years away from tangible development. Examples exist for nanoparticles that are given orally and 
reach their target site in the gastrointestinal (GI) tract [233–235]. However, if the nanoparticles are 
supposed to exit the GI tract and enter the blood stream numerous problems exist. Mainly, the 
nanoparticles are very unlikely to cross the mucosa of the intestine. This can be beneficial if a high local 
concentration is sought (e.g., when the nanoparticles should be degraded in the mucus), but mucus 
crossing of un-degraded nanoparticles to be further transported to the blood stream is very unlikely 
to happen. In addition, the natural route would take them to the portal vein directly to the liver where 
they are likely to accumulate.  
Therefore, the nanoparticle formulations discussed in this study are only applicable to intravenous 
injection (Figure 38). The ethical concern is that it is not justifiable to treat people, especially the elderly 
(that are more prone to infections and critical immune responses) with a prevention that needs to be 
intravenously applied. In addition, the patients’ compliance is expected to be very low. One possibility 
makes an intravenous preventive treatment more palatable for potential patients would be to increase 
the time span between recurrent applications. If it was possible to prepare a retard nanoparticle that 
consistently releases the drug in an e.g. monthly period, it would be conceivable that people would 
use it as prevention regimen.  
A common example for an injected prevention strategy is vitamin B12 supplementation for vegans. 
Vitamin B12 is only present in animal products (and its oral availability is generally low), but it is 
essential for neural development and memory performance. Therefore, vegans (and also non-vegans) 
often perform a vitamin B12 treatment where the drug hydroxocobalamin or cyanocobalamin (which 
is metabolized to vitamin B12 in the body) is intramuscularly injected monthly or weekly over a certain 
period of time. 
Analogously, certain risk factors for Alzheimer’s disease would justify a long-term intravenous drug 
therapy or prevention approach using nanotechnology. Indications could consist of predisposition of a 
familial variant of Alzheimer’s disease, caused by gene mutation in the APP or γ secretase-encoding 
gene. All current mouse models of Alzheimer’s disease make use of these mutations to mimic 
Alzheimer’s disease, where the proportion of the familial variant only covers 5-10 % of all Alzheimer’s 
disease cases. However, for the people suffering from the gene mutation, it would be legitimate to 
 Outlook & Scientific Context 
84 
 
intervene with e.g. NSAIDs that were repeatedly shown to modulate γ-secretase activity and are 
expected to be beneficial if they can reach brain parenchyma.  
Another indication for nanoparticle-based NSAID prevention could be a peculiar Alzheimer’s disease 
biomarker. Researchers and clinicians put a lot of effort into establishing an early diagnosis of 
Alzheimer’s disease. Particularly useful is the analysis of cerebrospinal fluid (CSF) for total τ (T-τ), 
phosphorylated τ (P-τ) and β-amyloid peptide (Aβ42) [236–238]. Hinting at neurofibrillary tangle 
formation and amyloid pathologies, these analyses can therefore identify patients at early Alzheimer’s 
disease stages that did not yet develop dementia (it also serves as differential diagnosis between 
Alzheimer’s disease and other dementias). These patients could actually benefit from nanoparticle-
mediated drug therapy in the early stage of the disease, justifying the perceived burden of a recurrent 
intravenous prevention approach.      
Ideally, the drug release profile of the nanoparticles should then be optimized to a retard profile, 
minimizing the frequency of injections. This could be achieved by a combination of basis material for 
the nanoparticles: e.g. if PLGA-based nanoparticles were used, the proportion of PLA and PGA in the 
PLGA composition varies the release profile of the drug. An injection could therefore include 
nanoparticles with increasing amounts of PLA in the PLGA composite to delay drug release. 
Furthermore, a subpopulation of the nanoparticles could be coated with protectants, such as chitosan, 
that would further delay degradation in the human body. 
 
Intervention possibilities profiting from nanotechnology  
The progression of Alzheimer’s disease creates the largest unmet medical need in neurology. A 
hindrance is that the etiology hypotheses are not elucidated up to today and that it seems likely that 
more than one pathogenic pathway causes the disease state. This section discusses the current 
disease-modifying and prevention strategies that could profit from using nanotechnology, focusing in 
detail on Aβ-related approaches and neuro-inflammation (other current approaches comprise 
targeting τ pathology, altered ApoE genotypes and metabolic dysfunction).  
In his review from 2010, Citron outlines different causal intervention strategies [122] focusing on the 
reduction of Aβ42 formation and Aβ42 plaque pathology (summarized in Figure 39). A lot of these 
strategies could profit from nanotechnology, because many of the substances worth considering as 
anti-Alzheimer’s disease drug candidate are not currently suited for blood-brain barrier crossing 
themselves - making nanoparticle-mediated drug transport a promising approach. 
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Figure 39: Disease modifying strategies against Alzheimer’s disease. The amyloid precursor protein (APP) is cleaved by β- and γ-secretase 
during the amyloidogenic pathway, resulting in aggregation-prone Aβ42 peptide that forms neurotoxic oligomers and amyloid plaques, which 
may cause neuroinflammation. The amyloid cascade may trigger downstream τ pathology. ApoE can affect Aβ deposition and/or clearance. 
Various approaches for possible disease-modifying strategies that causally target the proposed pathology processes are shown: (A)  Secretase 
inhibitors and modulators alter the proteolytic cleavage outcome, thereby reducing Aβ42 levels. (B) Aggregation inhibitors target plaque 
formation by decreasing Aβ-Aβ interaction. (C) Clearance mechanisms comprise degrading Aβ peptides e.g. by proteases. (D) Alternatively, 
Aβ-recognizing antibodies can be used to mark neurotoxic Aβ peptides for degradation by the immune system. (E) Independent from Aβ 
pathway, τ pathology can be interfered with by decreasing either τ aggregation or τ hyperphosphorylation. (F) As neuroinflammation is linked 
to Alzheimer’s disease, targeting inflammation processes is another causal tool. However, it is still unclear to what extent inflammatory 
responses are harmful or beneficial in Alzheimer’s disease pathology. Image adapted and modified from Citron [122].  
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The amyloid hypothesis blames pathologic amyloid plaque accumulation in the brain due to an 
imbalance of Aβ42 production and clearance as the origin for Alzheimer’s disease development. 
Consequently, drugs that influence the amyloidogenic outcome of APP cleaving and resulting in less 
Aβ production are a cornerstone in anti-Alzheimer’s disease drug development (Figure 39A). Despite 
some critical voices started to question the amyloid hypothesis in recent years, there is strong 
pathological and genetic evidence that Aβ peptide, especially the least soluble isoform Aβ42 plays a 
key role in all types of Alzheimer’s disease [239, 240]. However, in the last years, several therapeutics 
that were developed on behalf of the amyloid hypothesis failed in clinical tests. The next section 
summarizes recent efforts that failed, but might be revisited in nanoparticular formulations. 
The first target in Aβ42 reduction was γ-secretase. γ-secretase inhibitors (Figure 39A) decrease Aβ42 
burden by altering progressive proteolytic cleavage of APP. Concerns towards γ-secretase inhibition 
arose when scientists found that deleting the γ-secretase component PSEN lead to lethal phenotype 
(comparable to a Notch1 knock out) and that inhibiting Notch 1 cleaving interferes with thrombocyte 
differentiation and B-cell maturations [241, 242]. Nevertheless, companies developed γ-secretase 
inhibitors like semagacestat and avagacestat that were believed to be beneficial for Alzheimer’s 
patients [243–246]. Unfortunately, cognitive decline did not significantly improve with semagacestat 
and avagacestat therapy, but rather it worsened. However, since γ-secretase has many substrates, the 
outcome of these trials is hard to interpret and the negative effect might be due to other altered 
pathways affected by γ-secretase inhibitors [247–249]. To avoid safety issues, circumventing an effect 
on the Notch pathway was aimed for and lead to the development of γ-secretase modulators (not 
inhibitors). Some NSAIDs are able to decrease neurotoxic Aβ42 species (Figure 39A), whereas other Aβ 
isoforms increase [250], without affecting Notch [251]. This effect is not mediated by the classical COX 
inhibition, but by direct γ-secretase interaction [173] or the corresponding substrates [252]. This study 
used the γ-secretase modulator flurbiprofen. R-flurbiprofen (tarenflurbil) failed in an Alzheimer’s 
disease clinical trial, due to its poor transport capacity across the blood-brain barrier. Delivery of 
NSAIDs to the CNS is often inefficient, likely evoked by binding to plasma proteins [185–188, 253] . The 
incorporation of the drug within nanoparticles evoked an Aβ42 reducing effect in the in vitro 
BBB/Alzheimer’s disease model. Achieving targeted transport to the brain in vivo by surface 
modification of the flurbiprofen-loaded nanoparticles, may improve the prospects of disease 
modification in animal models or patients. Another explanation for the failure of R-flurbiprofen in 
clinical trials might have been the reduced impact on COX activity. Patients treated with high-dose, 
long-term NSAIDs were less likely to develop Alzheimer’s disease, but this effect was also believed to 
be due to anti-inflammatory reactions. Another strategy to avert the amyloidogenic pathway [254] is 
targeting β-secretase (BACE1), which is ubiquitously expressed but elevated in the brain and its 
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biological role is still not clear. In sporadic Alzheimer’s patients, BACE1 is not mutated, but β-secretase 
activity is still enhanced (not clear if this is the cause of the pathology or a late-stage consequence). 
Generally, β-secretase inhibitors are a promising anti-Alzheimer’s disease drug, but the development 
seems to be challenging as most of the candidates are large and hydrophilic peptides [255], prohibiting 
blood-brain barrier crossing. In these cases, nanoparticles could be an excellent approach to deliver 
these substances to the brain parenchyma since nanoparticles loaded with peptides or proteins have 
been successfully prepared in the past. Another (theoretically possible) approach is stimulation of 
α-secretase (e.g. through cell surface receptors [256]) providing less APP substrate for the 
amyloidogenic pathway. Nevertheless, far more APP enters the non-amyloidogenic pathway and for a 
measurable effect, α-secretase activity would need to markedly increase, changing not only APP but 
also various other membrane protein metabolism. The possible side effects are unknown and no 
α-secretase activator has entered clinical trials so far [122].  
It is also possible to target Aβ aggregation for AD intervention (Figure 39B). In the brain, different Aβ 
isoforms are generated, of which Aβ42 tends to aggregate in oligomers. Scientists originally assumed 
that only large fibrils would be neurotoxic, but later it was shown that even smaller Aβ oligomers can 
lead to synaptic dysfunction (for review see [240]). Consequently, one approach was developing 
substances that inhibit Aβ-Aβ interaction (Figure 39B), but not many of these drugs entered clinical 
trials. A prominent candidate, tramiprosate, keeps Aβ monomers in a non-fibrillary state [257] and 
reduced Aβ42 in the cerebrospinal fluid in a phase II trial. It was not effective in a phase III trial, and it 
is still unclear if the drug blocked Aβ42 in the brain. Nanoparticles could be used try and enhance 
tramiprosate (AlzhemedTM) transport to the brain.  
Furthermore, enhancing Aβ clearance can be aimed for (Figure 39C) by involving two key structures: 
Aβ-degrading proteases and Aβ-targeting antibodies. Proteases (also called peptidases or proteinases) 
ipso facto cleave proteins (or peptides) by hydrolysis of peptide bonds. For Aβ peptide cleavage, the 
most important proteases identified are neprilysin, insulin-degrading enzyme and plasmin [258]. 
Plasmin degrades Aβ peptides in vitro, but is inhibited in vivo by plasminogen activator inhibitor 1 
(PAI-1) (which prevents generation of plasmin from plasminogen). Consequently, blocking the PAI-1 
leads to activated Aβ-degrading plasmin and also more Aβ clearance (Figure 39C). PAI-1 inhibitors 
reduced Aβ burden in transgenic mice [258, 259], but the brain transport of PAI-1 inhibitors is expected 
to be problematic in patients due to the blood-brain barrier. Proteins can be incorporated into 
nanoparticular formulations. So, an interesting approach to target Aβ-degrading proteases to the brain 
could be packing the enzymes into nanoparticles of suited basis materials (e.g., PLGA) and using 
surfactant coating or direct coupling of surface ligands (e.g., ApoE3) to allow blood-brain barrier 
crossing and enhance protease concentration in the brain.  
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Concerning immunotherapy (Figure 39D), two pathways are assumed to support Aβ clearance (for 
review see [104]). Either a peripheral sink effect appears when antibody binding in the blood plasma 
causes a gradient that drives Aβ removal from the brain, or antibodies might tag Aβ species present in 
the brain making them recognizable for microglia (capable of phagocytosis). In active immunization, 
the Aβ42 antigen itself is injected; in passive immunization whereby, patients receive Aβ42-recognizing 
antibodies. However promising, up to today this stagey failed in terms of slowing cognitive decline and 
in some cases was even harmful to patients that developed a severe immune response [122]. 
Antibodies targeting the amyloid-β peptide repeatedly failed to slow cognitive declines in Alzheimer’s 
patients during clinical trials and raised questions about the effectiveness of Aβ42 reduction. In 2012, 
the Nature news blog reported that Bapineuzumab, a humanized monoclonal antibody, did not cause 
cognitive improvement in patients during two trials, even though Alzheimer’s disease biomarkers 
(amyloid brain plaque and phosphorylated τ protein) in the cerebrospinal fluid (CSF) were decreased 
after Bapineuzumab treatment. In response, the developing company Johnson & Johnson therefore 
wanted to discontinue the development. In two global, randomized phase III clinical trials, the lack of 
efficacy of Bapineuzumab was recently confirmed [112]. Eli Lilly and Company also failed with a similar 
antibody (Solanezumab) in two phase III clinical trials. However, as previously mentioned, maybe study 
designs should be adapted to try to treat asymptomatic patients that already show the including 
criteria in biomarkers, but do not yet suffer from cognitive decline or dementia.  
Another target in anti-AD drug development is reducing hyperphosphorylated τ (Figure 39E). The 
protein τ is a soluble and binds to and stabilizes microtubules in axons, thereby contributing to 
cytoskeleton functions and axonal transport. In Alzheimer’s disease, hyperphosphorylated, insoluble, 
aggregated τ tangles (one of the two hallmarks of AD) appear, which either directly cause neuronal 
toxicity or contribute to the degeneration by reduced axonal transport (for review see [260]). The 
burden of τ in specific brain areas correlates with the degree of cognitive decline [261]. Furthermore, 
τ mutations can lead to other forms of dementia [262]. Strategies to counteract τ pathology comprise 
inhibiting either τ aggregation or hyperphosphorylation [263, 264]. Anti-τ aggregators seem appealing, 
because it is generally believed that τ aggregates are harmful and a lot of effort is made in quest for a 
suitable substance, LMTXTM (proposed trade name: Rember) from TauRx Therapeutics, for example, 
showed positive results in phase II clinical trials and entered phase III recently [265–267]. Generally, 
nanoparticles could be used to maximize transport capacity across the brain. Inhibition of kinases 
(enzymes that transfer a phosphate group from phosphate-donors to substrates), is the logical 
consequence to avoid hyperphosphorylation. However, the main pathologic kinase for Alzheimer’s 
disease development is not yet identified. Nevertheless, for development of kinase inhibitors as anti-
Alzheimer’s disease drugs, nanoparticles could be advantageous to reduce the severe side effects that 
 Outlook & Scientific Context 
89 
 
follow chronic kinase inhibition by dose reduction and allow organ-specific targeting, thereby widening 
the number of potential substances and facilitating approval and regulating processes. 
Moreover, a link between inflammation and Alzheimer’s disease exists– as numerous studies have 
shown until today – making it a causal target in anti-Alzheimer’s disease drug therapy development 
(Figure 39F). However, from the recent literature, it is still confusing if inflammation initiates 
Alzheimer’s disease, if it is just a natural bystander or if it might be an advantageous response (for 
review see [215]). Therefore, the question remains: should neuro-inflammation be targeted in 
Alzheimer’s disease therapy or not?  
One the one hand, the early activation of the immune system can be beneficial in clearing Aβ species 
[215]. Aβ species themselves, for example, can activate innate immune responses to recruit activated 
microglia that are capable of phagocytosis, thereby counteracting Alzheimer’s disease pathology 
(Figure 40). One the other hand, neuro-inflammation processes are assumed to be harmful and directly 
related to Alzheimer’s disease development (Figure 40). Especially interesting is the interaction 
between astroglia, microglia and neurons. Astrocytes and microglia can recognize damage or injury to 
the brain (like trauma, infections or fibrillary Aβ) and consequently release pro-inflammatory signals 
(such as chemokines, interleukines, cytokines, prostaglandins, pentraxins, complement components 
and reactive oxygen species) that are up regulated in the affected brain areas [268–272]. If this 
secondary response is triggered constantly (e.g. by increased Aβ42 generation), the activated neuro-
inflammatory process leads to neuronal death [273].  Furthermore, activated microglia are correlated 
with senile plaques and it is believed that activated microglia cannot phagocytize Aβ in the presence 
of inflammatory cytokines, therefore promoting plaque formation [274].  
 
 
 
Figure 40: Inflammation in Alzheimer’s disease (Alzheimer’s disease). In Alzheimer’s disease, a chronic inflammation in certain brain regions 
appears that is supposed to be harmful and can further promote Alzheimer’s disease (up and down arrows). Other immune responses can 
be beneficial to supress pathogenesis (inhibitory arrows), such as microglial phagocytosis of Aβ species. Genetics or epigenetics (like 
traumatic injury, infections or inherited diseases) can influence both beneficial and harmful immune responses (curved arrows). NSAIDs 
affect disease progression or development, for example by reducing Aβ generation or suppressing inflammation (curved inhibitory arrows).  
Schema adapted and modified from Wyss-Coray [215].  
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Therefore, anti-inflammatory therapy has been proposed as an anti-Alzheimer’s disease therapy 
(Figure 40). As described earlier, the efficacy of chronic NSAIDs use regarding Alzheimer’s disease risk 
reduction is undeniable and supported by animal model and epidemiological data [120, 156, 170, 215, 
275]. However, the mechanism behind this beneficial effect is still not completely understood, because 
NSAIDs have multiple targets and modes of action that – apart from their potency to reduce Aβ42 
species - could be beneficial in the battle against Alzheimer’s disease: 
NSAIDs - Panacea or pharmacological sledgehammer?  
The original NSAID, Aspirin (first synthesized and patented in the 1890s), was described to mainly 
target COX-1 and COX-2, thus inhibiting prostaglandin synthesis (Figure 41A). Today, many other 
NSAIDs exist with various selectivity for COX-1 or -2. In the context of epidemiological studies with 
rheumatic patients, NSAIDs were proposed as anti-Alzheimer’s disease drugs, but largely failed in 
clinical trials (examples are celecoxib and rofecoxib (COX-2 selective) or naproxen [120] (mixed COX-
1/COX-2 inhibitor)). Interestingly, people affected with arthritis that used long-term high-dose NSAIDs 
showed a drastic decrease of major histocompatibility complex (MHC) class II-positive activated 
microglia (compared to people without arthritis or without NSAID consumption) [276], suggesting that 
NSAIDs can reduce microglia activation. Even more interesting, neither NSAID-use nor arthritis 
changed the proportion of Aβ deposits and neurofibrillary tangles in the study. The Aβ42-decreasing 
mechanism of NSAIDs is based on modulation or inhibition of γ-secretase (Figure 41B). Another target 
of certain NSAIDs is the small GTP-binding protein Rho and its kinase Rock (Figure 41C). Inhibition of 
Rho eventually leads to reduced Aβ production. Some NSAIDs (like R-flurbiprofen) seem to be capable 
of translocating NFκB to the nucleus leading to reduced COX-2 expression (Figure 41D), which could 
be relevant for a beneficial effect in Alzheimer’s disease patients. Activation of PPAR-γ by NSAIDs 
(Figure 41E) may lower the expression of β-secretase by repressing β-secretase cleaving enzyme 1 
(BACE1) promoter [277], however, clinical trials with PPAR-γ agonists were rather sobering. 
The NSAID failure in clinical trials regarding Alzheimer’s disease may be due to various reasons: Firstly, 
it is consistent that anti-inflammatory approaches (as well as Aβ targeting strategies) would rather 
work as Alzheimer’s disease prevention, but not Alzheimer’s disease treatment when clinical features 
became obvious. Secondly, it appears that celecoxib and rofecoxib were targeting the wrong enzymes. 
Both being COX-2 selective, both drugs are associated with less gastrointestinal side effects, but COX-1 
(not COX-2) is upregulated in activated microglia. Flurbiprofen, on the other hand is COX-1/-2 
unselective, but might not have reached relevant concentrations in the brain, again underlining 
nanotechnologies’ potential for enhanced drug transport.  
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Figure 41: NSAIDs have multiple effects in Alzheimer's disease. (A) The classical role of NSAIDs is (selective or non-selective) cyclooxygenase 
(COX) inhibition, which inhibits prostaglandin and thromboxane synthesis thereby evoking anti-inflammatory effects (B) Other effects 
relevant in Alzheimer’s disease are modulation or inhibition of γ-secretase (lowering Aβ42), (C) inhibition of Rho and Rock, (D) inhibition of 
NFκB translocation to the nucleus (reduces inflammation and BACE expression) and (E) activating PPAR-γ and the retinoid X receptor (RXR) 
(increases macrophage function and represses BACE expression). Schema adapted and modified from [215], examples for NSAIDs from [176, 
177, 251, 278–286].  
 
Furthermore, inflammatory processes are also discussed in various other diseases; therefore, NSAID-
loaded nanoparticles could also be indicated not only against Alzheimer’s disease. Neuro-inflammation 
does indeed appear to play a major role in other neurodegenerative disorders, such as multiple 
sclerosis [287], Huntington’s disease [288] or Parkinson’s disease [289, 290], where NSAID treatment 
was already reported to show beneficial effects in disease models [291]. Therefore, NSAID-loaded, 
brain-targeted nanoparticles could be used to enhance the drug transport to the brain to treat other 
disorders apart from Alzheimer’s disease. Furthermore, a multiple ligand coupling could be used to 
target brain-nanoparticles to substructures, such as the substantia nigra, targeting tissue specific 
receptors (dopamine receptor 2, short splice variant (D2Rs), the dopamine autoreceptor exclusively 
expressed in dopaminergic neuron presynapses).  
  
 Outlook & Scientific Context 
92 
 
As a closing remark, it should be noted that also life style factors such as the organization of leisure 
time and fitness [292, 293] and nutrition are debated to play a role in neurodegenerative disease 
development and outcome. Especially, the beneficial impact of food intake for Alzheimer’s disease 
prevention or therapy is a large research field today. For example, some studies pay high regard to 
high-dose B vitamin supplements (like folate, vitamin B6 and B12). Yet, in a randomized controlled trial 
patients with mild to moderate Alzheimer’s disease did not profit from the vitamins and cognitive 
decline was not slowed down [294]. Analogously, meta-analysis and systematic reviews controversy 
discuss caffeine intake to be beneficial for Alzheimer’s disease risk reduction [295, 296] 
Other studies focused on fats: Ω3 fatty acids and Ω3 fatty acid-rich fish. These acids are suspected to 
be neuroprotective during development and aging and numerous epidemiologic studies and clinical 
trials have appeared on this topic during the last decade. Although data from animal models and cell 
culture studies wa promising [297–301], the results in humans are inconsistent and difficult to 
interpret [164, 166, 302–308]. Especially docosahexaeoic acid (DHA) was proposed to be beneficial in 
dementia. At the moment, it seems that high Ω3 fatty acid intake prevents Alzheimer’s disease 
development rather than eases symptoms in the manifested disease state [309]. The protective 
mechanism is not understood yet, but anti-inflammatory effects are conceivable [166] as well as the 
ratio of Ω3 to Ω6 fatty acids in erythrocyte membranes [165]. It could be beneficial to provide more 
Ω3 fatty acids in the brain parenchyma, especially in individuals that have an increased risk for 
Alzheimer’s disease (biomarkers) without established symptoms. This would be problematic with usual 
oral intake because the amount of DHA would be too large. An option would be to prepare fatty acid 
nanoparticles as described in the literature [310], consisting of DHA and modifying the surface with 
brain targeting ligands such as ApoE3 and transferrin. The increased amount of DHA in the brain 
parenchyma might evoke neuroprotection and slow cognitive decline in very early stages of 
Alzheimer’s disease. 
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6 CONCLUSION  
Today, people achieve a remarkably prolonged lifespan compared with past decades and centuries, 
thanks to increasing wealth, less heavy physical labor, improved hygiene standards, healthier lifestyles,   
the development of new live-saving drugs and interventions, and better health care systems.  
However, the longevity accompanies a drastically increased prevalence for neurodegenerative 
disorders, like Alzheimer’s disease. For the etiology of Alzheimer’s disease is not yet completely 
understood, causal interventions or cures are currently still lacking, but desperately needed. In the 
search for potent anti-Alzheimer’s disease drugs, various promising substances were identified. 
However, hope often crumbled when it came to clinical trials. One example is the non-steroidal anti-
inflammatory drug (NSAID) flurbiprofen that was an anti-Alzheimer’s disease candidate. After 
promising phase II clinical trials, flurbiprofen eventually failed in a phase III clinical trial, probably due 
to its low penetration capacity to the brain.  
Here, flurbiprofen was revisited as an anti-Alzheimer’s disease drug by trying to enhance brain 
transport with the aid of molecular Trojan horses. The drug was incorporated in poly(lactic acid) 
nanoparticles in order to mask the original physico-chemical properties of flurbiprofen that hinder 
blood-brain barrier crossing.  
The appeal of flurbiprofen-loaded PLA-nanoparticles for anti-Alzheimer’s disease drug development 
lies in the excellent biocompatibility and the already existing approval of the separate components - 
both flurbiprofen and poly(lactic acid) were approved by regulatory authorities (like the FDA). 
Furthermore, incorporating flurbiprofen in drug-loaded nanoparticles is expected to impede 
flurbiprofen binding to plasma proteins, which was proposed as the main reason for flurbiprofen’s low 
blood-brain brain penetration capacity. As discussed in this study, flurbiprofen-loaded nanoparticles 
also bind to plasma proteins. However, in this case, the formation of a protein corona (partly consisting 
of apolipoproteins) on the nanoparticles surface after plasma incubation allows receptor-mediated 
transcytosis across the blood-brain barrier, rather than retention in the bloodstream. Enhancing the 
transport rate of flurbiprofen across the blood-brain barrier by nanotechnology is consequently 
expected to succeed. For NSAIDs, only less than 5 % of the originally applied drug amount reach the 
brain or the cerebrospinal fluid (CSF), resulting in less than 1.5 µM flurbiprofen at normal plasma 
concentrations in vivo [177, 185, 187, 188]. For an amyloid reducing effect in cellular Alzheimer’s 
disease models, about 50 µM flurbiprofen are needed [68, 172]. Increasing the transport rate of 
flurbiprofen to the brain by more than 30 fold with the aid of nanoparticles seems feasible when using 
a suitable nanoparticular formulation. For example, Chen et al. could increase loperamide permeability 
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across an in vitro BBB model by more than 20 fold when using a specific nanoparticle formulation [76]. 
Even more drastic effects for nanoparticle-mediated BBB crossing of loperamide were shown in in vivo 
nociceptive experiments, in which animals treated with loperamide-loaded nanoparticle reacted less 
sensitive to pain after nanoparticle-treatment than loperamide-treated control animals [49, 90].  
However, the question remains at which time point a nanoparticle-based anti-Alzheimer’s disease 
therapy or prevention strategy would be indicated. Would flurbiprofen still show beneficial effects in 
Alzheimer’s disease patients when symptoms were already apparent? It is more likely that an 
intervention would be too late in this disease state. Rather, predisposed patients could profit from an 
early, marker- or genotype-indicated prevention approach. It seems conceivable that e.g. an existing 
familial variant of Alzheimer’s disease or an accumulation of genetic risk factors - recognized before 
symptom occurrence – justifies nanoparticle-mediated NSAID or flurbiprofen prevention.  
Future steps resulting from this study’s data consist of optimizing nanoparticle preparation to combine 
drug-loading and ligand-modification in one formulation. Ideally, these nanoparticles should be 
traceable in vitro and in vivo e.g. by the inclusion of marker molecules. Furthermore, the aim should 
be to develop a retarded flurbiprofen-release profile to allow maximal effect in in vivo application. 
Other drugs (e.g. other non-steroidal anti-inflammatory drugs) that reduce Aβ42 burden or positively 
affect neuro-inflammation in Alzheimer’s disease could be incorporated in similar nanoparticles to 
enhance brain transport capacity in vivo.  
For pre-screening, better in vitro blood-brain barrier models for drug transport studies can be achieved 
by co-culturing brain endothelial cells together with other cells of the neurovascular unit (providing 
biochemical support) and introducing shear stress in three-dimensional model structures (mimicking 
blood flow to improve barrier integrity and achieving more realistic local drug concentrations than in 
a static in vitro model). Nevertheless, even by refining the already very promising in vitro results 
presented in this study, a success in in vivo experiments is still not guaranteed.  
 
Overall, it might seem like grasping at straws when reinvestigating drugs that already failed once. 
However, in the battle against Alzheimer’s disease, the fast-emerging field of nanotechnology offers 
the possibility to enlarge the pool of substances that may have a positive impact - giving us hope that 
development of effective pharmacological tools will become more realistic in the near future.  
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